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ABSTRACT
Ovarian androgens are products of steroidogenic processes that are integral to
follicular development, which culminates in ovulation. Follicle development involves
growth and differentiation of the different follicular cell types. These developments
enable maturing follicles to become steroidogenically competent and eventually release
mature oocytes capable of fertilisation. The follicular cells involved in steroidogenesis
are granulosa (GC) and theca cells (TC). Androgens are synthesised in TC. The main
ovarian androgens are androstenedione and testosterone, which are predominandy
substrates for aromatisation by GC into oestrogens, the most physiologically important
steroids in the female. Follicle stimulating hormone (FSH) and luteinising hormone
(LH) regulation of steroid synthesis is well documented. It is now also known that
locally produced regulators within the ovary modulate this endocrine control.
Autocrine/paracrine control modulates gonadotrophin-induced ovarian proliferation,
differentiation and steroidogenesis.
This thesis researches steroid 50C-androstanedione (50C-A), a product of da-
reductive metabolism of androstenedione. 5a-A is an aromatase inhibitor which
inhibits oestradiol production, and therefore has a potential intraovarian paracrine role
in modulating oestrogen biosynthesis. I investigated whether 5a-A was a product of
androstenedione metabolism in the rat ovary, as an animal model. Since 5a-A is a
metabolic product of 5a-reductase type 1 (5a-Rl), a steroidogenic enzyme present in
human GC and TC, the thesis also describes studies of the localisation and
gonadotrophic regulation of 5a-Rl in the rat ovary. Ovarian aromatase expression was
also investigated because 5a-Rl activity is associated with inhibition of oestrogen
production, which depends on aromatase activity.
The metabolism of androstenedione was investigated in in vitro cultures of
isolated ovarian GC and TCs. The steroid metabolites were investigated using
radiochromatography. In GC cultures, oestradiol was detected among the steroid
metabolites, but 5a-A was not. Additional investigations using oestradiol
radioimmunoassay (RIA) supported the findings. The lack of a method for
measurement of 5a-A led to the development and validation of a new RIA for this
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purpose. However, the assay crossreacted significantly with androsterone and
androstenedione as well as 5CC-A. Although thin layer chromatography (TLC) could
resolve the steroids, incorporation of the separation technique in the assay of biological
samples was problematic due to inconsistent steroid recoveries. Therefore, the assay
could only be used to measure total 17keto-androgens (17KAs) in unpurified biological
samples.
The location of 50C-R1 in the rat ovary was determined to identify the ovarian
cell types responsible for 5a-A production. 5CC-R1 messenger RNA (mRNA) and
protein were detected in the theca/interstitial cells (TIC) of the rat ovary, and strongly
expressed in immature ovaries. Although 50C-R1 tissue expression pattern was similar,
levels were markedly reduced in adult ovaries. Northern analysis and in situ
hybridisation (ISH) clearly showed that 50C-R1 mRNA was abundantly expressed in the
TIC. Additional evidence by immunocytochemistry (ICC) depicted the same location of
5a-Rl protein. 5a-Rl was not localised in rat GC. The expression of 50C-R1 in the
immature rat ovary was developmentally regulated by gonadotrophins because eCG
decreased its expression while it was transiently up-regulated by hCG. Because each
hormone acts on either granulosa or theca cells in immature ovaries, hCG stimulation of
5CC-R1 expression suggested that LH acts on theca cells to stimulate 5CC-R1 expression.
ECG down-regulated 50C-R1 expression, suggesting that FSH induced this action by
local agents produced in the granulosa cells. These factors are yet to be identified, but
this action of FSH indicates a paracrine product of GC that inhibits 5cc—R1 expression.
ECG and hCG induced developmental changes reflecting the follicular changes that
occur before ovulation. The findings, therefore, suggest that FSH, (the secretion of
which is known to increase early in follicle development) decreases ovarian 50C-R1
expression. However, expression is stimulated by LH, which rises around the time of
ovulation. Hence, 50C-R1 action and 5CC-reduced androgen production are reduced
when follicle development begins, probably to prevent an inhibitory action on oestrogen
synthesis. The transient increase in 5CC-R1 around ovulation suggests a regulatory role
of 5a-reduced steroids at this stage of follicle development.
The location of 5CC-R1 in rat TIC indicated that they were the cells of choice for
cell culture investigations of 5a-Rl activity. However, repeated attempts to
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demonstrate 50C-R1 activity in TC in isolated cell cultures were unsuccessful, even
though the cited literature reported 5a-Rl activity in rat GC and TC. The results of
aromatase investigations were similar to reported findings. Aromatase mRNA was
expressed abundantly in the GC of eCG-treated ovaries, but absent in GC of immature
or hCG-treated ovaries as well as the TIC. The findings also matched the well-known
stimulatory role of FSH on aromatase action.
Finally, other investigators had implicated 5CC-A in dysfunctional follicle growth
in women presenting with polycystic ovary syndrome (PCOS). Therefore, the
concluding clinical section of the thesis is devoted to the measurement of 50C-A levels in
follicular fluids (FF) obtained from the ovaries of women with normal ovarian function
and those with PCOS. Measurements of androstenedione and 50C-A in normal and
PCOS FF showed that both androgens were elevated in PCOS subjects, whether
ovulatory or anovulatory, compared to normal FF. The findings illustrated abnormal
steroid production in PCOS ovaries and are reflective of the characteristic
hyperandrogenaemia of the condition.
In summary, this is the first definitive description of the spatiotemporal
expression of 50C-R1 in the mammalian ovary. 5(X-R1 gene expression was located to rat
TIC and shown to be regulated developmentally by gonadotrophins. A new RIA was
developed and used to measure the 5(X-reduced androgens and androstenedione in
normal and PCOS FF. These androgens were shown to be elevated in PCOS, where
they probably contribute to the local intraovarian paracrine control that impairs
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Chapter 1. LITERATURE REVIEW
1.1. INTRODUCTION
Androgens are arguably the most important ovarian steroids because they are
the precursor substrates from which oestrogens are synthesised (Hillier, 1981; Adashi,
1994; Hillier et al., 1994; Shoham & Schachter, 1996). In addition to this main role,
androgens also have local paracrine functions where they modulate follicle development
via regulatory action on key steroidogenic enzymes (Hillier & De Zwart, 1981; Harlow et
al., 1986). Ovarian androgens are, therefore, cardinal in ovarian function on which
female fertility is critically dependent. This thesis focuses on the intraovarian role of
androgens, specifically 5CC-reduced androgens that are produced as a result of the
catalytic action of 5a-reductase (5CC-R), in normal and abnormal ovarian function.
Ovarian androgen secretion begins in ntero (Levina et al, 1976; Grinsted, 1982),
but the production of female sex steroids, which regulate fertility, begins at puberty
(Hilher, 1994a; Johnson & Everitt, 1995). In the female, the post pubertal changes
heralding an adult reproductive system manifest in cyclic patterns of ovarian
developments consisting of follicular maturation, ovulation, and formation and
regression of the corpus luteum, collectively known as the ovarian cycle. These
processes ensure the release, at ovulation, of developed female germ cells (oocytes)
capable of fertilisation. Concomitant secretion of steroids enhances the ovarian
developments and prepares the female reproductive tract for pregnancy. The release of
fertilisable oocytes and secretion of steroids are the two main roles of an adult ovary
(Tsafriri et al., 1994; Johnson & Everitt, 1995). The structure of the ovary (Fig. 1.1) is
developed to fulfil these roles, which are principally controlled by endocrine action of
the gonadotrophins, follicle stimulating hormone (FSH) and luteinising hormone (LH),
arising from the pituitary (Zeleznik, 2001). It is this control of ovarian function,
particularly, the regulation of 5a-reductive metabolism that is investigated in the studies
described in this thesis.
The ovarian tissues responsible for steroid production are the thecal and
granulosa cells within the follicles (Gore-Langton & Armstrong, 1988). It is essential
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that the levels of bioactive androgens required for normal ovarian function are kept
within physiological ranges because overproduction of these steroids is strongly linked
with states of infertility arising from dysfunctional follicle development and multiple
disorders of health associated with polycystic ovarian disease. Because of this
association, part of the studies described in this thesis analysed the levels of androgens
and oestrogens in follicular fluids from normal and polycystic ovaries. The purpose of
this chapter is to review the relevant literature used to set the scene for the laboratory






















FIGURE 1.1. Structure of adult ovary. The follicle is the gametogenic and steroidogenic
engine of the adult ovary. The ovary contains stromal tissue in which the primordial follicles
containing the female eggs (oocytes) and glandular tissue (interstitial tissue), are embedded.
The primordial follicles develop in utero and begin to develop into primary and secondary
follicles, which only develop further after puberty into larger antral and then preovulatory
follicles containing mature oocytes. At ovulation, a developed egg (ovum) is released from
the preovulatory follicle (in monovulatory species) with a residual layer of granulosa cells
surrounding it (corona radiata). The collapsed follicle develops into a yellowish corpus
luteum, which is the steroid-producing tissue of the ensuing luteal stage of the ovarian cycle.
Regression of the corpus luteum leaves a whitish scar tissue, the corpus albicans, which is
absorbed into the stromal tissue of the ovary over a period that varies from weeks to months,
depending on the species. Adaptedfrom Byer/Shainberg/Galliano. Dimensions ofHuman Sexuality,
5e.1999. TheMcGraw-Hill Companies, Inc.
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1.2. OVARIAN FUNCTION
1.2.1. Ovarian Follicle Development
Fertility in the adult female is dependent on oocytes that develop in the ovaries
during fetal development in utero (Wassarman, 1988). Development of the oocytes halts
in utero (human, cow, sheep, goat, mouse) or ends just after birth (rat, pig, cat, rabbit,
hamster) (Johnson & Everitt, 1995). At this stage, the ovaries contain mainly primordial
follicles bearing oocytes in a state of meiotic arrest.
The somatic (granulosa and thecal) cells surrounding these oocytes subsequendy
undergo developmental changes that transform primordial follicles into primary,
secondary (preantral) stages, and then antral follicles, which require post-pubertal levels
of gonadotrophins for further development (Greenwald & Terranova, 1988; Johnson &
Everitt, 1995; McGee & Hsueh, 2000). The duration of these stages of development
differs among species, but the preantral stages are invariably longer than the antral
stages. The sequence through which a primordial follicle develops into a mature, fully
developed follicle that releases an oocyte ready for fertilisation, constitute the process
called folliculogenesis (Fig. 1.2).
In man, the entire process of folliculogenesis takes more than 6 months whereas
in rat, it is less than 2 months. In both species, it occurs throughout life until the stock
of oocytes is exhausted (Gougeon, 1982; McGee & Hsueh, 2000). The initial
recruitment of primordial follicles into a pool of growing follicles is a continuous
process that probably begins just after the formation of the follicles, long before puberty
(McGee & Hsueh, 2000). As some primordial follicles initiate growth, others remain
quiescent for months or years. While attempts are being made to elucidate why
primordial follicle development begins (Vendola et al., 1999b; Fortune et aL, 2000), the
trigger of this initial development is not known. However, it is now known that the
process is gonadotrophin-independent (Hillier, 1994a; McNatty et al., 1999), and
possibly due to intraovarian and/or other unknown factors. Recruited follicles that
reach the secondary or early antral phases before puberty become atretic. Therefore,
folliculogenesis only becomes a fully gonadotrophin-controlled process at puberty
(Baird, 1991).
3















I??? j >120 days | 71 days | 14 days>30 days I 28 days I 2-3 days
FIGURE 1.2. Stages and duration of folliculogenesis in human and rat ovaries.
Primordial follicles undergo initial recruitment to enter the growing pool of follicles which
develop into primary, secondary and then antral follicles. Further development of antral
follicle occurs after onset of puberty when gonadotrophins begin cyclic stimulation of small
antral follicles that grow into larger antral follicles from which one or a few follicles
(dependent on the species) are "selected" during dominance for further development into
Graafian (preovulatory) follicles from which mature ova are released at ovulation. The whole
process of folliculogenesis takes longer than 6 and 2 months in man and rat, respectively.
(Adaptedfrom McGee and Hsueh, 2000)
1.2.1.1. Preantral follicle development
During preantral growth, as the follicle increases in size, major growth occurs in
the oocyte, which reaches a final diameter of 60-120 pm (Johnson & Everitt, 1995). At
these stages, oocytes remain "meiotically arrested", but are metabolically active in
synthesis of ribonucleic acids (RNA) and proteins in preparation for subsequent post-
ovulatory developmental changes (Greenwald & Terranova, 1988; Johnson & Everitt,
1995). As the follicle develops, the oocyte forms a translucent acellular,
glycoproteinaceous layer around itself called the zona pellucida. The zona pellucida
separates and protects the oocyte from the layers of granulosa cells that develop around
it. Cytoplasmic processes penetrating through the zona pellucida from surrounding
granulosa cells allow communication between the oocyte and the proliferating granulosa
cells. As the oocyte grows in size, the granulosa cells proliferate and become multi-
layered. The preantral follicle also increases further in size due to the condensation of
ovarian stromal cells on the outside of the follicle. This enveloping matrix of spindle-
shaped cells gives rise to the thecal layer of the follicle. By undergoing further
development and proliferation, the thecal and granulosa cells grow as two distinct
follicular layers separated by a basement membrane. These two cell types are the
steroidogenic engines of the ovary (Fig. 1.3). The thecal layer develops further,
becoming richly interlaced with blood vessels while the granulosa layer remains
avascular. Further development of the granulosa cell layers results in the accumulation
of a thick viscous serum exudate known as follicular fluid. The coalescence of this
follicular fluid, comprised mainly of mucopolysaccharides secreted from granulosa cells,
creates an antrum that marks the beginning of the antral phase of follicular development
(Greenwald & Terranova, 1988; Johnson & Everitt, 1995). It is follicles at this stage









FIGURE 1.3. Early antral follicle. The granulosa and thecal cells are proliferated with
thecal cells now comprising of two layers, an outer fibrous externa and an inner theca
interna, rich in blood vessels. Coalescing follicular fluid drops are evident within the
granulosa cells. (Adaptedfrom Johnson & Everitt, 1995)
Although the preantral stages of follicular development are gonadotrophin-
independent, antrum formation is evidently initiated by FSH in vitro (Gutierrez et al.,
2000) and in vivo (Hillier et al., 1980c; Gougeon, 1982). This endocrine action is
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supplemented by ovarian paracrine factors, which in turn are regulated by FSH (Hillier,
1999;2001). Circulating levels of FSH required to begin antrum formation and recruit
preantral follicles into the small antral stages are adequate throughout childhood.
The onset of puberty, characterised by increased secretion of gonadotrophins by
the anterior pituitary gland, occurs when follicle development proceeds to the cyclic
preovulatory type of recruitment, which culminates in the release, at ovulation, of
meiotically developed mature oocytes capable of fertilisation.
1.2.1.2. Cyclic follicle development
The cyclic release of fully developed oocytes capable of fertilisation and the
follicular production of sex steroids that regulate female reproduction are the hallmarks
of the normal functioning adult ovary (Tsafriri et al, 1994; Johnson & Everitt, 1995).
The length of the ovarian cycle varies between species, taking about 28 and 4-5 days in
man and rodents, respectively, but the gonadotrophin-induced ovarian events are similar
as illustrated in Fig. 1.2. In man, the end of the ovarian cycle, as marked by the
regression of the corpus luteum, is followed by disintegration of the developed uterine
lining which is lost from the body during menstruation, and hence the ovarian cycle is






FIGURE 1.4. Summary of follicular activity in the menstrual cycle. On average, the
menstrual cycle takes 28 days. The pivotal position of ovulation separates the cycle into a first
half (follicular phase) which is essentially an oestrogen-secreting phase and a second half
(luteal phase) which is a progesterone-secreting phase. Functionally, the two phases are
responsible for follicle maturation, and regression of the corpus luteum, respectively.
Luteinising hormone (LH) is the endocrine trigger for ovulation. The relative blood
hormones levels are as indicated. (Adaptedfrom Johnson &Everitt, 1988)
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referred to as the oestrous cycle. The follicular phase of the ovarian cycle preceding
ovulation takes approximately 14 days and 2-3 days in man and rat, respectively
(Johnson & Everitt, 1995; McGee & Hsueh, 2000). A scheme showing the major
endocrine events associated with the human menstrual cycle is shown in Fig. 1.4. The
transformation of the immature (preantral/early antral) follicles into preovulatory
follicles is also associated with dramatic changes in the synthesis and metabolism of
androgens, which are the main focus of this thesis.
I. Preovulatory recruitment of antral follicles
Small increases in the levels of FSH mark the beginning of the ovarian cycle
(Baird, 1991; Hillier, 1991a), resulting in the recruitment of small antral follicles into
preovulatory stages of development. This advanced antral stage is predominantly a
phase of extensive growth which is mainly due to great increases in the size of the
follicular antrum (Fig. 1.5). Proliferation of granulosa and thecal cells, due to
gonadotrophic stimulation, also contributes to the preovulatory increase in follicle size
(Greenwald & Terranova, 1988). Generally, FSH is the gonadotrophin responsible for
initiation of development of the preantral follicles in most species (Hillier, 1991b;
Zelinski-Wooten et al., 1995; Gutierrez et al., 2000), but there are indications that LH
also probably has a role during this period to prime thecal cells in preantral follicles for
subsequent development-related responses (Wu et al., 2000).
Thecal and granulosa cells show differential responsiveness to FSH and LH as
die follicle matures. Throughout the follicle life-cycle, thecal cells possess receptors for
LH, and hence respond to LH stimulation. On die other hand, granulosa cells respond
to FSH because of their preferential expression of FSH receptors (Hillier et al,., 1994).
However, during advanced preovulatory development, granulosa cells also develop LH
receptors. Thus, whereas FSH generally induces the early stages of follicular
recruitment and growth-related changes within the ovary, LH is required to complete
them (Spears et al., 1998).
Within the cohort of growing preovulatory follicles, FSH increasingly induces
further granulosa cell proliferation and antrum expansion (Hillier, 1994a; b). This
mitogenic action is enhanced by locally produced oestrogens, particularly oestradiol, the
increased production ofwhich becomes the hallmark of the follicle destined to ovulate.
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FIGURE 1.5. Follicle development during follicular phase of the ovarian cycle. During
the ovarian cycle, transformation of preantral follicles into preovulatory follicles, which are
released at ovulation occurs through a series of developmental stages termed the follicular
phase of the ovarian cycle. Progression through the follicular phase is principally regulated by
gonadotropic signals, follicle stimulating hormone (FSH) and luteinising hormone (LH),
which recruit follicles for development and complete follicular maturation through selection
of usually one dominant follicle in monovulatory species, for example, humans and sheep.
(Adaptedfrom Hitter, 1994a)
Due to the specific response to gonadotropins exhibited by granulosa and thecal cells
at this stage, thecal cells respond to LH and synthesise androgens, which are converted
to oestrogens within the granulosa cells (Hillier, 1994a;b). By creating this local
positive-feedback loop, the thecal-granulosa co-operative action amplifies oestrogen
production, which enhances the FSH-induced stimulation of follicle proliferation. As a
result, the developing follicles are stimulated by both endocrine and paracrine signals,
which enhance follicle development.
The number of follicles selected for ovulation varies among species and is
species-specific (Baird, 1991). In multiovulatory species like rats and pigs, development
of several follicles occurs synchronously and as a result, multiple ovulation occurs. In
monovulatory species such as man, single follicles are usually selected for further
development while the others become atretic. Only the dominant follicle(s) selected
from among the recruited follicles grows further to ovulatory or near-ovulatory size.
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Selection and dominance are accompanied by further increases in the ability of thecal
cells to produce androgens and granulosa cells to aromatise them to oestradiol. Hence,
dominant follicles secrete steroids that ensure their continued development.
Locally, oestrogens are important for another crucial development in the
follicles. Together with FSH, oestrogens induce the expression of LH-receptors on the
outer layers of granulosa cells, which hitherto lacked them (Richards et al., 1987). This is
vital for the progression of the dominant follicle(s) into the final preovulatory stages of
development prior to ovulation (Figs 1.2 and 1.4). In the face of decreasing FSH
stimulation, the dominant follicles continue to develop because they have acquired the
capacity to respond to LH (Hsueh et al, 1984; Sullivan et al., 1999). The switch from
dependence on FSH to LH-responsiveness indicates that the dominant follicle(s) is
ready to enter the final preovulatory phase in preparation for ovulation.
II. Final development of preovulatory follicles
The preovulatory stage of follicle development is characterised by dependence
on LH and growth of the dominant follicle. Progression of the dominant follicle to
ovulation is dependent on a brief surge of very high levels of LH (see Fig. 1.4), which
provides the impetus that pushes the dominant follicle through the final stages of
growth before the expulsion of the oocyte from the follicle at ovulation. The follicle
structure breaks down and the pattern of steroid secretion also changes. The LH surge
is cmcial because absence of the transient LH peak results in the death of the expanded
follicle which manifests as a failure to release a developed ovum, a condition known as
anovulation.
The surge coincides with the expression of LH receptors on the outer granulosa
cells of the dominant follicle(s) such that, aromatase, the key enzyme in ovarian
endocrinology, becomes functionally coupled to LH at this stage (Adashi, 1994;
Zeleznik & Hillier, 1984; Richards, 1994). As a result, LH stimulates both androgen
synthesis and aromatisation in dominant follicles, thereby directly stimulating oestrogen
production. The dominant follicle produces more androgens than the non-dominant
follicles within its cohort due to its need for higher amounts of substrate for conversion
into oestrogens. The exposure to high LH levels is only beneficial to follicle growth at
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this stage of folliculogenesis because premature elevation of LH induces atresia or
impairs oocyte development in immature follicles (Chappel & Howies, 1991; Filicori,
1999).
The LH surge is also responsible for the endocrine changes that occur in the
follicle and continue after ovulation. At the time of the transient LH rise, the granulosa
layer has also undergone changes in its steroidogenic activity. Because they express LH
receptors at this stage (Hsueh et al., 1984; Hickey et al., 1990), granulosa cells, together
with the thecal cells, respond to LH during the LH surge and switch to synthesising
progesterone instead of aromatising androgens to oestrogens. The LH surge, which
initially stimulates thecal cell activity, subsequently stops the endocrine action of the
thecal cells. Therefore at this stage, LH is bifunctional in that in that it stimulates
steroidogenesis in the granulosa cells of the ruptured follicle, but inhibits further cell
proliferation (Hugues & Cedrin-Durnerin, 2000).
The structural changes that occur concurrently with the LH surge enhance the
steroidogenic function within the ovary. As the basement membrane breaks down and
blood vessels invade and infiltrate the disrupted granulosa cell layers (a process called
angiogenesis), acetate and cholesterol are carried into the granulosa-stromal-thecal
matrix which gives rise to the corpus luteum, the predominant structure in post-
ovulation ovaries (Johnson & Everitt, 1995). At this stage, the expression of FSH
receptors on granulosa cells is decreased. However, due to the expression of LH
receptors on luteinised granulosa cells of the corpus luteum, this stage is predominantly
a phase of LH-induced progesterone synthesis (Adashi, 1994; Tsafriri et al., 1994). In
some species like the rat and mouse, luteinised granulosa cells also acquire prolactin
receptors because prolactin is essential for the maintenance of the luteal phase in these
animals (Johnson & Everitt, 1995).
Subsequent developmental changes in ovarian follicles depend on whether or
not fertilisation takes place. In man, if fertilisation and implantation occur, the ovary
continues producing progesterone in response to stimulation by trophoblast-derived
choriogonadotrophic hormone, which is necessary for the maintenance of pregnancy.
In the absence of fertilisation, the luteal phase terminates, heralding a new ovarian cycle
(McGee & Hsueh, 2000). Therefore, oocyte development and steroidogenesis are
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coupled functions of the adult ovary. In some species like the rat and mouse, the length
of the cycle depends on whether or not the animal mates. In the absence of mating at
the time of ovulation, the luteal phase takes 2-3 days. It can be longer, 11-12 days
(pseudopregancy) if the female has an infertile mating.
It is also worthwhile noting that besides the regulatory interplay between the
steroidogenic cells, paracrine communication between the oocyte and granulosa cells is
crucial during folliculogenesis for the formation of the antrum, granulosa cell
steroidogenesis, and for the maturation of the oocyte (Reynaud et al., 2000). Other
endocrine factors also affect folliculogenesis. Growth hormone, produced in the
pituitary, acts direcdy on the ovary where it stimulates steroidogenesis in granulosa cells
in vivo or in vitro, thereby acting as a co-gonadotrophin (Franks, 1998). Kawagoe &
Hiroi (1990) showed that prolactin, another pituitary hormone modulates
steroidogenesis and follicle development of small follicles.
1.2.2. Ovarian Steroidogenesis
As described above, ovarian follicles respond to gonadotrophic stimuli and
concurrently produce increasing amounts of steroids while undergoing follicle
development. The antral stages of follicular development are by far the most important
source of ovarian steroids during the female cycle (Gore-Langton & Armstrong, 1988).
Steroids are lipids with structures based on the perhydrocyclopentane- phenanthrene
fused ring system (Lieberman et al., 1984; Strauss & Miller, 1991; Granner, 1996). In
mammals, most of the commonly occurring steroids are molecules containing between
18 and 27 carbon atoms, which are related to or derived from cholesterol. The
mammalian ovary produces all three major classes of steroids; oestrogens, progestagens
and androgens, which are products of the same biosynthetic pathway (Fig. 1.6; Hsueh et
al., 1984; Gore-Langton & Armstrong, 1988; Strauss & Miller, 1991). It is worth noting
that the preovulatory follicle is not an important source of circulating progestagens
because ovarian steroidogenesis at this stage is geared towards synthesising oestrogens
from androgenic precursors until ovulation occurs.
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FIGURE 1.6. Pathways of steroid synthesis. The major classes of ovarian steroids are
synthesised in the same pathway which originates from cholesterol. Progestogens (C21
steroids) are converted into androgens (CI 9 steroids) which are aromatised into oestrogens
(CI8 steroids). (Adaptedfrom Strauss &Hitter, 1991a)
1.2.2.1. Cellular sources of ovarian steroids
I. Thecal and interstitial cells
Thecal cells express enzymes that perform de novo synthesis of steroids
(oestrogens and androgens) from acetate and cholesterol, but the predominant
expression of the 17a-hydroxylase/C17,20 lyase enzyme complex, the rate-limiting
enzyme in the biosynthesis of androgens, encoded by the CYP17 gene (CYP17),
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essentially specifies thecal cells as androgen producers (Strauss & Miller, 1991; Adashi,
1994). The main androgens produced in the ovary are androstenedione and
testosterone. The expression of high density lipoprotein (HDL) receptors on drecal and
interstitial cells, while absent on granulosa cells, enables these cells to use circulating
cholesterol for steroid synthesis (Li et al., 1998).
It is now well known that LH is the endocrine signal that thecal cells respond to
for the production of androgens from the precursor substrates, acetate and cholesterol
during the antral phase of follicle growth (Hugues & Cedrin-Durnerin, 2000). Signalling
through LH receptors which are present constitutively on thecal cells, and mediated
through cyclic AMP (Bogovich & Richards, 1984; Hillier, 1985), LH stimulates
androgen secretion by upregulating 17a-hydroxylase/17,20 lyase (Bogovich & Richards,
1982; Johnson & Crane, 1995). The ability to metabolise cholesterol for steroid
production is related to stage of follicular development. Equine chorionic
gonadotrophs (eCG), which has FSH and LH bioactivity, increases the expression of
HDL receptors in thecal/interstitial cells indicating that gonadotrophins stimulate
cholesterol uptake by thecal/interstitial cells during the early stages of the follicular
phase. Increased cholesterol uptake provides the steroid precursor from which
androgens are synthesised via progestogens in thecal/interstitial cells, as indicated in Fig.
I.6. Only after expression of LH receptors on granulosa cells, later in the follicular
phase, do the granulosa cells also respond to LH and begin the cholesterol uptake as
shown by the presence of the HDL receptor mRNA in luteinised granulosa cells
(Johnson & Crane, 1995).
II. Granulosa Cells
Mature granulosa cells express several steroidogenic microsomal enzymes. The
major one is aromatase cytochrome P450 (P450arom), which is a product of the CYP19
gene (Richards, 1994; Simpson et al., 1994) that synthesises oestrogens (see Fig. 1.6).
Granulosa cells also express other enzymes that synthesise progestins, pregnenolone
and progesterone de novo from acetate and precursor steroids (Hsueh et al., 1984;
Richards, 1994). However, granulosa cells of all species studied, with the apparent
exception of the bovine (Lacroix et al., 1974) do not have significant 17a-
hydroxylase/17,20 lyase activity and as a result, synthesise little or no androgens from
either pregnenolone or progesterone (Gore-Langton & Armstrong, 1988).
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The main oestrogens produced in the ovary are oestradiol and oestrone, which
are produced by aromatisation of the androgens secreted by the thecal cells. Granulosa
cells secrete oestrogens in response to FSH, which acts through its receptors that are
constitutively present on the cells (Hillier, 1985; Adashi, 1994; Richards, 1994; McGee &
Hsueh, 2000). In some species such as pigs, chickens and tree shrews, oestrogens are
also synthesised by thecal cells (Rosenfeld et al, 2001). However, in most species, man
included, it is the transfer of androgens from theca and granulosa cells that is
responsible for the oestrogen in the follicular fluid and most of the oestrogen found
circulating in blood.
Another major steroid enzyme expressed by granulosa cells is 17(3-
hydroxysteroid dehydrogense type 1 (17(3-HSD1; (Makris & Ryan, 1980; Nimrod et al.,
1980; Moon & Duleba, 1982). Belonging to a class of enzymes with reversible
hydroxysteroid/dehydrogenase and ketosteroid/reductase (HSD/KSR) activities, 17(3-
HSD1 inter-converts 17-keto and 17-hydroxy steroids (see Fig. 1.6) (Penning, 1997;
Peltoketo et al., 1999). Both oestrogens and androgens have the highest affinity for their
receptors in the 17(3-hydroxy form. Therefore, testosterone and oestradiol are more
potent than androstenedione and oestrone, respectively. Hence, 17(3-HSD1 regulates
the biological activity of the sex hormones. Although androstenedione is the major
ovarian 17-keto androgen in most species, the ovarian 17(3-HSD isozyme, 17(3-HSD1
favours the production of oestradiol as the main ovarian oestrogen, thereby, making
ovarian 17J3-HSD1 essentially an enzyme for oestradiol production.
Thus, due to the enzymes expressed in the thecal and granulosa cells, various
steroids are secreted in the follicular fluid, but only the steroid class of main interest to
this thesis, androgens, is reviewed extensively here.
1.2.2.2. Ovarian androgens
Androgens are C19 compounds synthesised by the steroid biosynthetic pathway
shown in Figs. 1.6 and 1.7 (Gore-Langton & Armstrong, 1988; Strauss & Miller, 1991).
Ovarian androgens are synthesised from the C21 steroids by the afore-mentioned, rate-
limiting enzymes, 17a-hydroxylase/C17-20 lyase that are present in a single
steroidogenic cytochrome P450cl7 (P450cl7) encoded by the CYP17 gene (Fevold et
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al., 1989; Draincourt et al., 1993). In ovarian follicles, the CYP17 gene is expressed only
in thecal/interstitial cells (Smyth et al., 1993), which explains why ovarian androgens are
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FIGURE 1.7. Biosynthetic pathway of androgens. Dihydrotestosterone and
androstenedione are also metabolised to 5a-androstane-3P,17p-diol and epiandrosterone,
respectively by 3P-hydroxysteroid dehydrogenase. (Adaptedfrom Gore-Langton & Armstrong
1998).
The main C21 steroids available for the 17a-hydroxylase/C17-20 lyase reaction,
as shown in Fig. 1.6, are progesterone and pregnenolone. They are metabolised to
androstenedione, and dehydroepiandrosterone (DHEA), respectively, which are
consequently the major C19 steroids produced by the ovary. DHEA is a substrate for
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the enzyme 3|3-hydroxysteroid dehydrogenase (3(3-HSD) which catalyses the conversion
°f A5-3(3-hydroxy steroids into the corresponding A4-3(3-oxo steroids (Fig. 1.6). As a
result, androstenedione (androst-4-ene-3,17-dione), the major androgen secreted by the
human ovary (McNatty et al., 1979a) can be produced by both the A4 (progesterone —>
androstenedione) and A5 (pregnenolone —> DHEA —> androstenedione) routes of
biosynthesis (Miller, 1988). In the ovary, androstenedione is converted to testosterone
by 17(3-HSD1 (Andersson et al, 1995).
Other quantitatively minor androgens with indistinct biological roles are also
produced in the ovary. These are either precursor steroids in the androstenedione and
testosterone steroidogenic pathways, i.e., DHEA and androstenediol, respectively (Fig.
1.6), or the 5a-reduced metabolites of the two steroids i.e., 50C-androstanedione (5a-A)
and dihydrotestosterone (DHT), respectively (Fig. 1.7).
Besides the steroid-secretory roles of the thecal and granulosa cells,
"communication" between the two cell types is necessary for intraovarian regulation of
normal ovarian function mediated by both steroidal (Hillier, 1987; Ainsworth et al.,
1990; Conway et al., 1990; Fitzpatrick & Richards, 1991; Hillier, 2001) and non-steroidal
(Cara & Rosenfield, 1988; Adashi et al., 1991; Flillier & Miro, 1993; Wood et al., 1994;
Mason & Franks, 1997; Slee et al., 2001) factors. The intraovarian paracrine regulation
of ovarian function modulates gonadotrophin action, thereby increasing the sensitivity
of the developing follicles to FSH and LH.
Although this review focuses on androgen function within the ovary, steroids
are also important endocrine hormones. Steroids are carried by blood to peripheral
tissues, for example, breast, prostate, and uterine where they are metabolised by local
enzymes into bioactive steroid hormones (Labrie, 1991; 1995). By creating
tissue/cellular steroid-producing environments that are distinct from the main steroid-
producing organs, namely, the gonads and adrenals, the steroidogenic and steroid
metabolising enzymes generate intracrine hormone action where the locally produced
steroids are physiologically active. This intracrine production of steroid hormone
accounts for 75% of bioactive steroid in premenopausal women, approximately 100% in
postmenopausal women, and approximately 50% of androgens in men (Labrie, 1991;
16
Labrie et al., 2000b). Examples of enzymes involved in intractinology are 50C-R in skin
which converts testosterone to DHT that stimulates hair growth locally (Azziz et al.,
2000; Labrie et al., 2000a), and 17(3-HSDs which catalyse the last and key step in the
formation of all estrogens and androgens (Labrie et al., 2000b). Intracrinology is key to
understanding steroid biosynthesis and action in peripheral tissues. The remainder of
this review is limited to the paracrine role of intraovarian androgens.
1.3. PARACRINE ACTION OF ANDROGENS
Paracrine action takes place where cellular products are secreted and affect
neighbouring cells, the secretory cells themselves not being affected due to lack of
suitable receptors (Murray, 1996). Because the thecal and granulosa cells perform the
steroidogenic function of the ovary, the paracrine/autocrine regulations are "liaisons"
between the two cell types, as illustrated by Smyth et al., (1995). Paracrine action of
androgens on granulosa cells is exerted through androgen receptors that are located in
the nuclei of granulosa cells (Schreiber & Ross, 1976; Hillier & Tetsuka, 1997; Szoltys &
Slomczynska, 2000).
1.3.1. Paracrine Action ofAndrogens on Ovarian Follicle Development
In immature rats, LH-induced androgen action enhanced follicular atresia by
antagonising oestrogen-enhanced follicle development (Louvet et al., 1975; Ross, 1985).
Therefore, in immature rats, the paracrine action of androgens suppresses the FSH-
induced effects of oestrogen action. In addition, androgens decreased the number of
granulosa cells per follicle in vivo, of eCG-stimulated rats (Conway et al., 1990). The
involvement of the androgen receptor in these androgenic effects was illustrated in
granulosa cells where DHT down-regulated the expression of androgen receptor mRNA
expression in immature granulosa cells via a mechanism that was reversible by FSH
(Tetsuka & Hillier, 1996). Therefore, in immature rats, the androgen-induced inhibitory
effects on follicle growth are mediated through the androgen receptor, which is also
regulated paracrinally by androgens as shown by their down-regulation of androgen
receptor mRNA and protein (Tetsuka et al., 1995; Hillier et al., 1997).
It is important to point out that intraovarian paracrine androgen action is not
limited to granulosa and thecal cells. Androgens also affect ovarian stromal tissue
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because they induce thecal hyperplasia and capsular thickness in immature follicles, in
the short term (Vendola et al, 1998). This stimulatory role is supported by clinical
evidence where androgen-producing tumours, congenital adrenal hyperplasia (an
androgen-secreting condition) and exogenous androgen treatment are associated with
the development of hypertrophic polycystic ovary (PCO) phenotypes. The
mechanism(s) whereby androgens stimulate ovarian growth are still unclear. Some of
the intermediary factors thought to be involved are members of the IGF family, IGF-1
in murines (Adashi, 1998), and IGF-II in man (Bondy et al, 1993) and pigs (Zhou et al,
1996). By stimulating the production of these IGFs (Vendola et al, 1999a; Vendola et
al, 1999b), which are known to enhance oestrogen production (Wood et al., 1994) and
follicle development (Yong et al, 1992), androgens probably modulate follicle growth
indirectly.
Androgens, therefore, decrease follicle growth and development by inhibiting
FSFI-mediated action on granulosa cells, but stimulate hypertrophy of stromal tissue.
1.3.2. Paracrine Action ofAndrogens on Ovarian Steroidogenesis
Due to the critical role of steroids in reproduction, it is not surprising that there
are multiple regulatory systems available to modulate their production and release.
Although aromatisable androgens induce atresia in the absence of FSH, they augment
gonadotrophin-stimulated steroidogenesis in its presence (Hsueh et al, 1984; Conway &
Mills, 1991). For example, testosterone increased oestradiol synthesis in vitro by a
synergistic interaction with FSH (Hillier & De Zwart, 1981). Therefore, androgens
enhance FSH-stimulated aromatase activity not only by acting as substrates for
oestrogen production, but also by exerting direct paracrine effects which up-regulate the
activity of this steroidogenic enzyme. It is thought that the mechanism of androgenic
paracrine action is mediated via cyclic AMP, the formation of which is stimulated by
androgens in the presence of FSH (Knecht et al, 1984; Hillier & Tetsuka, 1997).
Androgens, therefore, enhance granulosa cell production of cAMP via which FSH
actions are mediated.
Intracellular cAMP is the major second messenger that mediates FSH action in
granulosa cells (Hillier & Tetsuka, 1997). By inducing post-receptor signalling within
the cells, cAMP provides the link between the extracellular FSFI signal and the
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intracellular responses. Although androgens do not stimulate cAMP formation in the
absence of FSH, in its presence, androgens are stimulatory (Hillier & Tetsuka, 1997).
Aromatisable androgens are more potent paracrine steroids than non-
aromatisable androgens (Daniel & Armstrong, 1983). Both types of androgens also
exhibit different paracrine action on aromatase activity. While the major aromatisable
androgens, testosterone and androstenedione enhanced oestradiol production, the non-
aromatisable androgen, DHT suppressed oestradiol production by inhibiting FSFI-
induced expression of LH receptors on granulosa cells (Farookhi, 1980), thereby
illustrating that DHT inhibits the production of oestrogens from preovulatory follicles.
On the other hand, both aromatisable and non-aromatisable androgens
stimulated progesterone production from developed follicles in intact animals (Lucky et
al., 1977). Similar action has been shown in vitro where androgens acted synergistically
with FSH to stimulate progesterone production in granulosa cells (Armstrong &
Dorrington, 1976; Nimrod, 1981). Therefore, androgens stimulate the side chain
cleavage enzymes of cytochrome P450 and enhance the formation of the precursor
substrates (progestins), from which they are formed.
The androgenic paracrine role changes during follicle development. In vitro
studies using primate granulosa cells showed that the androgenic effect on FSPI-induced
ovarian function changed from being stimulatory to inhibitory as the pre-ovulatory
development progressed (Harlow et al., 1986; Harlow et al., 1988). Hence, androgens
seem to have bimodal paracrine functions during follicular development. Similar
findings in the rat where the androgen receptor was also down regulated (Szoltys &
Slomczynska, 2000) suggest that the mechanism of androgenic paracrine action involves
androgen-induced down-regulation of the expression of the androgen receptor.
Since follicular fluid contains 5a-reduced androgens, it is likely that some of the
androgenic antagonistic effects are executed through the actions of DHT, androsterone
and 5a-A. McNatty et al. (1979b) showed that there were high levels of DHT in
human ovaries. In fact, studies of the regulation of follicular maturation and the
subsequent aromatisation of androgens in human (Hillier et al, 1980b) and rat ovaries
(Hillier et al., 1980a) showed that 5a-reduced androgens inhibited granulosa cell
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aromatase activity in vitro. DHT reduced granulosa cell FSH-induced aromatisation of
testosterone. Further evidence in the rat showed that naturally occurring
5a-androstane-3a, 17(3-diol and 5a—androstane-3(3,17(3—diol inhibited FSFI-stimulated
secretion of oestradiol by granulosa cells even in the presence of exogenous
testosterone, the precursor steroid from which oestradiol is metabolised (Ebong &
Peddie, 1990). The evidence suggests that 5a—reduced androgens reduce oestrogen
production by down-regulating aromatase activity.
5a-reduced androgens showed differences in their abilities to inhibit aromatase
activity. Whereas 5a—A greatly inhibits aromatisation of its precursor, androstenedione,
DHT does not similarly affect testosterone (Agarwal et al., 1996). Of the reduced
metabolites studied, 5a—A showed the greatest inhibition of oestradiol production
(Ebong & Peddie, 1990; Agarwal et al, 1996; Hutchison et al., 1996). This steroid may,
therefore, have an important intraovarian role in regulating follicle development due to
direct inhibition of oestradiol secretion in maturing antral follicles.
Therefore, the paracrine role of ovarian androgens in regulating follicular
development is dependent on the stage of follicular development. Generally,
aromatisable androgens exert antagonistic actions on ovarian follicular development in
preantral and early antral follicles, presumably to inhibit premature secretion of
oestrogens. They switch to a facilitatory role on maturing follicles that have developed
to the large antral stages of development, which require more substrates from which
oestrogens are synthesised. However, the facilitation is transitory because the
androgenic effect becomes inhibitory as pre-ovulatory development progresses (as
discussed above). The dual role ensures that androgens contribute to the maintenance
of immature small follicles at preantral stages until such a time when the ovary has
attained reproductive maturity. Only then can follicles respond properly to the various
stimuli among which the androgens contribute to the facilitatory mechanisms, which
ensure that only mature follicles are prepared for ovulation.
The main role of the ovarian paracrine action is to regulate the balance between
androgen output and conversion to oestrogens, so avoiding the premature secretion of
excess androgens, which can impair follicle development.
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1.4. OVARIAN METABOLISM OF ANDROGENS
In the ovary, androgens are principally present as intermediates in steroidogenic
pathways, the main one being the synthesis of oestrogens (Hsueh et al, 1984; Adashi,
1994). Minor pathways involve 5(X-reduction of androgens whose physiological roles
are addressed later.
1.4.1. Aromatisation ofAndrogens
Androstenedione and testosterone are the main androgens in ovarian follicular
fluid (McNatty et al, 1979b). Androstenedione and to a much lesser extent testosterone,
are synthesised by ovarian follicles throughout their most active phase of antral growth.
They are aromatisable androgens and largely present as intermediates in the oestrogen
biosynthetic pathway of the ovary (Hillier, 1981). This aromatisation reaction has been
demonstrated in vitro in granulosa cells (Hillier et al, 1980a; Wood et al, 1994), whole
follicles (Smyth et al, 1994) and also in vivo (Amri et al, 1993). Androstenedione and
testosterone are aromatised into oestrone and oestradiol, respectively (Figs. 1.6 and 1.7).
The ovarian aromatisation of androgens is a developmentally regulated process (Hsueh
et al, 1984; Tsafriri et al., 1994).
1.4.2. 5a-Reductive Metabolism ofAndrogens
Androgens bearing a 4-ene-3-oxo-structure (like similar progestins) are
metabolised by steroid 5a-Rl into 5a-reduced steroids (Gore-Langton & Armstrong,
1988: p337; Russell & Wilson, 1994). Some of the 5a-reduced androgens that have been
identified in various species are 5a-dihydrotestosterone (DHT), 5a-androstanedione
(5a-A), androsterone and epiandrosterone (Smith et al, 1974; Gore-Langton &
Armstrong, 1988). The presence of 5a-androgens in follicular fluid (Khalil & Lawson,
1983; Dehennin et al, 1987; Haning et al, 1991; Anderson et al, 1992; Jakimiuk et al,
1999) indicates an alternative metabolic pathway (see Fig. 1.7) for androgens in the
ovary. Therefore, 5a-androgens are evidently produced in the ovary, but the function
of 5a-R is still unclear and has been addressed separately below.
1.5. 5a-REDUCTASE
To date, the expression of 5a-R in the ovary is indicated by the metabolism of
5a-reduced androgens (as explained above) and other 5a-reduced steroids (Karakawa et
al, 1976; Inaba et al, 1978; McNatty et al, 1979b) in follicular fluid. 5a-R is a class of
21
microsomal enzymes that catalyse the saturation of the C-4,5 double bond of the A-ring
of steroids Fig. 1.8; (Russell & Wilson, 1994). The biochemical step is stereospecific
and requires NADPH which direcdy transfers a hydride ion to the carbon-5 position of
the steroid (Abul-Hajj, 1972; Wang et al., 1999). The enzymes are hydrophobic proteins
and hence, extremely insoluble.
o o
FIGURE 1.8. 5a-reductase reaction. Conversion of the double bond between
carbons 4 and 5 of ring A of the steroid molecule is an NADPH-dependent reaction.
The enzyme exists in different species; including fish (Schlinger et al., 1989),
rodents (Normington & Russell, 1992; Russell & Wilson, 1994), and man (Russell &
Wilson, 1994; Haning et al., 1996). It also exits mainly as 2 isozymes, namely 5a-R type
1 and type 2, i.e., 5a-Rl and 5a-R2, respectively (Russell & Wilson, 1994). The amino
acid sequences show that the type 2 isozymes of different species are more closely
related to each other than to the type 1 isozymes. In fact, both isozymes are actually
two different proteins encoded by the two different genes (Normington & Russell,
1992). As a result, the biochemical characteristics of the two types are distinguishable
and can be used to identify them. For example, the type 1 isomers have neutral to basic
pH optima while the type 2 isomers have acidic pH optima. The isozymes are also
pharmacologically different, and are expressed differentially in reproductive and
peripheral tissues (Russell & Wilson, 1994). The two isozymes have been described in
the reproductive tissues of the human male (Andersson et al., 1991) and female (Haning
et al., 1996), and also in the rat (Normington & Russell, 1992). The protein and gene
structures of the rat and human forms also indicate that they are true homologues
(Andersson & Russell, 1990; Russell et al., 1994; Russell & Wilson, 1994) making the rat
enzyme a good model for use in investigations aimed at studying the function and
control of the human enzyme. Both the rat and human enzymes reduce steroids with
the 3-oxo-A4'5 structure, such as progesterone, testosterone and androstenedione, and
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have been shown to have preference of progesterone as substrate (Andersson & Russell,
1990).
1.5.1. Tissue Expression of 5a-Reductase
5(X-reductase type 1 is present in various tissues; skin (Harris et al, 1992), brain
(Yokoi et al, 1998), liver (Berman & Russell, 1993), and urogenital system (Berman et al.,
1995). Its expression is also present in utero (Berman et al., 1995), where it is thought to
control the formation of genitalia. Because 5CC-R is essential in male sexual
differentiation, its expression in tissues has mostly been studied in relation to male
physiology (Andersson & Russell, 1990; Habib et al., 1998; Wright et al, 1999;
Soderstrom et al., 2001), and its role in females, particularly, reproduction, is only
emerging. The enzyme has very low levels of expression, even in androgen-responsive
tissues, which has made its investigation difficult. In addition, its expression in female
reproductive tissues such as the human ovary, is still controversial. While Haning et al.,
(1996) identified only 5CX-R1 isozyme in the human ovary, Jakimiuk et al, (1999) reported
the expression of both 5CC-R1 and 5CC-R2 isozymes in the human ovary. The ovarian
cellular expression of 5(X-R1 is yet to be specified because studies of the enzyme's
activity suggest that it is located in both steroidogenic cell types of the ovary (Aono et
al., 1981; Payne et al, 1992), and yet its activity is stimulated by LH in immature ovaries
(Fukuda et al., 1979), which suggests specific thecal expression.
1.5.2. Regulation of 50C-Reductase Activity
Introductory studies on the activity of 5CC-R showed that it was controlled by
LH (Fukuda et al., 1979; Aono et al., 1981), progestins (Eckstein et al., 1970; Lerner &
Eckstein, 1976; Payne et al., 1992), as well as androgens (Smith et al., 1974; Andersson &
Russell, 1990). While the activity of the enzyme is higher in ovaries of immature rats
compared to adults (Karakawa et al., 1976), the intraovarian roles in either stage of
development are still to be identified. Evidence in brain tissue suggests that 5CC-
reductase activity begins during neonatal life and decreases with age and sexual
maturation (Lephart & Ojeda, 1990). Although it is unclear whether a similar ontogeny
is present in the ovary, some evidence suggests such a gonadal role whilst still in utero
(Schindler, 1976).
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In spite of the meagre information about the role of 5(X-R in female
reproduction, particularly in relation to the production of 5CC-reduced androgens, it is
clear that these steroids are inhibitors of oestrogen production as explained in section
1.5.3. It is possible that the elevated levels of 5(X-reduced androgens in PCOS
exacerbate the arrested follicle development characteristic of polycystic ovaries as
postulated by Jakimiuk et al, (1999).
1.5.3. Physiological Role of 5a-reduced Androgens
Although 5(X-reduced androgens have been identified as a major component in
follicular fluid, studies of their roles in female physiology are still largely inconclusive.
Specifically, there is not much information about the role of 5a-reduced androgens in
ovarian function. However, it has been shown that 5a-reductive metabolism is an age-
related biosynthetic step. Immature rat ovaries secreted large amounts of
5a-androstane-3a,17P-diol unlike adult rats (Eckstein et al., 1970; Karakawa et al.,
1976). It has been suggested that 5a-reduced androgens have an important role in
controlling the onset of puberty (Ebong & Peddie, 1990). However, other work failed
to support the relationship between 50C-reduced androgen production and puberty
(Ojeda et al., 1984).
The role(s) of 5(X-reduced androgens in female reproduction is/are difficult to
compare with earlier studies which mostly focussed on male fertility where they are
crucial for development of secondary sexual characteristics (Booth, 1977; Andersson et
al., 1991; O'Donnell et al., 1996). It is clear though that until puberty, the major
metabolites of progesterone in immature female rats, unlike the adults were 5a-reduced
progestins (Eckstein et al., 1970; Lerner & Eckstein, 1976) and 5a-reduced androgens
(Eckstein et al., 1970; Karakawa et al., 1976). Thus, the steroidogenic activity of the
immature rat gonad is considerably different from that of the adult. Specifically, the
steroidogenic pathways in ovaries of immature rats lead to the formation of 5a-
androstane-3a,17|3-diol via 5a-reduced progestins while the pathways in adult ovaries
form oestrogens via the A4-steroids.
5a-reduced androgens cannot be aromatised and, therefore, do not have a
substantive role in oestrogen synthesis. In addition, naturally occurring 5a-reduced
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androgens, DHT and 5CC-A, competitively inhibited granulosa cell aromatase action in
vitro (Hillier et al, 1980a) suggesting an intraovarian mechanism for inhibition of
oestrogen synthesis. It has also been demonstrated that they inhibit gonadotrophin
secretion in rats (Zanisi et al, 1973). It is possible that the role of these androgens is to
suppress development-related production of oestrogen in immature animals because
lack of oestrogen contributes to the non-developmental state of prepubertal follicles.
Interestingly, 5a-androstanediol, a metabolite that is produced in immature rats causes
vaginal opening in rats (Eckstein et al, 1970) suggesting as yet unclarified roles of 50C-
reduced androgens in female physiology.
Thus, 50C-reduced androgens act at the hypothalamic and ovarian levels as part
of the mechanisms that inhibit oestrogen production. Although not clear, the role of
5(X-reduced androgens is probably related to the inhibition of oestrogens in immature
animals that have not yet attained puberty. In doing so, these androgens probably
contribute to the intraovarian environment, which ensure that primordial follicle
development does not start until such a time when adult changes in the ovary ensure
that oestrogen production will be in synchrony with follicle development and support
normal pre-ovulatory development that can result in reproduction.
1.6. POLYCYSTIC OVARY SYNDROME
Polycystic ovarian syndrome (PCOS) is a very common endocrine disorder in
women, ranging 10-20% in different populations and is the major cause of anovulatory
infertility (Franks, 1997; Knochenhauer et al, 1998; Rodin et al, 1998; Franks et al,
1999a; Dunaif & Thomas, 2001). It is a classic example of the consequences of
dysfunctional follicle development and steroid biosynthesis. However, the condition
has a very broad spectrum of clinical and biochemical presentations, which confound
studies of its aetiology. Clinically, the women present with hirsutism, oligomenorrhea,
chronic anovulation, and hence infertility, obesity and morphological changes of the
ovaries. The biochemical abnormalities are elevated testosterone, androstenedione, LH,
oestrone, oestradiol levels, increased LH:FSH ratio, hyperinsulinism and reduced
concentration of sex hormone binding globulin (SHBG) (Speroff et al, 1983; Conway et
al., 1989; Franks, 1989; Rebar, 1995; Dewailly, 1997).
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Generally, diagnosis of PCOS is made when the typical ultrasound features of
polycystic ovaries are present with oligo/amenorrhoea and/or clinical symptoms of
hyperandrogenism such as hirsutism or acne without specific underlying diseases of the
adrenal or pituitary glands, (Homburg, 1996). Polycystic ovary diagnosis is based on the
presence of more than 8 discrete follicles of less than 10 mm diameter (cysts) in the
ovary, usually peripherally arrayed around an enlarged, central stroma which occupies
more than 25% of the ovarian volume (Homburg, 1996; Dunaif & Thomas, 2001). The
ovaries are usually, but not always enlarged. In fact, the clinical picture of women with
PCOS does not seem to vary with change in ovarian size and so, there is seemingly no
basis for classification of polycystic ovaries into those of normal or greater than normal
size (Goldzieher & Young, 1992).
Although the morphological identification of polycystic ovaries by ultrasound is
the basis of PCOS diagnoses, but by itself, is not definitive of the syndrome because
polycystic ovaries are found in normal women (Poison et al., 1988; Clayton et al., 1992;
Farquhar et al., 1994; Knochenhauer et al, 1998; Koivunen et al., 1999) and in other
endocrine disorders such as adrenal 21-hydroxylase deficiency (Abdel Gadir et al.,
1992a). Therefore, the presence of polycystic ovaries must be supplemented with an
endocrine biochemical disorder to diagnose PCOS (Swanson et al., 1981; Poison et al.,
1988; Franks, 1989; Abdel Gadir et al., 1992b). Generally, PCOS is a syndrome that is
clinically associated with hyperandrogenism, anovulation and metabolic disorders.
1.6.1. Follicle Development in PCOS
The cause of the abnormal follicle development in women with PCOS is still
unknown. The characteristic "cysts" are not atrophic, apoptotic or fibroid tissue, but
follicles whose development was held-in-check when they had attained a size of 6-8mm
in diameter (Fauser, 1994; Takayama et al., 1996). They are still steroidogenically robust
and can undergo further growth and development when supplied with adequate
endocrine stimulation (Takayama et al, 1996; Anderson et al., 1997).
It was also shown that the anomaly in PCOS does not seem to result from
abnormalities in the hormone primarily responsible for follicle growth, i.e., FSH.
Circulating immunoreactive FSH levels (Van Dessel et al., 1995) as well as bioactive
FSH serum levels (Fauser et al., 1991) and follicular fluid levels (Erickson et al., 1992) in
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anovulatory women with PCOS are within normal preovulatory range. In addition, the
granulosa cells from polycystic ovaries showed normal or even elevated FSH-induced
aromatase activity in vitro (Speroff et al., 1983). Since FSH stimulation and granulosa
aromatase activity per se seemed to be within normal limits, the arrested follicle growth
observed in PCOS is probably due to altered intra-ovarian regulation of FSH-induced
actions. It is possible that locally produced ovarian factors such as cytokines (Homburg
& Amsterdam, 1998), cyclic AMP (Franks et al., 1998) or steroids (Mason & Franks,
1997) are involved in the atypical follicle development.
As in normal follicles, developmental progress to the size of follicles noticed in
polycystic ovaries occurs without an associated increase in oestrogen biosynthesis
(Hillier, 1994a), but further development of the follicles that is "arrested" in these
ovaries. The cause of this "arrest" is still controversial. Various hypotheses have
.suggested hypothalamic-pituitary origins (Weisz & Lloyd, 1965), intraovarian origins
(Gilling-Smith et al., 1997; Dewailly, 1999; Rosenfield, 1999; Franks et al., 2000), genetic
factors (Franks et al., 1999b), altered insulin metabolism (Panidis et al., 1997; Dewailly,
1999), and nutritional and environmental factors (Crosignani & Nicolosi, 2001) as the
cause of PCOS. The causal debate of PCOS still continues and it is more likely that the
syndrome arises as a result of a combination of some of these factors. Whatever the
cause of PCOS, the major consequence of the altered ovarian function is the creation of
an intraovarian environment that is inhibitory to further follicle development, the result
being the formation of increased numbers of pre-antral follicles (cysts) and stromal
hyperplasia, the two main morphological features of polycystic ovaries.
As already mentioned, abnormal endocrine profiles are also a feature of PCOS.
The syndrome is associated with disorders of gonadotrophs secretion, acyclic
oestrogen production, hyperandrogenism and hyperinsulinaemia (Marshall, 2001).
There is no single biochemical marker of PCOS. Confounding still, hyperandrogenism
together with insulin resistance are common features of other aetiologies other than
PCOS (Goldzieher & Young, 1992). However, elevated levels of serum androgens are a
consistent symptom in all women with the syndrome's typical ovarian morphology
(Rodin et al., 1994; Rebar, 1995; Homburg, 1996).
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1.6.2. Hyperandrogenaemia in PCOS
The characteristic steroidogenic abnormality of PCOS is increased androgen
production (Speroff et al., 1983; Franks & White, 1993; Rodin et al., 1994). In particular,
elevated testosterone and androstenedione concentrations are the most common
abnormal hormonal features of the syndrome (Conway et al., 1989; Franks, 1989).
However, there is controversy over the source of the excess androgen secretion.
Evidence that both androgen-producing organs, the ovaries and adrenals (Fruzetti et al.,
1995; Rosenfield, 1999; Dunaif & Thomas, 2001) contribute to the hyperandrogenemia,
lies alongside that which argues for (Rodin et al, 1994; Azziz et al., 1998; Moran &
Azziz, 2001) and against (Wajchenberg et al, 1986) an adrenal contribution. Direct
measurements of androgens in blood samples from left adrenal and left ovarian veins
suggested that the ovary is the predominant source of the excess androgen observed in
PCOS (Wajchenberg et al., 1986).
Functional ovarian hyperandrogenism is found in 70% of women with PCOS
(Franks & White, 1993; Rosenfield, 1999). The thecal -interstitial compartment, due to
exaggerated enzyme(s) activity produces excess steroids, particularly androgens.
Immunohistochemical studies of polycystic ovaries showed that the small follicles (< 7
mm in diameter) had increased expression of P45017OC lyase (Tamura et al, 1993)
indicating that the hyperandrogenemia in PCOS was definitely related to upregulation of
the androgen-synthesising enzymes. The dysregulation of P450cl7OC within ovarian
thecal cells, either by excessive stimulation by LH or by escape from desensitization to
LH was indicated as a cause of the hyperandrogenemia (Rosenfield et al., 1990). The
excessively increased enzyme action in PCOS, also reported by others (Qin &
Rosenfield, 1998) was thought to result from an intrinsic intraovarian flaw in the
paracrine feedback mechanism by which thecal androgen biosynthesis is inhibited.
Investigations using activity assays indicated specifically that thecal cells from
PCOS follicles secreted increased amounts of androstenedione, and 17-
hydroxyprogesterone, an intermediate steroid between the androgen and glucocorticoid
biosynthetic pathways (Fig. 1.6; Gilling-Smith et al., 1994). The increased conversion of
progesterone to androstenedione in the thecal of polycystic ovaries was independent of
the ovulatory status. The ovarian follicles from women with PCOS were also seen to
have small numbers of granulosa cells and hardly expressed aromatase (Tamura et al.,
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1993). Therefore, whether due to increased androgen production and/or decreased
androgen metabolism, hyperandrogenemia in PCOS is basically a condition resulting
from dysfunctional ovarian steroidogenesis.
There is also a correlation between increased stromal size and overproduction of
thecal -derived steroids, particularly, androstenedione (Kyei-Mensah et al., 1998). In
light of this and the increased expression of the enzyme, 5C6-R in polycystic ovaries
(Jakimiuk et al., 1999), it is plausible that androstenedione is metabolised to 5a-A, and
that the androgenic effects in PCOS are partly enhanced by the formation of 506-
reduced androgens. Measurements of 5C6-androstandiol glucuronide, a metabolite
showing 5a-R activity in peripheral tissues, indicated that serum concentrations of the
enzyme were higher in women with PCOS than among normal controls (Franks, 1989)
suggesting increased activity of the enzyme in women with PCOS. In fact, 506-A was
shown to be greatly increased in follicular fluid from polycystic ovaries compared to
normal follicular fluid (Agarwal et al, 1996). Being a competitive inhibitor of aromatase
(Hillier et al., 1980a), 506-A is probably one of the ovarian steroids that modulate ovarian
processes locally. It is thought that the increased levels of 5C6-A in polycystic ovaries, by
decreasing aromatase activity, result in decreased oestradiol production, which in turn
hinders further growth and development of the ovarian follicles (Agarwal et al., 1996).
This mechanism suggested an intraovarian system in PCOS that acted on itself to
amplify the formation of polycystic ovaries. Undoubtedly, the lack of adequate levels of
oestrogen in polycystic ovaries contributes to maintain the antral follicles in the arrested
state since dominance is dependent on a surge in ovarian oestrogen production.
High levels of androgens become a problem when they are available to tissues as
biologically active steroids. The physiological effects of androgens are controlled by
their availability, which is partly dependent on the proteins that transport them around
the body. Androgens are mainly carried in blood bound to SHBG, and some are carried
by albumin. Androgens carried by SHBG are unavailable for bio-action, but albumin-
bound steroids are readily available. The latter and "free" androgen (unbound to
SHBG) are responsible for the androgenic physiological responses. Androgenic effects
can also be enhanced by further metabolism into more potent forms, for example,
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5CC reduced androgens that are generally more potent than aromatisable androgens in
target tissues.
1.6.3. 5a-Reductase in PCOS
Although the role(s) of 50C-reduced androgens are still unclear in the female, 5a-
R is evidently up-regulated in PCOS as shown by the increased ovarian 5a—R activity
(Jakimruk et aL, 1999), and a high ratio of 5a— to 5(j-cortisol metabolites in the urine of
women with PCOS (Stewart et al., 1990). Women with polycystic ovaries also had
increased peripheral conversion of testosterone and androstenedione to the more potent
5a-reduced forms (Franks, 1989). Earlier work by Forleo et al. (1971) showed that
stromal tissue and the "cysts" in wedge resections of ovarian tissue from polycystic
ovaries had 5 a—R activity, and could metabolise 5a—A and androsterone in vitro.
Clearly, 5a-R activity is elevated and functional in PCOS where its metabolites probably
aggravate the abnormal follicle development and steroidogenic patterns which are
potential causes of infertility.
1.7. SUMMARY OF THESIS OBJECTIVES:
To investigate further the role of 5a-reduced androgens in the paracrine control
of ovarian function, the use of an animal model was adopted complementing
observations on human ovaries. The aims were (1) to establish the extent to which
individual cell types in the rat ovary metabolise androgens to 5a-reduced androgens and
oestrogens, respectively, (2) to study the location and developmental regulation of 5a-
R1 gene expression in the rat ovary, and (3) also to obtain evidence for increased




Immature and mature female rats of the Wistar strain were obtained from
Charles Rivers (Margate, Kent, UK) and housed in a temperature and light-controlled
room. All animals used in experimental procedures were killed by carbon dioxide
asphyxiation.
Antisera
50C-Reductase-1 antibody used in immunocytochemical studies was donated by
Dr. Gerhard Aumuller, (Department of Anatomy and Cell Biology, Philipps-University
Marburg, Germany). Antiserum used in tire 17KA RIA was rabbit anti-androsterone-3-
hemisuccinyl-BSA. Major crossreactivities were: 5oc—androstane-3,17-dione, 100%;
androstenedione, 70%; androsterone, 63.6%; and less than 0.5% for all other steroids
tested. Androstenedione RIA used rabbit anti-androst-4-ene-3,17-dione-7a-
carboxyethyl thioether conjugated to BSA. Major crossreactivities were:
androstenedione, 100%; androsterone, 46.3%; 5a-androstene-3,17-dione, 50%;
testosterone, 37%; and less than 0.5% for all other steroids tested. Oestradiol RIAs
were performed using rabbit anti-oestradiol-6-(0-carboxymethyl)-oximino-BSA serum
with crossreactivities: 17(3-oestradiol, 100%; oestrone, 2.3% and less than 0.1% for all
other steroids tested.
Chromatography sheets
20 x 20 cm aluminium oxide- and silica-coated TLC sheets with and without
UV254 detection were obtained from CamLab Ltd., Cambridge, UK.
Enzymes
All restriction endonucleases and DNA modifying enzymes were obtained from
Promega Corporation, Southampton, UK.
Fixatives
Bouins fixative was obtained from Triangle Biomedical Sciences (Skernersdale,
UK) and normal buffered formaldehyde (NBF) was prepared with reagents obtained
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from BDH, Lutterworth, Leicester, UK: 100 ml 40% formaldehyde v/v, 4g sodium
dihydrogen phosphate monohydrate and 6.5g disodium hydrogen phosphate anhydrous
dissolved in 1 L distilled water.
Follicular fluids
Follicular fluids from normal women and women with PCOS were obtained
from follicles at different stages of development as described by Mason et al., (1994).
Samples were donated by Professor Steve Franks (Department of Reproductive Science
and Medicine, Imperial College School ofMedicine, London, UK).
Gene Cloning
Gene cloning reagents were obtained from Stratagene, Cambridge, UK. Unless
stated otherwise, plasmid DNA purification systems were obtained from Qiagen Ltd.,
(UK). Gene sequencing was performed with ABI Prism™ BigDye™ Terminator Cycle
Sequencing Ready Reaction Kit obtained from PE Applied Biosystems, Warrington,
Cheshire, UK.
Histology
All the reagents used for in situ hybridisation (ISH) were obtained from
Sigma/Aldrich Ltd. (Poole, Dorset, England) unless mentioned otherwise.
Hormones
Equine CG (2000 IU eCG/mg) and hCG (14,000 IU LH/mg) were obtained
from Sigma/Aldrich Ltd. Working concentrations were 100 IU/ml PBS (tissue culture
grade). Recombinant human FSH (3860 IU FSH/mg) and recombinant human LH
(17,500 LH IU/mg) were donated by Dr. Howies (Serono Laboratories, Inc., Welwyn
Garden City, UK). Concentrations of stock solutions were 10 ng/ml in PBS.
Nucleic acid markers
1 Kb DNA ladder (Cat. No. 15615-016) was obtained from GibcoBRL, Life
Technologies Ltd., Paisley, UK.
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Nucleic acid probes
Complementary RNA probes were synthesised with MAXIscript™ in vitro
transcription kit (Ambion, Cat. No. 1324) or Strip-EZ RNA™ StripAble™ RNA probe
synthesis and removal kit (Ambion, Cat. No. 1368) obtained from A.M.S. (UIC)
Biotechnology, Abingdon, Oxon, UK. Complementary DNA probes were synthesised
with Rediprime™II random prime labelling system (Amersham Pharmacia Biotech,
Little Chalfont, Buckinghamshire, UK). The synthesised probes were purified with
MicroSpin™ G-50 columns (Amersham Pharmacia Biotech, Cat. No. 27-5330).
Oligonucleotides
5CC-R1 and aromatase primer oligonucleotides were obtained from Cruachem
Ltd., Glasgow, UK.
RNA analyses
Unless stated otherwise, reagents, buffers, enzymes used for RNA analyses were
obtained from A.M.S. (UK) Biotechnology. RNAzol B was bought from Tel-Test, Inc.
(Friendswood, USA). Hybond-N nylon hybridisation transfer membrane was supplied
by Amersham Pharmacia Biotech (Cat. No. RPN 203 N) was used for RNA blotting.
Solvents
HPLC grade ethanol and diethyl ether were obtained from BDH. All other
reagents, unless mentioned otherwise were obtained from Sigma/Aldrich Ltd.
Steroids
All the non-radiolabelled steroids were obtained from Sigma/Aldrich Ltd. The
steroids were stored as stock solutions of 1 mg/ml in ethanol at 4°C. With the
exception of tritiated androsterone, all the radioactive steroids were purchased from
Amersham Pharmacia Biotech. Tritiated androsterone was purcahsed from NEN1M
Life Science, Hounslow, UK. The radiolabelled steroids were stored as stock dilutions
(1:10) in 100% HPLC grade ethanol at 4°C. Radiolabelled nucleotides were obtained
from Amersham Pharmacia Biotech and stored at -70°C. The specific activities of the
radiolabelled compounds are listed in Table 2.1.
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TABLE 2.1. Radiolabeled steroids























toluene 3.18 TBq/ mmol
86.0 Ci/mmol
Molecular Biology Reagents
p5S]UTP aqueous solution >1000 Ci/mmol
20 mCi/ml
[a-32P]UTP aqueous solution 800Ci/mmol
20 mCi/ml
Redivue [a-32P]CTP aqueous solution ~3000 Ci/mmol
10 mCi/ml
Tissue culture
Antibiotics, enzymes and buffer constituents used in tissue culture studies were obtained
from Sigma/Aldrich Ltd., (Dorset, England).
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Chapter 3. Gonadotrophic regulation of ovarian androgen
metabolism
3.1. INTRODUCTION
Androgen metabolism, as explained in Chapter 1, is central to ovarian
steroidogenesis and follicle growth during the antral stages of follicle development that
culminate in ovulation. Androstenedione, the principal aromatisable androgen in
human and rat ovaries (among other species) for oestrogen synthesis (Gore-Langton &
Armstrong, 1988), was used as the androgenic substrate in this study's investigation of
androgen metabolism in the ovary. In addition, the implication that
hyperandrogenaemia of PCOS was partly due to androstenedione metabolism via its
50C-reduced metabolite, 50C—A, made androstenedione the androgen of choice when
investigating androgen metabolism in the ovary. The presence and metabolism of high
levels of androstenedione in rat follicular fluid indicate that androstenedione
metabolism is a normal physiological process in rat ovary (Karakawa et al., 1976; Fujii et
ai, 1983; Anderson et al., 1992), thereby making the rat an ideal animal model for
studying androstenedione metabolism.
In normal pre-ovulatory follicles, androstenedione is mainly metabolised to
oestradiol via two principal pathways. It is converted to either oestrone or testosterone
by the enzymes aromatase and 17(5 HSD, respectively (see Chapter 1, Fig. 1.2). An
alternative minor metabolic pathway catalysed by the steroidogenic enzyme, 5a-R
converts androstenedione to 5a-A. Steroid 50C-R, a membrane bound enzyme, converts
3-oxo-A4'5 unsaturated steroids into 5a-reduced metabolites with altered endocrine
potential (Russell &Wilson, 1994).
The roles of gonadotrophins, FSH and LH in regulating aromatisable ovarian
androgen synthesis, which precedes oestrogen production, are well documented. In
essence, LH selectively stimulates androgen production (Erickson et al., 1985) while
FSH stimulates the bio-conversion of androgens to oestrogens (Hillier, 1985). However,
the roles of gonadotrophins in the synthesis/metabolism of 50C-reduced androgens are
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less clearly defined. Inconclusive studies of the gonadotrophic effects on the
production of 5(X-reduced androgens have led to uncertainties over their roles
(Armstrong & Papkoff, 1976; Karakawa et al., 1976) in relation to disease processes
(Agarwal et al., 1996; Jakimiuk et al., 1999), and in normal adult ovarian cycles (Lephart et
al., 1992). Studies of 5(7.-11 and gene expression are also incomplete (Jakimiuk et al,
1999).
To investigate the role of gonadotrophins in the biosynthesis of 50C-reduced
androgens, the production of 50C-reduced androgens from androstenedione metabolism
was investigated under conditions that reflected pre-ovulatory follicular development
(see Chapter 1). Using in vivo and in vitro experimental strategies, androstenedione
metabolism was investigated in conditions that favoured or inhibited oestrogen
production. Since the ovary is enzymically designed to synthesise oestrogens from
androgens (Hillier, 1985; Richards, 1994), blocking oestrogen production should steer
the steroidogenic ability to alternative pathways such as the 50C-reductive pathway
because the androstenedione substrate is not then converted into oestrogens. Inhibition
of oestrogen production was effected by Arimidex (Anastrozole), a highly potent and
selective non-steroidal inhibitor of aromatase, which has no detectable pharmacologic
activity aside from aromatase inhibition (Plourde et al., 1994; Dukes et al., 1996). Of
particular interest to this study, Arimidex has no discernible effects on other steroid
biosyntheses, making it an ideal compound to inhibit aromatase specifically.
Follicular development was induced in immature female rats in vivo by equine
chorionic gonadotrophin (eCG) and human chorionic gonadotrophin (hCG). In all the
studies, 21 day old rats were used for the treatments because at this age, ovulation has
not begun, but their ovaries are morphologically and histochemically well developed
(Kaczkowska & Liebhart, 1984). Equine CG, although a composite gonadotrophin in
the mare, acts principally as an FSH in many other species including rats (Hoppen,
1994) and was therefore used to induce follicle growth. Human CG, bearing LH
activity was used to induce ovulatory changes. This chapter describes a study designed
to determine the androgen metabolic profile during eCG and hCG stimulated ovarian
developments, using granulosa and thecal/interstitial cell culture systems. Most





Intact immature female rats were injected once subcutaneously (s.c) with 10 IU
eCG followed 48 h later by a single injection of hCG (s.c), and the removal of ovaries
12 h or 24 h later. Control animals received no hormonal treatment. Sham-treated
controls were not used since pilot experiments showed no non-specific response at the
ovarian level. The outline of the treatment protocol is illustrated in Fig. 3.1. All the
animals were killed by carbon dioxide asphyxiation on the same day after completion of
the hormonal treatments.
• treatment #Control
$ c i1 ^ eCG-treatment only (48 h)
$ cCG 0 ^ hCG^ + hCG 12 h
f eCG ++ hCG j~rfZ + hCG 24 h
* ,
START END
FIGURE 3.1. Outline of hormonal treatment regimen administered to induce
preovulatory follicle growth. Treatments were started on different days so that all the
tissues could be harvested on the same day.
3.2.2. Isolation ofGranulosa Cells
Ovaries were harvested and immediately placed in medium Ml99 (Ml99)
supplemented with L-glutamine (2 mM), penicillin (100 units/ml) and streptomycin
(100 (Xg/ml). Using stereomicroscopic visualisation, fat surrounding the ovary and
associated structures such as attached oviducts were removed. The ovaries were then
transferred into fresh culture medium, for isolation of granulosa cells. Viewed by the
stereomicroscope, all visible follicles were punctured using a 27G hypodermic syringe
needle to release granulosa cells. The cell clumps were then combined in fresh Ml 99
and resuspended by gentle, repeated pipetting. The suspension was transferred to a 12
ml conical centrifuge tube and gravity sedimented for 5 min so that cellular debris could
settle at the bottom of the tube. Granulosa cells remaining suspended in medium were
pipetted into a fresh centrifuge tube in which they were centrifuged at 200 g for 10 min.
The cell pellet was gently re-suspended in 10 ml fresh Ml 99 and aliquots of this cell
suspension were used to set up granulosa cell cultures, after determination of viable cell
number.
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Cell counts were performed using a haematocytometer. An aliquot of 20 jll of
the cell suspension was mixed with an equal volume of 0.4% trypan blue dye, which
stains dead cells blue because the ruptured cell membranes allow the dye to penetrate
the cytoplasm while viable cells appear colourless. After counting the numbers of dead
and viable cells, cell counts were corrected for the various factors to obtain total and
viable cell numbers. Cell viability estimated this way was typically 20% (n—4).
3.2.3 Isolation and Culture ofThecal/Interstitial Cells.
Thecal/interstitial cells were harvested from residual ovary after removal of
granulosa cells as explained above. Residual ovarian tissue was rinsed in Ml 99 and re-
suspended in 5 ml fresh Ml 99 containing 0.1% (w/v) collagenase CI. histolyticum type II
and 0.01% DNase for enzymic digestion at 37°C for 30 min in a shaking waterbath.
Complete dispersal into a single-cell suspension was achieved by repeatedly pipetting the
digest at the end of the incubation. The cells were then collected by centrifugation at
800 g for 5 min and resuspended in 2 ml fresh Ml99. At this stage, the
thecall/interstitial cell preparations were contaminated with granulosa cells, which were
removed by discontinuous density centrifugation (Magoffin & Erickson, 1988). The
thecal/interstitial cell fraction was purified by separating the cell mixture through a
centrifugation ladder created by layering two Percoll solutions of different specific
gravities prepared in Ml99 (Fig. 3.2). Two ml of a Percoll solution of specific gravity
1.055 were layered on top of 1 ml of 44% Percoll solution. The suspension of dispersed
thecall/interstitial cells was carefully layered on top of the d=1.055 Percoll layer. The
tubes were then centrifuged at 400 g for 20 min, by which time the cell types were
separated as in Fig. 3.2. Thecal/interstitial cells were removed by aspiration from the
d=1.055 layer, washed in 5ml fresh M199 and centrifuged at 800 g for 5 min. After
removal of the wash supernatant, the cell pellet was resuspended in 2 ml fresh medium
containing 5.0% donor calf serum. An aliquot of 20 |ll of the suspension was used to
determine the viable cell count. Cell viability, determined by staining with trypan blue
was consistently greater then 90%.
3.2.4. Whole Ovaries
Whole ovaries from immature rats were put on dry ice immediately after
removal and stored at -70°C until use. (5a-reductase activity is stable for at least 3









Vo = volume of Percoll (ml)
do = specific gravity of Percoll (1.130 g/ml)
dx = specific gravity ofM199 (1.058 g/ml)
V = volume required for final working solution (ml)
d — specific gravity required for final working solution (g/ml)
FIGURE 3.2. Purification of ovarian thecall/interstitial cells by discontinuous
Percoll centrifugation. Dispersed residual ovarian tissue was centrifuged though a Percoll
gradient (A). Percoll solutions of specific gravity d= 1.055 were obtained using indicated
formula (B).
3.2.5. Cell Cultures for Studies ofAndrostenedione Metabolism
3.2.5.1. Cell cultures of in vivo gonadotrophin-stimulated ovaries
Granulosa and thecal/interstitial cells from ovaries of rats stimulated in vivo as
described in section 3.2.1 were used to set up cell cultures as follows.
B. Formula
Vo = V
d - O.ldx - 0.9
do -1
I. Granulosa cell cultures
Except as noted, replicate 250 jil aliquots of Ml99 containing 1 x 104 viable
granulosa cells were pipetted into 24-well (16mm) polystyrene culture dishes that had
been pre-coated with donor calf serum (DCS) for 24 h (Hillier and de Zwart, 1982).
The incubate was adjusted to a final volume of 500 p.1 by addition of 200 |il non¬
radioactive androstenedione (final concentration 1.8 |XM), and 50 |Ull Arimidex (6.1 (XM)
in culture medium. 'Blank' medium replaced Arimidex solution in cultures lacking the
aromatase inhibitor. Parallel cultures containing a trace amount of 5 |Xl tritiated
androstenedione (1 x 105 cpm; final specific activity- 9.2 x 10 7 pCi/mmol), were set up
to study the formation of 3H-labelled androstenedione metabolites. The cell cultures
were incubated for 24 h at 37°C in a humidified atmosphere of 5% (v/v) C02in air. At
the end of the incubation, the culture medium was aspirated and pooled into 12 x 75
polystyrene test tubes, which were stored at -20°C until analysis. Thawed 0.5 ml
39
aliquots of culture medium were extracted with 4.0 ml diethyl ether for analysis of
steroid metabolism by RIA or radiochromatography as described below.
II. Thecal cell cultures
Replicate thecal/interstitial cell cultures were set up at a cell density of 0.5 - 2 x
10 cells per 500 pi M199 and incubated under similar conditions to granulosa cells in
the presence of [ Hjandrostenedione (~3.1 x 10"4 nmols; final specific activity- 9.2 x 107
pCi/mmol).
3.2.5.2. Cell cultures of thecal/interstitial cells stimulated in vitro
To study gonadotrophin action in vitro, thecal/interstitial cells from untreated
immature ovaries, were incubated in triplicate in 12-well (32 mm) DCS-coated
polystyrene tissue culture dishes at a cell density of 1 x 105 viable cells per 1.0 ml Ml 99
containing androstenedione (30 |lM), in the absence or presence of LH (3 ng/ml). The
cultures were incubated at 37°C in a humidified atmosphere of 5% (v/v) C02in air for
24-96 h. At the end of the culture period, medium was collected and stored at -20°C
until analysis by RIA. The cell monolayers were washed with fresh serum-free medium
followed by the addition of fresh Ml99 containing 3H-labelled steroid substrate (1 x 105
dpm; 9.2 x 10"7 pCi/mmol) for 24 h. The medium was then collected and stored at -
20 °C until analysis by radiochromatography.
3.2.6. 5(X-Reductase Assay
Except as noted, whole ovaries (~2 mg wet weight whole ovary per ml) or
viable thecal/interstitial cells (1 x 105 per ml) from immature rats were homogenised in
assay buffer on ice using a manual glass/glass (Wheaton, USA) homogeniser. The assay
buffer contained 50 mM potassium phosphate, 1 mM EDTA, 2 mM MgCl2,1 mM
dithiothreitol and 0.25 M sucrose at pH 7.4. Various tritiated steroid substrates (1 x 10"
dpm), added together with corresponding non-radiolabelled steroids to give the required
specific activity, were added to the tissue homogenates. The reactions were started by
adding NADPH to a final concentration of 1 mM in a total reaction volume of 1 ml.
Following incubation at 37°C for 0.5 to 2 h in a shaking waterbath, the reactions were
stopped by transferring the tubes to a -20°C refrigerator where they were stored. The
steroid metabolites were extracted with 4.0 ml diethyl ether and detected by
radiochromatography.
40
3.2.7. Ether Extraction of Steroids
Incubation medium (0.5 ml from cell cultures) or reaction buffer (1.0 ml from
5(X-reductase assay) was transferred to 16 x 100 mm glass test tubes to which 4.0 ml
diethyl ether was added. The tubes were mixed vigorously on a multi-rack electric mixer
(S/P Multitube vortexer, Baxter Scientific) at high speed (speed number 5) for 1 min
and left to stand until separation of the aqueous and organic phases. The upper organic
phase, containing steroids was decanted into fresh tubes after snap freezing the contents
of the extraction tubes on a mixture of solid CO 2 pellets in alcohol. The organic phase
was then evaporated at 55°C under a stream of N2 gas. The dry residues were then
available for analysis by radiochromatography.
3.2.8. Analysis of Androstenedione Metabolites
3.2.8.1 Thin-layer radiochromatography of androstenedione metabolites
Dry steroid residues recovered by ether extraction were redissolved in 3 drops
of acetone for separation by TLC. Using a 10 JLtl pipette, each steroid solution was
"spotted" at a pre-marked position on the origin of a demarcated 20 x 20cm Polygram
aluminium oxide (alumina)-pre-coated TLC sheet containing UV254 detection
(Macherey-Nagel, Germany; Fig. 3.3) with evaporation under a stream of hot air. The
dissolution in acetone and spotting were repeated to ensure thorough transfer of all
extracted steroids onto the TLC sheets. Loaded TLC sheets were developed twice with
cyclohexane:toluene: ethanol (100:95:5 v/v/v) as solvent system in pre-saturated 27.0 x






Migration distance = 16.5 cm
(direction of beta scanner)
■Origin
FIGURE 3.3. TLC sheet. The sheets were demarcated into lanes for easy spotting of
sample and identification of spots of separated steroids. Loading was done in spots less than
3 mm in diameter to ensure narrower peaks and more distinct separation of steroids.
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developed TLC sheets were air-dried, and the tritiated metabolites located using a beta
emission scanner (Bioscan System 200 Imaging Scanner-IBM, Bioscan, INC.,
Washington). The radioactivity of the tritiated metabolites was also determined as cpm
counts by the scanner. The positions of the non-radiolabelled steroids on the
developed TLC sheets were identified using fluorescence or iodine vapours.
Illuminating the sheets with 254 nm ultraviolet light made the A4-3-ketosteroids visible
and iodine vapour was used to visualise the 50C-reduced forms i.e., 50C-A and DHT that
stained as dark spots. The Rf value of each steroid was recorded.
3.2.8.2. Oestradiol radioimmunoassay of androstenedione metabolites
Oestradiol was measured in non-extracted culture medium as described (Hillier
& De Zwart, 1981). The inter-assay coefficients of variation for the 'low" (50 pg/100
JLll) and "high" (100 pg/100 pi) quality control solutions were 17.0% and 18.2%,
respectively. The intra-assay coefficient of variation was 8% for both solutions.
3.2.9. Data Analysis
The results of the oestradiol RIAs were calculated using AssayZap Universal
Assay Calculator (Biosoft Ltd., Cambridge, UK). The steroid levels of the experimental
treatments were analysed by one way ANOVA and student's t-test after statistical
computation with Microsoft Excel computer software. Graphical presentation was
done using Cricket Graph computer software (Cricket Software, Malvern, PA, USA).
3.3. RESULTS
3.3.1. Evidence for Androgen Aromatisation by Granulosa Cells
To study aromatisation of androstenedione by granulosa cells, metabolism of
[3H]androstenedione and unlabelled androstenedione were studied by radio¬
chromatography and specific RIA, respectively.
3.3.1.1. Radiochromatography
I. Validation ofTLC system
Alumina pre-coated sheets were used initially for the separation of
androstenedione metabolites by TLC because they achieved distinct separation of
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androstenedione from 5cc-A, androsterone, and DHT, the main 5a-reduced metaboHtes
of androstenedione as shown by the developments of authentic steroid solutions by
TLC (Fig.3.4; Table 3.1). Distinct separation of oestradiol was also achieved, but DHT









FIGURE 3.4. TLC separation of ovarian steroids on alumina pre-coated sheets.
Solutions of authentic non-radiolabelled steroids were separated by TLC on alumina pre-
coated sheets by development in a solvent system of cyclohexane:toluene:ethanol (100:95:5,









TABLE 3.1. Steroid Rf values after TLC on alumina pre-coated sheets. The mobility
of each steroid relative to the solvent front (Rf value) was computed after two developments
on alumina sheets in the solvent system, cyclohexane:toluene:ethanol (100:95:5, v/v/v).
Distance from the origin to the solvent front — 16.5 cm.
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II. Effect of in vivo gonadotropin treatment on aromatisation of
androstenedione
Metabolism of [ H]androstenedione occurred in immature and eCG-stimulated
granulosa cells, as shown in Fig. 3.5. Testosterone was produced as the major steroid
metabolite indicating a predominance of 17(3-hydroxysteroid dehydrogenase type 1
(17(3 HSD1) activity in rat granulosa cells. Oestradiol biosynthesis occurred as one of
the minor metabolic processes, thereby indicating aromatase action. The oestrogens
peaks were reduced -30-40% by Arimidex (Fig. 3.5 F and H). The other minor
metabolites indicated as peak 1 and peak 2 could not be identified. It is worth noting
that 50C-androstanedione was not synthesised by the granulosa cells as a product of
androstenedione metabolism. Therefore, inhibition of oestrogen biosynthesis did not
potentiate the alternative 5a-reductive pathway (Fig. 3.6. F and H).
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FIGURE 3.5 Granulosa cell production of steroid metabolites from 1.8|XM
androstenedione. Steroids were extracted from 0.5 ml granulosa cell culture medium
obtained from pooled 24 h incubations of 6 replicate cultures set up with
[3H]androstenedione (A4, 1 x 105 dpm; specific activity 9.2 x 10-7 pCi/mmol) and 1.8 pM
non-radiolabelled androstenedione. Separation of the steroids by TLC on alumina pre-coated
sheets showed that metabolism of androstenedione occurred in rat granulosa cell cultures
soon after addition of substrate (Time Oh cultures, A-D) and after incubation for 24 h (E-H).
The cell cultures contained granulosa cells from unstimulated, control ovaries in the absence
(A & E) and presence (B and F) of Arimidex, and granulosa cells from eCG-stimulated
ovaries in the absence (C & G) and presence (D & H) of Arimidex. The identified steroid
metabolites were testosterone (T) and oestradiol (E2). (*) represents the oestradiol peak.
Peaks 1 and 2 are unidentified steroid metabolites. 5a-androstanedione (5a-A) steroid
metabolite was absent from the expected position. Replicate experiments (n=3) gave similar
results.
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Oestradiol, as a percentage of total androstenedione metabolites increased
10 /o when the androstenedione substrate concentration was reduced to the nanomolar
range (18 nM), which has been indicated to maximise aromatase activity (Brandt et al,
1990) (Fig. 3.6.). At this concentration, oestradiol production accounted for —20% of
the steroids synthesised from androstenedione, compared with 10% at the higher, albeit
physiological, 1.8 fXM androstenedione concentration. Consistent with the metabolism
of the higher concentration of androstenedione substrate, enzymic conversion of
androstenedione was greater in eCG-stimulated granulosa cells (Fig. 3.6C and D) than
the controls (Fig. 3.6A and B) as shown by further reduction (-50%) of the
androstenedione peak in the eCG-treated panels. Arrmidex reduced oestradiol synthesis
(Fig. 3.6B and D). However, testosterone was not singly dominant as the main steroidal
product at this substrate concentration. Oestradiol and peak 1 were major metabolites
of both immature and eCG-stimulated granulosa cells. While peak 2 was also a major
metabolite in immature granulosa cells, little was produced in eCG-stimulated granulosa
Thus, oestradiol biosynthesis, as result of androstenedione metabolism by granulosa
cells was demonstrated in vitro, but conversion of androstenedione to 50C-A was not
evident in these experiments.
FIGURE 3.6. Granulosa cell production of steroid metabolites from a reduced
(18nM) androstenedione substrate concentration. After 24 hour cell cultures, steroid
biosyntheses in pooled culture medium of immature (control) and eCG-treated granulosa cell
cultures containing [3H]androstenedione (A4; 1 x 10* dpm; 9.2 x 10-7 pCi/mmol) and 18 nM
non-radiolabelled androstenedione substrate were demonstrated after TLC on alumina
sheets. Oestradiol (E2) biosynthesis (*) was illustrated in the absence (A and C) and
presence (B and D) of Arimidex in the cell cultures. Testosterone (T) and the unidentified





Oestradiol biosynthesis, as a product of non-radiolabelled androstenedione
metabolism (at a substrate concentration of 1.8 pM), was significant in the 24-h
incubations of granulosa cells from immature, unstimulated ovaries (controls; P <
0.001) and eCG-stimulated ovaries (P < 0.001) as shown in Fig. 3.7. However,
oestradiol biosynthesis was significantly greater in granulosa cells from eCG-stimulated
ovaries compared to the control ovaries whether at time 0 h (P< 0.0001) or 24 h (P <
0.001) in the absence of Arimidex. Arimidex significantly reduced oestradiol
biosynthesis in the 24-h cultures of granulosa cells from both control (P < 0.001) and
eCG-stimulated (P < 0.001) ovaries.
*
I 1
Time Oh Time 24 h
FIGURE 3.7. Oestrogen biosynthesis by granulosa cells. Oestradiol, produced as a
product of androstenedione (1.8 pM) metabolism in non-incubated (time Oh) and 24-h
incubations (24 h) of granulosa cells, was measured in duplicate by specific RIA on pooled
culture medium of immature, unstimulated (control) and eCG-stimulated granulosa cell
cultures containing (hatched bars) and lacking (solid bars) Arimidex. Each bar represents
mean oestradiol production in 3 replicate experiments. Asterisks denote significant
differences between the group means indicated (*P< 0.001; **P< 0.0001). (ANOVA:
F=82.1, P< 0.0001).
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3.3.2. Evidence for Androgen 5a-Reduction by Granulosa Cells
To study 5a-reduction of androgens by ovarian cells, metabolism of
[ HJandrostanedione was studied by radiochromatography using a modified TLC
system, designed to resolve multiple 5cx-reduced androgen metabolites.
3.3.2.1. Validity ofTLC system
Silica pre-coated sheets developed with dichloromethane:ethyl acetate:95%
ethanol (100:95:5, v/v/ v) were used for the subsequent separations of the steroid
metabolites because in studies of aromatisation, it was noted that alumina pre-coated
sheets were problematic in the complete separation of [3H]androstenedione metabolites
(Figs. 3.5 and 3.6). 5a-A was separated distinctly from androstenedione and its
hydroxylated form, 5-androstene-3|3,17|3-diol (A-diol), and other 5a-reduced androgens,
androsterone, DHT, 5a-androstane-3a,17(3-diol and 5a-androstane-3|3,17|3-diol, as
shown by the developments of authentic steroid solutions by TLC (Fig.3.8; Table 3.2).
Separation of testosterone was also achieved. However, DHT and androsterone were
incompletely separated, and 5a-androstane-3a,17(Tdiol and 5a-androstane-3("),17(Tdiol
















FIGURE 3.8. TLC separation of ovarian steroids on silica pre-coated sheets.
Solutions of authentic non-radiolabelled steroids were separated by TLC on silica pre-coated
sheets by development in a solvent system of dichloromethane:ethyl acetate:95% ethanol
(100:95:5, v/v/ v). Repeated separations gave similar results.














TABLE 3.2. Steroid Rf values after TLC on silica pre-coated sheets. The mobility of
each steroid relative to the solvent front (Rf value) was computed after two developments on
silica pre-coated sheets, in the solvent system of dichloromethane:ethyl acetate:95% ethanol
(100:95:5, v/v/ v). (Distance from the origin to the solvent front = 16.5 cm).
3.3.2.2. Effect of in vivo gonadotrophin treatment on 5a-reduction of
androstenedione
Since ovarian 5 CC-reductase expression was previously shown to be
developmentally regulated, at least in adult rat ovary (Lephart et al., 1992), granulosa cells
from ovaries induced to attain follicular development by treatment with eCG (see
"Experimental Procedures", 3.2.1) were used to investigate 50C-reduction in vitro,
comparing metabolism of androstenedione and testosterone as substrates.
5CC-A was not synthesised from either androstenedione (Fig. 3.9A) or
testosterone (Fig. 3.9B). Nor was testosterone converted to DHT, whereas oestradiol
synthesis clearly occurred (Fig. 3.9B). Therefore, once again, 5a-reduction could not be
demonstrated in granulosa cells. Flowever, the formation of testosterone as the
principal androstenedione metabolite in stimulated ovaries again indicated 17-oxo-
reduction by 17J3-HSD1 as the predominant route of androgen metabolism by
granulosa cells of preovulatory follicles (Fig. 3.9A). Although, 5a-reduction could not
be demonstrated in granulosa cell cultures, the concentration of non-radiolabelled
androstenedione substrate used (1.8 |4M) was within the Km range (1-5 pM) of 50C-
reductase for steroid substrates reported in other studies (Russell and Wilson, 1994).
To check the influence of substrate concentration on 5a-R activity in granulosa
cells, androstenedione at concentrations of 0.03, 0.3, 3.0, 30 or 300 pM was incubated
for 24 h with a constant number (1 x 105) of viable granulosa cells from unstimulated
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control ovaries, but 5a-A could not be identified as a steroid metabolite. In fact, the 30















FIGURE 3.9. Androgen metabolism by granulosa cells at different stages of
follicular development. Granulosa cells isolated from ovaries stimulated in vivo (see
"Experimental Procedures, 3.2.1) were incubated for 24 h with either 1.8 |0.M
androstenedione (A) or 1 pM testosterone (T) as substrate. Conversion of the steroid
substrates (i) into respective 5a-reduced steroid metabolites (v), 5a-androstanedione (5aA)
and dihydrotestosterone (DHT) was investigated in control (ii), eCG-stimulated (48-h
treatment) (iii), and eCG followed by 12-h treatment with hCG (iv). Separation of the
steroids was done on silica pre-coated sheets developed with dichloromethane:ethyl
acetate:95% ethanol (100:95:5, v/v/ v). Peaks 1,2 and 3 are unidentified steroids, but peak 3 is
a composite peak made up of oestradiol and other unidentified steroids.
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3.3.3. EVIDENCE FOR 5a-REDUCTlON INWHOLE OVARY
Despite the inability to demonstrate 50C-reduction in isolated granulosa cells,
homogenates of whole ovary clearly possessed this enzymic activity. Androsterone, as
shown by radiochromatography, was the main product of androstenedione metabolism
in immature rat ovary, thereby indicating 5CC-R activity (Fig.3.10). Although,
homogenates of whole ovary, unlike the granulosa cells, metabolised androstenedione
substrate concentrations of 30 (iM, the 50C-reductive conversion of androstenedione
was greater at 3 p.M substrate concentration, which approximates the Km of the rat





















FIGURE 3.10. Identification of steroid products of androstenedione metabolism by
whole ovarian homogenates. Homogenates representing 2 mg immature ovary were
incubated (see Experimental Procedures, 3.2.6) with [3H]androstenedione (1 x 105 dpm) and
either (B) 3.0 pM or (C) 30 pM non-radiolabelled androstenedione substrate. Identification
of androsterone (Ao), the main metabolic product in immature rat ovary was achieved by
developing extracts of the homogenates alongside the authentic tritiated steroids, oestradiol
(E2), testosterone (T), dihydrotestosterone (DHT) and androstenedione (A4) on silica pre-
coated TLC sheets. 5a'-androstanedione (5a-A) was among the expected metabolites.
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By adapting a method designed to investigate 50C-R1 activity in vitro (Terakawa et
al1978), 5a R1 activity was clearly demonstrated in whole ovary homogenates
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FIGURE 3.11. 5a-reductase activity assay in whole ovary at different stages of
development. Adapting the method used by Terakawa et al. (1978), homogenates of whole
ovaries collected from rats stimulated as indicated ovaries were incubated for 30 minutes with
~1 x 105 dpm counts of [3H]androstenedione (A) or [3H]testosterone (B) as substrate.
Conversion of steroid substrates (i) into 5a-reduced steroid metabolites (vi) was investigated
in control (ii), eCG-stimulated (48-hour treatment) (iii), eCG followed by 12-hour treatment
of hCG (iv) and eCG followed by 24-hour treatment of hCG (v). Separation of the steroid
metabolites was done on silica procoated sheets. Veak, 1 is an unidentified steroid. Peuk, 2 is a
composite peak made up'of ogsttadiolpandrosterone and other unidentified steroids.
peak 2 of ovaries from immature, untreated rats (Fig. 3.11Aii) was androsterone as
shown in Fig. 3.10. Production of androsterone-containing peak 2 was decreased ~40%
(compared to control value) by eCG (Fig. 3.11A iii), but was increased by hCG (Figs.
3.11A iv and v) indicating the inhibitory and stimulatory effects of eCG and hCG,
respectively, on the action of 50C-R1. However, consistent with metabolic studies of
granulosa cells, the main enzyme activity in rat ovary stimulated by gonadotrophins was
again shown to be 17(3-HSD1, as shown by the production of testosterone as the
principal metabolite of eCG- and hCG-treated ovaries (Fig. 3.11 iii and iv). Similarly,
too, 5a-A was not shown as a major metabolite of androstenedione (Fig. 3.11A) or
testosterone (Fig. 3.1 IB), even though oestradiol was clearly synthesised in stimulated
ovaries (Fig. 3.11B iii-v). Nor was testosterone converted to DHT.
Therefore, although whole ovaries of immature rats had 5(X-reductive activity, it
was essentially absent from the granulosal cell compartment.
3.3.4. Evidence for 5a-Reduction in Thecall/Interstitial Cells
The inability to identify 5a-reductase activity in isolated granulosa cells when it
was clearly present in whole ovarian homogenates suggested that the activity might
reside in another ovarian cellular component. However, thecal/interstitial cells whether
freshly isolated or LH-treated in vitro, failed to demonstrate 5CC-reductive activity in
cultures containing physiological and higher (10-fold Km) concentrations of non-
radiolabelled androstenedione. Therefore, as a final resort, a comparison was made
between androgens (testosterone and androstenedione), and progesterone as potential
5a-reductase substrates. Viable thecal/interstitial cells were incubated with
concentrations of progesterone (0.5 (iM), androstenedione (2.8 |iM) or testosterone (2.5
|iM) which are approximate to the Km of the rat enzyme for each steroid (Andersson &
Russell, 1990). However, steroid metabolism did not occur as shown by absence of
other metabolite peaks after 2 h-incubations of steroid substrates (Fig. 3.12). Non-
radiolabelled steroid 20a-dihydroprogesterone (20a-DHP) was also used as a steroid
substrate for 5a-reductase activity in thecal/interstitial cells, but no metabolism
occurred (results not shown). The absence of authentic radiolabelled 20a-F)Hl made it
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FIGURE 3.12. 5(X-reductase assay of thecal/interstitial cells using different steroid
substrates at physiological Km. As described (Experimental Procedures, 3.2.6), 5(X-
reductase activity was studied in viable thecal/interstitial cells (5 x 105), but metabolism of the
substrates did not occur. Enzymic reactions (1 mM NADPH, 2 hours at 37°C) in ruptured
cells prepared in assay buffer contained [3H] steroid and non-radiolabelled steroid substrates;
A, 0.5 pM progesterone (P); B, 1 pM testosterone (T); C, 3 pM androstenedione (A4).
3.4. DISCUSSION
This study shows that short-term granulosa cell cultures are suitable systems in
which to study androgen metabolism by ovarian enzymes, with a 24-h incubation being
adequate for major metabolites to accumulate. Under these conditions, granulosa cells
metabolised androstenedione, an aromatisable androgen, into several steroid metabolites
which included testosterone, 17(3-oestradiol and androsterone. Metabolism to differing
degrees occurred in cultures of both immature and hormonally-stimulated granulosa
cells. However, although thecal/interstitial cells synthesise steroids in vitro (Payne et al.,
1992), the culture system used here was unable to show steroid metabolism by these
cells.
It is now well established that metabolism of androgens by granulosa cells is
central to the steroidogenic function of the mammalian ovary undergoing preovulatory
follicular developments (Gore-Langton & Armstrong, 1988). Granulosa cells in
preovulatory follicles are enzymically equipped to metabolise androgens into a variety of
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steroids, the principal endocrine secretion being 17p-oestradiol (Hillier, 1985; Richards,
1994). The increased ability of eCG-treated granulosa cells to metabolise
androstenedione (Figs. 3.5 and 3.6) is reminiscent of the changes that occur during
preovulatory follicle development. As preovulatory ovarian follicles develop due to
FSH action, they increasingly convert androgenic precursors into oestrogens (Hillier,
1985) as shown by the dramatic increase in oestradiol synthesis by the eCG-stimulated
granulosa cells (Fig. 3.7). FSH induces this action during ovarian follicle development
by up-regulation of the expression of steroidogenic P450 aromatase gene which
synthesises oestrogens from androgens in vivo (Hillier, 1985; Richards, 1994). This
response fulfils the requirement of increasing levels of oestrogen that drive further
preovulatory follicle growth and development, preparing the uterus for pregnancy and
initiating the ovulation-inducing LH surge.
The main androgens for oestrogen synthesis in follicular fluid, androstenedione
and/or testosterone, are increasingly converted into oestrone and oestradiol,
respectively. In man and rat, as in most species studied, androstenedione is the main
substrate for aromatisation (Gore-Langton & Armstrong, 1988). In this study, the
immediate and significant production (P< 0.0001) of oestradiol by non-incubated eCG-
stimulated granulosa cells (Fig. 3.7) suggested that stimulation by eCG raised the
potency of aromatase to such an extent that it readily converted androgenic substrates
into oestradiol. Therefore, during follicle development, FSH-induced aromatase action
readily converts androstenedione into intermediate steroids, oestrone or testosterone,
which are sequentially metabolised into 17(3-oestradiol (see Chapter 1, Fig. 1.2).
In rat ovary, the favoured androgen metabolic pathway involves the enzyme
17(3-HSD which is expressed constitutively in granulosa cells (Bogovich & Richards,
1984). Steroid 17(3-HSD1 belongs to a class of enzymes possessing 17(3-hydroxysteroid
dehydrogenase/17-ketosteroid reductase (17HSD/KSR) activities (Peltoketo et al.,
1999). The specific 17(3-HSD isozyme present in ovarian follicles, 17(3-HSD type 1
(17(3-HSDl)(Zhang et al, 1996) is the principal isozyme involved in oestradiol
production both in humans and rodents (Poutanen et al, 1995). Generally, 17(3-HSD1
is essentially an enzyme of oestradiol synthesis and abundandy expressed in granulosa
cells (Peltoketo et al., 1999). In this study, its action was illustrated by the synthesis of
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testosterone as the principal metabolite of androstenedione metabolism by rat ovary
(Fig. 3.11), specifically the granulosa cells (Figs. 3.5, 3.6 and 3.9). Steroid 17P-HSD1
readily converts androstenedione into testosterone prior to its aromatisation to
oestradiol. The action of 17|3-HSD action is up-regulated by FSH, as indicated by the
increase in the testosterone peak in eCG-stimulated ovaries (Fig. 3.11). Although the
human enzyme prefers phenolic substrates over neutral ones (Peltoketo et al, 1999) and
hence, androstenedione metabolism transpires via oestrone, then oestradiol (Gore-
Langton & Armstrong, 1988), the rodent enzyme catalyses effectively both oestrogenic
and androgenic substrates (Peltoketo et al., 1999). Thus, androstenedione metabolism in
rodents occurs through formation of testosterone which is converted into oestradiol.
However, in cultured cells that reflect in vivo conditions, 17(3-HSDs are mainly 17HSDs
or 17KSRs (Peltoketo et al, 1999). This explains why the reductive reaction converting
testosterone substrate into androstenedione was not found in granulosa cell cultures
even though similar cultures converted androstenedione substrate into testosterone by
the oxidative reaction of 17|3-HSD1. By comparison, the favoured pathway of
oestradiol synthesis in humans is via aromatisation of androstenedione into oestrone,
which is then converted into oestradiol by 17P-HSD (Peltoketo et al., 1999). Regardless
of the steroidogenic pathway involved, the dominant steroid synthesised in preovulatory
ovaries is oestradiol. Thus, the findings in the granulosa cell cultures were concordant
with the current concepts of androgen metabolism in the ovary.
In subsequent studies described in this thesis, theca and interstitial cells are
evidendy shown to be the specific ovarian cell types expressing 5CC-R1 (Chapters 3 and
4). This would explain why 5a-reduction of androstenedione into 5a-A could not be
demonstrated as the immediate product of androstenedione metabolism by granulosa
cell cultures. Although whole ovary homogenates were shown to synthesise
androsterone (Fig.3.10), thereby indicating 5CC-R activity and sequential 3CC-HSD
metabolism of 5CC-A), the high Km of 5CC-R for androstenedione (2.8 |lM; (Andersson
& Russell, 1990) suggests minimal direct conversion of androstenedione into 5a-A via
the 50C-reductive pathway. The abundant expression of 17P-HSD1 in ovarian follicles
(Zhang et al, 1996) that is induced by FSH (Poutanen et al., 1995), readily channels the
metabolism of androstenedione through testosterone as a steroid intermediate. It is,
therefore, more likely that sequential metabolism of androstenedione via testosterone
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which is 5a-reduced to DHT before conversion to 5a-androstanediol-3a,17|3-diol was
the favoured pathway leading to androsterone production (see Chapter 1, Fig. 1.4).
Physiologically, however, the 5a-reductive pathway possibly favours conversion of
progestins as shown by the synthesis of detectable amounts of 5(X-reduced progestins
from 20cc-dihydroprogesterone and progesterone in vitro (Lerner & Eckstein, 1976;
Payne et al., 1992). The low Km of 50C-R1 for progesterone (0.5 |TM) (Normington &
Russell, 1992) favours 50C-reduction of progesterone over androgen reduction by 50C-R1.
The detection of high levels of 5<X-reduced progestins in vivo (Inaba et al., 1978) and in
follicular fluid (McNatty et al., 1979; McNatty et al., 1981) seems to support this.
However, it is likely that in conditions where follicular levels of androstenedione are
greatly elevated such as in PCOS, some of the androstenedione escapes metabolism via
the principal A4 or A5 pathways and is metabolised via the alternative 5(X-reductive
pathway, as suggested by Agarwal et al., 1996.
The synthesis of androsterone as the main product of androstenedione
metabolism in immature ovaries (Fig. 3.10) correlates with the high activity of the
enzyme in immature ovaries (Fukuda et al., 1979; Aono et al., 1981). The immediate
product, 5a-A was not detected presumably because it was converted to androsterone
due to the action of 3CX-HSD. Similar effects of 3CC-HSD action have been reported by
(Payne et al., 1992), and therefore, the absence of 5CC-A in cultures of whole ovary
homogenates did not signify absence of 5a-R activity, but swift conversion of the
immediate product, 5a-A into androsterone. Mammalian 3a-HSDs work in concert
with 5a-and 5(1-reductases to produce 5cc,3(X-and 5(3,3a-tetrahydrosteroids (Penning,
1997). An example is the conversion of 50C-DHT by 3CC-HSD into 3a-androstanediol,
which has a much lower affinity for the androgen receptor. Therefore, the 5a-reductive
metabolism of androstenedione followed by 3a-HSD action results in the formation of
steroids with less androgenic ability. This is important physiologically in immature rats
where precocious synthesis of oestrogens is inhibited by formation of androsterone.
Being non-aromatisable, androsterone can not be converted to oestrogens. It is also an
aromatase inhibitor (Adashi, 1994) and its property as a 5a,3a-tetrahydrosteroid
reduces its affinity for the androgen receptor. Therefore, it not only constrains the
formation of oestrogen, but also has weak potential as a paracrine androgen such that
the atretic androgenic effects are somewhat inhibited possibly allowing immature
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follicles to remain undeveloped but viable and potentially able to be recruited as
preovulatory follicles after puberty.
The change in the patterns of androgen metabolism and the ensuing steroid
biosyntheses reflect the changing steroidal requirements of developing follicles.
Although androsterone was not resolved in Fig. 3.11, prior identification had shown it
to be the major metabolite of androstenedione in immature ovaries (Fig. 3.10). Hence,
studies of androstenedione metabolism in homogenates of whole ovaries at different
stages of follicular development (Fig. 3.11), indicate that androsterone was a major
component in peak 2 of immature, unstimulated ovaries (Fig. 3.1 lii). This is in support
of earlier studies where the main androgenic metabolites of ovaries from immature
female rats at 20 and 28 days age where androsterone and 5a-androstane-30C,17(3-diol,
(Karakawa et al.1976). As immature follicles develop, androsterone biosynthesis
decreased transiently while testosterone synthesis increased due to FSH-mediated
actions (Fig.3.11A i and ii). This is crucial in preovulatory steroidogenesis because
developing follicles critically require oestrogens, specifically oestradiol, to complete
follicular maturation. Hence, synthesis of aromatisable steroid intermediates such as
testosterone that can be converted into oestrogens over rides the synthesis of the non-
aromatisable 50C-reduced androgens. As follicles approach ovulation, androsterone
synthesis rose again suggesting a role of 5oc-reductive metabolism during the peri-
ovulatory period. The dominant hormone at this stage of the cycle increasingly
becomes progesterone, but it is not yet clear why the ovary requires 5a-reduced
steroids, presumably 5(X-reduced progestins at this stage.
The present focus on androstenedione metabolism illustrates the difficulty of
targeting specific steroidogenic pathways for study. Most steroid-metabolising enzymes
act on more than one substrate, and thus the flow of steroids through any one pathway
is highly dependent on the relative efficiency (substrate specificity) of the enzymes for
the steroids. In addition, enzyme activity in experimental culture conditions is
determined greatly by the substrate concentration. Suppression of granulosa cell
metabolism of androstenedione by concentrations that were 10-fold the physiological
Km or higher, showed the importance of substrate concentration in experimental
procedures investigating enzyme activity. Androstenedione concentrations within the
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nM range were optimal for most ovarian enzymes as shown by the increased number
and levels of steroid metabolites synthesised from androstenedione when the substrate
concentration was 18 nM (Fig.3.6). High levels of substrate become inhibitory to
enzyme action, and this is the reason why the levels of substrates in physiological
processes such as steroid metabolism are tighdy regulated within narrow physiological
ranges, which ensure enzymic action. Thus, androgens, although being the steroid
precursors of ovarian oestrogens, also have a kinetic role in regulating the enzymatic
processes within the ovary. This dual role, which embodies paracrine action, can only
operate normally if androgen biosynthesis is properly balanced with metabolism such
that no accumulation of androgens occurs to offset the finely tuned intraovarian
processes, which ensure specific steroid formation at different stages. A classic example
of the effects of altered ovarian steroidogenesis, particularly androgen metabolism, is the
endocrine disorder, PCOS which is studied in chapter 6.
In summary, metabolism of androstenedione in rat ovary occurs in granulosa
cells where aromatisation of androgens into oestradiol occurs among the synthesis of
other steroids. The patterns of the steroids synthesised from androgenic precursors
change as preovulatory development progresses. Synthesis of androsterone, a 50C-
reduced androgen in immature ovaries changes to synthesis of testosterone, an
aromatisable steroid from which oestradiol is synthesised. While oestradiol completes
follicular maturation, the rise in 5cc-reduced steroids during the peri-ovulatory window
suggests a role of these steroids at this stage in the oestrous cycle. This open up further
scopes for research in the role of 5tt-reduced steroids during and around ovulation.
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Chapter 4. Gonadotrophic Regulation of Rat 5tt-Reductase Type 1
mRNA Expression during the Preovulatory Period.
4.1. INTRODUCTION
5tt-Reductase is a component of the intra-ovarian steroidogenic pathways which
determine steroid synthesis and secretion (Clarke, 1986; Gore-Langton & Armstrong,
1988). The enzyme also exists as the 5p-isomer, 5p-R (Lisboa & Holtermann, 1976;
Charbonneau & Luu-The, 1999;2001). Both isoforms are expressed in several organs
where they inactivate A4'5-3-oxo-steroids in preparation for excretion (Russell & Wilson,
1994; Charbonneau & Luu-The, 2001). Whereas the detection of 5P-reductase activity
illustrated the expression of the isomer in the foetus (Stern et al., 1975), males
(Ingelman-Sundberg, 1976), non-reproductive tissues (Collins & Cameron, 1975;
Stenberg, 1976; Hutchison & Steimer, 1981), and in adult chicken ovary (Gomez et al.,
1998), no evidence suggests a role for the 5P-isoform in steroidogenesis of the adult
mammalian ovary.
5(X-Reductase is encoded by two genes encoding two different isozymes
designated as type 1 (50C-R1) and type 2 (5CC-R2) which have different biochemical
properties and tissue distributions (Russell & Wilson, 1994). The synthesis and
detection of 5(X-reduced steroids in follicular fluid suggest an active intra-folhcular role
of the 5a-R enzymes in metabolising ovarian steroids, and hence modulating ovarian
function at the paracrine level (Lerner & Eckstein, 1976; Inaba et al., 1978; Aono et al.,
1981; Haning et al., 1996). Whereas the activity of the enzyme was found to be higher in
immature compared to adult ovaries (Karakawa et al., 1976), studies on the expression of
the 50C-R gene in immature ovary are still inconclusive. Reports of the expression of the
5a-R mRNA gene illustrate its regulation in adult ovary by gonadotrophic stimuli
(Lephart et al., 1992). While studies by Aono et al., 1981 suggested a similar
gonadotrophic role in immature ovaries, the expression of the 5CC-R1 mRNA, the
isozyme expressed in the ovary, has not yet been demonstrated.
During androgen metabolism, 5a-reduction is an alternative pathway to
aromatisation, which is critical for maturation of ovarian follicles beyond early antral
stages (McGhee and Hsueh, 2000). It is therefore, one of the intraovarian mechanisms
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that control/impinge on the aromatisation step, and hence critically important in
preovulatory development. As part of a programme investigating 5(X-reduced
androgens in the ovary, identification of the 5(X-R isozymes present and their gene
expression in rat ovary provides insights to understanding the role of 5a-R in ovarian
physiology, and its regulation of oestrogen production which is pivotal to follicle
development, and hence fertility.
Using ovarian tissues from immature and hormonally-stimulated rats, this study
investigated the expression of 5CC-R1 and 5(3-R genes in rat ovary by reverse
transcription polymerase chain reaction (RT-PCR) and ribonuclease protection assay
(RPA). The expression of 50C-R1 mRNA as a "competitor" with aromatase mRNA for
androgen metabolism was investigated during preovulatory development.
4.2. EXPERIMENTAL PROCEDURES
4.2.1. Rat Tissues.
Ovarian tissue, used in reverse transcription polymerase chain reaction (RT-
PCR) and ribonuclease protection assays (RPA) was obtained from intact, immature
female rats injected once subcutaneously (s.c) with 10 IU eCG followed 48h later by a
single injection of 10 IU hCG (s.c) and removal of ovaries after 0, 3, 6, 9, 12, 24 and
120h. Diethylstilboestrol (DES)-treated animals were injected once (s.c) with 1 mg/100
pi DES. Control rats received no treatment. The non-ovarian tissues were collected
from control rats. The tissues used in northern analyses were obtained from animals
given in vivo treatments as described (Chapter 3, section 3.2.1). All the animals were
killed by carbon dioxide asphyxiation and the tissues transported on solid C02 pellets
prior to storage at -70°C until RNA was extracted.
4.2.2 Extraction and Quantification ofTotal RNA
4.2.2.1 RNA extraction using phenol-choloroform
Total RNA was extracted from rat tissues using the acid-guanidium-phenol-
chloroform method of Chomczynski and Sacchi (1987). The RNA samples were
dissolved in 0.5 ml DEPC-treated water and stored at -70 C.
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4.2.2.2. RNA extraction using RNazol B
RNAzol B (a guanidium-based reagent, TEL-TEST. Inc, Friendswood, Texas)
was also used to isolate total RNA as described by the manufacturer. The isolated RNA
was air-dried and dissolved in 400 pi DEPC-treated water to which 40 pi sodium
acetate and 1.0 ml ethanol were added. The RNA samples were stored at -20°C until
analysis by northern blotting.
4.2.2.3. Quantification and checking quality of RNA
Aliquots (50 j-ll) of total RNA suspensions in sodium acetate/ethanol were
transferred into autoclaved 0.2 ml Eppendorf tubes. After centrifugation at 21,000 g for
15 min at 4°C, the supernatant was removed, and 0.2 ml cold 85% ethanol (-20°C) was
added to the tubes. Following a brief recentrifugation, purified RNA was pelleted out,
then air-dried and dissolved in 10 pi DEPC water. A gene quantifier (GeneQuant
RNA/DNA calculator, Pharmacia-Biotech) was used to measure the RNA
concentrations. The ratios of the optical densities of the RNA measured at 260 and 280
nm were typically greater than 1.8 and protein contamination was generally negligible,
that is, less than 0.2 mg/ml.
4.2.3. Cloning of 5CC-R1 and Aromatase Complimentary DNA (cDNA)
4.2.3.1. Generation of 5CC-R1 cDNA by RT-PCR
Unless mentioned otherwise, the 50C-R1 cDNA used was generated as explained
below. Total rat liver RNA (2 pg/5 j-ll in DEPC water) isolated from immature female
rats was reverse transcribed with 0.4 pi 25 pM 50C-R1 antisense primer 5'-
CGCTAACAGA GCACTAAAGC ACAA-3', representing amino acids 767-790 of rat
5a-Rl gene (Anderson et al., 1989) for 1 h at 37°C. The total reaction volume (20 pi)
contained 2 pg total RNA, 5a-Rl AS primer (0.5 pM-final concentration), 2 pi 10X RT
buffer, 0.4 pi 200 pM deoxyribose nucleotides (dNTPS), 1 pi rRNasin (40 u/pl), 1 pi
MMLV reverse transcriptase (200 u/pl) and 10.2 pi distilled water. The cDNA,
containing a Pst I cleavage site at the 5'-end, was amplified with a pair of 5a-Rl primers,
5'-CACCCTCCTG GTCACCTTTG TCTT-3' (sense; ammo acids 330-353 of 50C-R1
gene) and antisense (see above) by PCR using Pfu-DNA polymerase as follows. An
initial 60-s denaturing step at 94°C was followed by 29 cycles, each consisting of a 45-s
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denaturing reaction at 94 C, a 45-s annealing reaction at 55°C and a 2-min extension at
72°C- The final PCR step was a 10-min extension at 72°C. Genomic DNA
contamination was analysed by amplifying 1 |!g RNA without RT. To verify die 50C-R1
PCR product, 10 (ll of the PCR reaction were size-fractionated and visualised by
electrophoresis on 2% agarose gels stained with ethidium bromide (2 JXg/ml). The 5cc-
R1 cDNA was approximate in size to the 456 bp insert DNA fragment.
The remaining PCR reaction was size-fractionated similarly and the 5CC-R1 DNA
band was excised from the gel, and transferred into a 1.5 ml Eppendorf tube, which was
heated at 70°C for 10 minutes. The melted agarose was processed as described (Wizard
PCR Preps DNA Purification System, Promega Cat. No. A7170). Extracted DNA was
eluted with 50 pi TE buffer.
4.2.3.2. Generation of aromatase cDNA by RT-PCR
Aromatase cDNA, corresponding to positions 1411 -1715 of rat aromatase gene
(Hickey et al., 1990), was generated by RT-PCR as described above with the following
exceptions. The primers used were 5'-ACTGGAAGAC TGTATGGATT-3' (sense)
and 5'-CCAAGTCCAC GACAGGCTGA TA-3' (antisense), and the cDNA was
reverse transcribed using total RNA isolated from PMSG-treated immature rat ovaries.
The PCR reaction was as described above except for the 45-s annealing reaction which
was performed at 60°C. The aromatase cDNA was approximate in size to the 305 bp
insert DNA fragment.
4.2.3.3. Preparation of plasmid DNA expressing 5a-Rl or aromatase
The 5CC-R1 and aromatase cDNAs were sub-cloned into pBluescript II SK(+)
vectors, a 2961 bp bacteriophage, and transformed overnight into Epicurian coll Xli-
Blue MRF' electroporation cells as described (PCR-Script™ Amp Electroporation -
competent cell Cloning Kit, Stratagene Cat. No. 211186). The transformed cells were
plated on agar plates supplemented with ampicillin and coated with 2% X-gal and 10
mM IPTG. Single white colonies were used to inoculate starter cultures of 5 ml LB
medium containing ampicillin. Using the protocol as described (Plasmid Maxi Kit,
Qiagen Cat. No. 12162), the starter cultures were used to innoculate 500 ml ampicillin-
62
containing LB broth from which plasmid DNA was extracted as per protocol. Plasmid
DNA was dissolved in 1 ml TE buffer.
4.2.3.4. Purification of plasmid DNA using phenol-chloroform
Plasmid DNA (500 pi) was mixed with an equal volume of
phenol:chloroform:IAA (25:24:1) in 1.5 ml Eppendorf tubes which were centrifuged at
15,800 g for 5 minutes at 4°C. The top aqueous layer (—500 pi) was transferred to fresh
tubes to which an equal volume of chloroform:isoamyl alcohol (IAA) solution (49:1)
was added. The tubes were recentrifuged as above and the top aqueous layer (-500 pi)
was transferred to a fresh tube. Sodium acetate (3M, 50 pi), pH 5.2 and 1.25 ml
ethanol were added to the aqueous solution and the reaction was incubated at 4°C for 2
h. After recentrifuging, the supernatant was removed and 500 pi ice-cold 70% ethanol
was added to the pellet. Following resuspension, the tubes were recentrifuged for 2
min. The ethanol was removed, and the DNA pellets were air-dried in inverted tubes
for 10 min and then dissolved in 800 pi TE buffer. The concentration of 5CC-R1
plasmid DNA (as determined by the gene quantifier) was 906 Pg/ml with an OD260/280
ratio of 1.849 and a protein concentration of 0.1 mg/ml.
4.2.3.5. Checking for orientation of 5CC-R1 gene insert in plasmid DNA
I. By restriction digest of plasmid DNA
In a 20 pi reaction volume, 1 pg 50C-R1 plasmid DNA was mixed with the
restriction enzyme, Pst I (lu), IX restriction enzyme buffer H, and the total reaction
volume was made up with nuclease-free water. The reaction was incubated for 1 hour
at 37°C. 6X Loading Dye (4 pi) was added to the products of the restriction digest.
Untreated plasmid DNA (1 pi) was diluted to 10 pi with DEPC-treated water before
addition of 2 pi 6X-Loading Dye. The reaction products and untreated plasmid DNA
were analysed by agarose gel electrophoresis.
II. Direct sequencing of cloned 5(X-R1 DNA
Purified 5(X-R1 plasmid DNA (300 pg) was incorporated into a sequencing
reaction as described (ABI PRISM Big dye terminator cycle Sequencing ready Reaction
Kit) for a DNA thermal cycler. The products of the sequencing reaction were
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precipitated using ethanol/sodium acetate protocol as described in the protocol.
Electrophoresis of the samples on the ABI PRISM analysed the sequence of the cloned
5CC-R1 plasmid DNA. The identity of the cloned sequence was confirmed by a BLAST
search at the National Centre for Biotechnology Information (NCBI, Bethseda, MD,
USA), and the orientation of the cloned sequence was identified using Gene Jockey II
Sequence Processor computer programme (Biosoft, Cambridge, UK).
4.2.4. Preparation ofRNA and DNA Hybridisation Probes
4.2.4.1. 32P-Iabeled RNA probes for ribonuclease protection assay
5CC-R1 and 5(3-R RNA 3~P-labeled RNA probes were synthesised by in vitro
transcription as described (Tetsuka & Hillier, 1996) from PCR-generated 717 bp and
285 bp cDNA fragments corresponding to rat 5a-Rl gene (location 1 to 717;
(Andersson et al., 1989) and rat 5(3-R gene (location 1487 to 1771; (Onishi et al, 1991)).
The 5CC-R1 cDNA was provided by Prof. D.W. Russell (University of Texas,
Southwestern Medical Centre, Dallas, TX). Ribosomal RNA (rRNA) probes were
synthesised from cDNAs containing 80 bp fragments of a highly conserved region of
human 18S rRNA gene (pT7 RNA 18S; Ambion Inc). The specific activities of these
probes were 6.7 x 105, 6.7 x 105 and 2.2 x 103 cpm/pg for 5CX-R1, 5(3-R and 18S,
respectively.
4.2.4.2. 32P-labeled RNA probes for northern analyses
I. Generation of linearised 50C-R1 plasmid DNA template
Linearised 5a-Rl plasmid DNA (template) was generated by cleaving the plasmid
cDNA as described (section 4.2.3.5. I) with the exception that the restriction enzyme,
10X buffer and incubation period used were EcoR V, buffer D and 2 hours, respectively.
Aromatase DNA template was generated similarly with EcoR I and buffer H.
II. In vitro transcription of 50C-R1 RNA probe
5CC-R1 and aromatase 32P-labeled RNA probes were synthesised in vitro from
linearised DNA templates as described (MAXIscript™ In vitro Transcription Kit,
Ambion, Cat. No. 1324) using a32P-(Dejager et al., 2001) (800Ci/mmol, 20 mCi/ml) and
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purified usingMicroSpin G-50 columns (Amersham Pharmacia, Cat. No. 27-5330). The
probes used for detecting 18S rRNA were 32P-labeled DNA probes prepared using
® P-[CTP] (10 mCi/ml) as described (Rediprime II random prime labelling system,
Amersham Pharmacia Biotech, Cat.No. RPN 1633) from a cDNA fragment
corresponding to a highly conserved region of human 18S gene. The specific activities
of the 5CC-R1, aromatase and 18S probes were 1.4 x 105, 1.5 x 102 and 2.1 x 103 cpm/pg,
respectively.
4.2.5. Ribonuclease Protection Assay (RPA)
Total RNA (20 |Xg) was hybridised with approximately 1 x 104 cpm 50C-R1 or
5(3-R RNA probes and 1 x 104 cpm 18S rRNA probe for 16 h at 52 °C in 20 ml
hybridisation buffer containing 80% deionised formamide, 40 mM PIPES (pH 6.7),
0.4M sodium chloride and 1 mM EDTA. After hybridisation, unprotected RNA was
digested by RNase A/Tl and protected fragments of mRNA/RNA were extracted by
phenol/chloroform prior to precipitation by ethanol. Protected RNAs were size-
fractionated by electrophoresis on 5% acrylamide gels containing 8M urea. The gels
were analysed by autoradiography.
4.2.6. Northern Analysis
Total RNA (20 (Xg) was size fractionated in a denaturing gel, and transferred
onto Hybond-N nylon membranes as described (NorthernMax™ Northern Blotting
Kit, Ambion, Cat. No. 1940). The hybridisations and the subsequent washes of the
northern blots, performed at 68°C and 42°C for the RNA and DNA probes,
respectively, were performed as described in the protocol.
4.2.7. Data Analysis
The radioactive signals of RNA were quantified by electronic autoradiography
(Instant Imager, Packard, Downers Grove, IL, USA) followed by exposure of the
membranes to Kodak XAR-5 film (Eastman Kodak, Rochester, NY, USA) with
intensifying screens for 16-48 h at -70°C. The abundance of mRNA was normalised to
the 18S rRNA signal. Results of 50C-R1 and aromatase gene expression were expressed
as percentages of the control and eCG-treated values, respectively, and analysed using
one way ANOVA with paired Student's t-test.
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4.3. RESULTS
4.3.1. Expression of 5a-reductase 1 and 5|3-reductase in Rat Ovary
To study the expression of 50C-R1 and 5(3-R mRNA in die ovary (among other
rat tissues), total RNA isolated from ovaries collected from immature and hormonally-
stimulated rats in vivo, was analysed by RT-PCR and RPA.
4.3.1.1. Expression of 5a-reductase 1 in rat tissues
5(X-Reductase-1 mRNA was expressed abundantly in the reproductive tissues,
ovary uterus and testis, and non-reproductive tissues from immature female rats, liver,
intestines, kidney and lung in immature rats (Fig. 4.1). The spleen and brain expressed
very low levels of the enzyme. 5tt-Reductase-l mRNA was not detected in heart and
muscle tissues. As a result, the mRNA used as control samples was isolated from liver
(positive control) and heart (negative control) tissues.
FIGURE 4.1. Expression of 5CC-R1 mRNA in rat tissues. 5a-Rl expression in rat tissues
was analysed by RT-PCR followed by electrophoresis on a 2% agarose gel. With the
exception of the testis, total RNA was isolated as described (Chomczynski and Sacchi, 1987)
from the indicated tissues collected from 21-day old (immature) female Wistar rats. Ovarian
and uterine RNA was isolated from (C) immature untreated rats (controls), (P) immature rats
injected with single dose of eCG (10 iu) for 48 hours, and (H) immature rats injected with
eCG (as explained) followed by a single dose of hCG (10 iu) for 12 hours. Testicular RNA
was isolated from adult male Wistar rats. Nuclease-free water (H20) was used as a negative
control for the PCR reaction.
4.3.1.2. Expression of 5f3-reductase in rat tissues
5(3—Reductase mRNA was not expressed in rat ovary or muscle, but was




FIGURE 4.2. Expression of 5P-reductase (5P-R) mRNA in rat ovaries. The
autoradiogram (see "Experimental Procedures, 4.2.5") shows the expression of 5P-R mRNA
analysed by RPA of total RNA (20 |tg) isolated from rat ovaries collected from controls,
immature untreated rats (C), and rats treated with a single injection of 10 IU eCG for 48 h
followed by a single injection of 10 IU hCG for 0, 3, 6, 9, 12, 24, 120h. Female rat liver (L)
and muscle (M) were positive and negative controls, respectively. Transfer RNA (tR) was
used as the negative control for the assay. (18S - ribosomal RNA)
4.3.2. Effect of gonadotrophins on 50C-R1 mRNA expression in rat ovary
To study the effect of gonadotropic stimuli on ovarian 5CX-R1 expression, total
RNA isolated from whole ovaries collected from rats stimulated for different periods of
time, was analysed by RPA.
The expression of 5CC-R1 mRNA was highest in immature, unstimulated ovaries
(controls) as shown in Fig. 4.3. The expression was down-regulated after treatment with
eCG to levels that were about 20-30% of the control value. Subsequent treatment with
hCG caused an initial drop in the levels of 5CC-R1 to 10% of the control levels during
the first six hours after which hCG gradually stimulated 50C-R1 mRNA expression. The
increase in 5a-Rl mRNA expression continued to increase 12 h after hCG treatment
and was highest after 24 h when it had returned to 80% of the control value. However,
the hCG-stimulatory effect was transient because 5CC-R1 mRNA expression had
decreased to almost 10% of the control levels at 120 h after hCG treatment. Because
5CC-R1 mRNA expression was re-expressed at 12 h and 24 h after hCG, the time-points
were used in subsequent experiments to study the effects of eCG and hCG on the
expression of 50C—R1 in rat ovaries during preovulatory development.
4.3.3. Preparation of Plasmid 5CX-R1 cDNA
4.3.3.1. Synthesis of 5CC-R1 cDNA by RT-PCR
A 5a-Rl PCR product sized between 396 and 506 bp, encompassing the target
construct size (-456 bp), was detected in the rat liver samples and ovary, but none was
present in distilled water (Fig.4.4). There was no genomic DNA contamination in the
amplified 5CC—R1 cDNA.
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FIGURE 4.3. Expression of 5a-reductase type 1 in rat ovaries. A. The autoradiogram
of RPA products (see "Experimental Procedures, 4.2.5") shows the expression of 5CC-R1
mRNA in rat ovaries collected from controls, immature untreated rats (C), and rats treated
with a single injection of 10 IU eCG for 48 h followed by a single injection of 10 IU hCG
for 0, 3, 6, 9, 12, 24, 120 h. Female rat liver (L) and muscle (M) were positive and negative
controls, respectively. Transfer RNA (tR) was used as the negative control for the assay. B.
Quantitative analysis of 5a-Rl expression shows the levels of 5CX-R1 mRNA in the described
groups. The abundance of 5a-Rl mRNA was normalised using ribosomal RNA (18S) and
expressed as percentage of the control value.
RT +ve RT -ve
FIGURE 4.4. Preparation of 5CC-R1 cDNA. Duplicate aliquots of total RNA isolated
from immature female rat liver and ovary, liver 1 (LI) and 2 (L2), and ovary (Ol) and (02),
respectively, were amplified by reverse transcription-polymerase chain reaction (RT-PCR) as
described under "Experimental Procedures, 4.2.3.1." Distilled water samples (W) were used
as negative control samples. The PCR was performed after RT (RT +ve) and without RT
(RT -ve) to analyse genomic DNA contamination. The sizes of the constituent fragments of
the 1 Kb DNA ladder (GIBCO, Cat. No. 15615-016) are indicated on the right side of the
gel.
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4.3.3.2. Cloning of5a-Rl cDNA
The 5a-Rl PCR product (probe), containing a Pst I cleavage site, was cloned
successfully into pBluescript II in a 5' - 3' (sense) orientation that was identified by
cleavage of the plasmid cDNA with Pst I and direct sequencing. Fig. 4.5 shows a sketch
of the 5a-Rl probe and the site at which Pst I cleaves the 5a-Rl DNA probe. The
identity of the 5ct—R1 probe, confirmed by a blast search at the National Centre for
Biotechnology Information (NCBI; Bethesda, MD), was shown to have 100%
homology with rat 5a-Rl mRNA gene, which corresponds, to loci 10 - 777 of the
complete rat 5a-Rl gene. Fig. 4.6 shows the sequence of the rat 5a-R gene that is
encompassed by the 5a-Rl cDNA probe.
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FIGURE 4.5. Graphic representation of the 5a-Rl probe and the Pst I restriction site.
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AGACCACATCCTGAGGAATCTGAGAAAACCAGGGGAAACTGGATACAAGATACCCAGGGGAGGCCTGTTrGAATACGTATCTGCAGCCAACTATTTTGGG £QQ
AGACCACATCCTGAGGAATCTGAGAAAACCAGGGGAAACTGGATACAAGATACCCAGGGGAGGCCTGTTTGAATACGTATCTGCAGCCAACTATTTTGGG
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GAGCTCGTGGAGTGGTGTGGCTTOGCACTGGCCAGCTGGTCCCTCCAGCGTGTAGTGTTTGCACTGTTCACACTCAGCACACTGCTCACCAGAGCGAAGC JQQ
GAGCTCGTGGAGTGOTGTGGCTTTGCACTGGCCAGCTGOTCCCTCCAGGGTGTAGTGTTTGCACTOTTCACACTCAGCACACTGCTCACCAQAOCGAAGC
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AGCStCCATCAGTGGTACCATGAGAAGTITGAAGATTACCSlCAAGTCAAGAAAAATACTGATTCCATTTGTGCTTTAGTGCTCTGTTAGCGCTGTTGCCTC gQQ
AGCACCATCAGTGGTACCATGAGAAGTTrGAAGATTACCCCAAGTCAAGAAAAATACTGATTCCATTTGrGCTTTAGTGCTCTGT
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CCATGAGCT^GTCTGTCrGTCTCCCTGGTGACTTTGCTCTGAGCACTTACGAATGAArTGTTITCCTTAATTCTCCTGCAGCCCCTTTCTCAGGAAAGG QQQ
CTGGGGGTGGGGQGGTGTCGTCCCCTGQTAAAGGACAAAGCCAATGATAAACTAATCCACCACATGCAOTTAGGGGCTACACTGCCTGCTGGATCCG... 997
FIGURE 4.6. Nucleotide sequence of cloned rat 5a-Rl insert aligned with the rat
5a-Rl gene. The verification of the sequence of the cloned 5a-Rl plasmid DNA by Blast
searching at the National Centre for Biotechnology information (NCBI; Bethesda, MD)
revealed that the insert (456 bp; red font) had 100% homology with rat 5a-Rl gene (black
font; Anderson et al., 1989). The insert represented the amino acids 330-785 of the complete
rat 5a-Rl gene. The nucleotides in 5a-Rl gene are numbered on the left. The black dots
represent every tenth nucleotide.
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4.3.4. Expression of 5CC-R1 and aromatase mRNA in rat ovary during the
preovulatory period.
To show the expression of 5CC-R1 and aromatase mRNA in specific tissues in
the rat ovary, total RNA isolated from granulosa, residual and whole ovary was analysed
by northern analysis.
4.3.4.1. Comparison of 50C-R1 and aromatase mRNA expression in granulosa
cells and residual ovary.
The expression of 50C-R1 mRNA was more abundant in residual ovary tissue
than the granulosa cells (Fig. 4.7). The gene expression was highest in the residual ovary
of immature untreated rats and was significandy reduced to 35% of the control value by
treatment with eCG (P< 0.001). Subsequent treatment with hCG for 12h induced a
transient increase in the expression of 5CC-R1 mRNA expression to 60% of the control
value. At 24h after hCG treatment, 50C-R1 mRNA had decreased significantly to 40%
of the control value (P< 0.001). Due to the evidence in Chapter 5, the similar pattern of
expression of lower levels of 50C-R1 mRNA in granulosa cells is due to contamination
of granulosa cells with theca/interstitial cells. The expression of 5a-Rl mRNA in the
residual ovary of DES-treated rats was similar to that in the control animals. The liver
expressed very high levels of 5a-Rl mRNA, but the gene was absent in the heart tissue.
Re-hybridising the RNA blots shown in the top panel of Fig. 4.7 with aromatase
riboprobes showed that the aromatase probe hybridised to three mRNA transcripts (3.3,
2.6 and 1.9 Kb in size) in rat ovarian tissues (Fig. 4.7, middle panel). The most
abundant transcript was the 3.3 Kb band. It was expressed in granulosa cells, and was
essentially absent in the residual ovary tissue. The aromatase mRNA transcripts,
particularly the 3.3 Kb and 1.9 Kb bands, were most abundant in the eCG-treated
granulosa cells. Both transcripts were detected in the granulosa cells from immature
and hCG-treated rats, but at levels lower than in eCG-treated granulosa cells. The famt
signal detecting the 3.3 Kb aromatase mRNA transcript in the residual ovary of eCG-
treated rats was due to contamination of the residual ovary tissue with granulosa cells.
The 1.9 Kb transcript, evidently expressed in the granulosa cells and less so in the
residual ovary, was also expressed in the heart and liver tissues. However, the 3.3 Kb
and 2.6 Kb transcripts were not expressed in residual ovary of immature, hCG-, DES-
treated rats, or heart and liver tissue.
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Granulosa cells Residual Ovary
FIGURE 4.7. Expression of 5(X-R1 and aromatase mRNA in rat ovarian tissues.
Northern blots of total RNA (20 |lg) isolated from ovarian tissues of rats treated with
hormones as described (Experimental Procedures, 3.2.1) showed the expression of 5a-Rl {top
panels) and aromatase {middle panels) mRNA in granulosa cells and residual ovarian tissue in
immature untreated rats, controls (C), eCG-treated rats (P), rats injected subsequently with
hCG for 12 h (PH12) and 24 h (PH24). In addition, 5CC-R1 mRNA expression was detected
in diethylstilboestrol (DES)-treated residual ovary. RNA isolated from heart and liver tissue
was included as negative and positive control material, respectively. The blots were prepared
as described (NorthernMax Northern Blotting Kit. Ambion Cat. No. 1940) and analysed by
autoradiography after overnight exposure to Kodak X-ray film at -70°C. 50C-R1 and
aromatase mRNA were hybridised with 32P-labeled riboprobes prepared by in vitro
transcription of PCR-generated cDNAs specific to 5a-Rl and aromatase genes, respectively.
The aromatase probe hybridised to three mRNA transcripts, 1.9 Kb, 2.9 Kb and 3.3 Kb in
size. Ribosomal RNA (18S) was hybridised by 32P-labeled DNA probes (bottompanels).
ECG and hCG regulated aromatase and 5CC-R1 mRNA in the rat ovary in an
inversely related pattern during preovulatory development (Fig. 4.8). While eCG down-
regulated 5CC-R1 mRNA expression in residual ovary, it up-regulated aromatase mRNA
expression in granulosa cells significandy (P< 0.05), and whereas hCG up-regulated 5a-
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FIGURE 4.8. Inverse relationship between 5ct-Rl and aromatase mRNA expression
during preovulatory development. Quantitative analysis of the radioactive signals of 5ct-Rl
and aromatase mRNA performed as described (Experimental Procedures, 4.2.7), shows the
patterns of each mRNA expression in preovulatory rat ovary. C= control; P= eCG-treated
rats; (PH12)= rats injected subsequently with hCG for 12 h; (PH24) = rats injected
subsequently with hCG for 24 h. Each bar represents mean ± SD percentage of relative
abundance of mRNA in 3 replicate experiments. Asterisks denote significant increase (P<
0.05) in gene expression compared to other groups.
4.3.4.2. Comparison of 5(X-R1 and aromatasemRNA expression in whole ovary
The expression of rat 5CC-R1 and aromatase mRNA in whole ovary was clearly
defined (Fig. 4.9). The abundant expression of 50C-R1 mRNA gene in immature ovary
was reduced by treatment with eCG to levels that were non-detectable by northern
analysis while eCG stimulated aromatase mRNA expression. The aromatase gene (all
three mRNA transcripts) was only detected in the eCG-treated ovary where it was
expressed abundandy. Aromatase mRNA was not detected in the immature and hCG-
treated ovaries. Subsequent treatment with hCG for 12h restored a transient increase in
5a-Rl mRNA gene expression, which was decreased after 24h to levels that were higher



























FIGURE 4.9. Relative expression of 5CC-R1 and aromatase mRNA in whole ovarian
tissue. A. Northern blots of 5a-Rl (top panel) and aromatase (middle panel) mRNA in whole
ovaries that were harvested from rats treated with hormones as described (Experimental
procedures, 3.2.1) were set up with 20 pg total whole ovary RNA as described (NorthernMax
Northern Blotting Kit, Ambion, UK, Cat. No. 1940). The indicated mRNA in the ovaries of
immature untreated rats, controls (C), eCG-treated rats (10 iu for 48 h) (P), and rats
subsequently injected with hCG (10 iu) for 12 h (PH12) and 24 h (PH24) was hybridised with
specific 32P-labeled riboprobes generated by in vitro transcription as described (MAXIscript In
vitro Transcription Kit, Ambion, Cat. No. 1324). The skzes of the three transcripts of
aromatase mRNA are shown alongside the gel. H- heart; L-liver; 18S- ribosomal RNA. B.
Quantitative analysis of whole ovary 5a-Rl and aromatase mRNA was normalised using 18S
rRNA and expressed as a percentage of the control and eCG-treated value, respectively. Each
bar represents mean ± SD percentage of relative abundance of mRNA in 3 replicate
experiments. Asterisks denote significant increase stimulation (P< 0.05).
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4.4. DISCUSSION
It is well documented that the metabolism of ovarian androgens is central to the
normal function of the ovary (Hillier, 1985; Adashi, 1994; McGee & Hsueh, 2000). In
addition to aromatase as the main ovarian enzyme, minor enzymes such as 5CC-R also
convert androgens into alternate metabolites (Eckstein et al., 1970; Lerner & Eckstein,
1976, McNatty et al., 1981; Gore-Langton & Armstrong, 1988). The different steroids
have distinct roles during follicular development and, hence the expression of the
enzymes responsible for their metabolism is tighdy regulated as the ovary undergoes the
developmental changes (Richards, 1994). It has been reported that the enzymes,
aromatase and 50C-R have opposing effects on follicular development in the adult ovary
(Lephart et al, 1992). To study the regulation of both enzymes in the studies described
in this chapter, the gonadotrophic control of the enzymes was investigated in ovaries of
immature rats, the animal model of choice used in these studies.
5a-Reductase exists as two isozymes (Russell &Wilson, 1994), but it was shown
that the isozyme expressed in the rat ovary is 5a-Rl (Figs. 4.1, 4.3 and 4.4) and not 5|3-
R (Fig. 4.2). The 5CC-R isozyme also exists as either type 1 or type 2 (Normington &
Russell, 1992; Russell & Wilson, 1994). Although the 5a-R2 enzyme has been reported
in the human ovary (Jakimiuk et al., 1999; Akahira et al., 2001), no conclusive evidence
illustrates 50C-R2 expression or activity in the rat ovary to date. During the studies
described in this manuscript, attempts to develop methodologies to illustrate 50C-R2
expression alongside the 5CC-R1 studies were unsuccessful due to failure to develop a
5CC-R2 cDNA probe corresponding to a specific sequence of 50C-R2 gene as clarified by
BLAST searching at National Centre for Biotechnology information (NCBI; Bethesda,
MD). The riboprobes used to hybridise the 5a-Rl gene (either by RPA or northern
analysis) detected a single mRNA species approximately 2.5 Kb in size and homologous
with the 5a-Rl mRNA detected previously in rat liver (Andersson et al., 1989). The
findings showed that the enzyme was expressed selectively in various rat tissues
including the ovary (Fig. 4.1) and that the expression of ovarian 5CC-R1 mRNA is
regulated by both gonadotrophins, FSH and LH (Figs 4.3, 4.7 & 4.9).
Specific gonadotrophic regulation of 5CX-R1 mRNA expression was shown by
the in vivo studies illustrated in Fig. 4.3. Equine CG suppressed 5a-Rl expression which
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was transiently restored by hCG indicating opposing roles of the pituitary hormones on
ovarian 5CC-R1 expression. In earlier studies, (Aono et al, 1981) showed that FSH had
an inhibitory effect on 50C-R1 activity and the results suggest that the effect occurs at the
gene level where the gonadotrophin downregulates 50C-R1 mRNA expression (50C-R1
panels; Figs. 4.7 & 4.9).
Knowing that ovarian tissues respond essentially to either gonadotrophin,
northern analyses of granulosa cells and residual ovary tissue which was enriched in
theca/interstitial cells showed that 5CC-R1 mRNA was expressed more abundantly in
residual tissue than granulosa cells (Fig. 4.7). The expression of the gene in the residual
ovary was highest in ovaries of immature rats and was reduced by eCG, but increased
again by hCG, albeit transiendy. A similar trend was observed in the granulosa cells, but
this was a result of contamination of granulosa cell preparations by theca/interstitial
material, and localisation studies described in later studies (Chapter 5) clarify the tissue
specificity of 50C-R1. The response of 5CX-R1 mRNA to hCG was also highly indicative
of the enzyme's location in thecal/interstitial cells because LH action is mediated
through receptors that are located on theca cells in immature ovaries. However, eCG
(which is FSH-like in action) decreased the expression of 5a-Rl mRNA. FSH action is
mediated through granulosa cells because they, unlike theca cells, express FSH
receptors. This suggests that down-regulation of 50C-R1 mRNA by FSH must involve
other FSH-induced granulosa cell factors that decrease 5CC-R1 expression. These
paracrine modulators of 50C-R1 expression are yet to be identified.
In contrast to 50C-R1 expression, ovarian aromatase expression was upregulated
by eCG and downregulated by hCG. Similarly to the well-documented regulation of
aromatase by FSH (Hillier, 1985; Adashi, 1994; Richards, 1994; McGee & Hsueh, 2000),
the almost negligible levels of aromatase mRNA detected in granulosa cells of immature
ovaries were increased by eCG treatment in vivo (aromatase panels; Figs. 4.7 & 4.9).
Human CG suppressed the eCG stimulatory action on the expression of aromatase
mRNA. The opposing effects of eCG and hCG on the regulation of ovarian 5CC-R1 and
aromatase were also described by Lephart et al., (1992). Whether in specific ovarian cell
types (Figs. 4.7 & 4.8) or whole ovary (Fig. 4.9), the inverse relationship of the
expression of 5a-Rl and aromatase suggested that that during preovulatory
75
development the stimulatory action of FSH on aromatase expression is upregulated
when the expression of 5CC-R1 is inhibited. Likewise, 50C-R1 expression is stimulated by
LH when aromatase is inhibited suggesting that 5(X-reductive metabolism is a favoured
pathway when aromatase activity, (i.e. oestrogen production) is suppressed. Since
oestrogens are required for follicular maturation, it is likely that 50C-reduced steroids are
only synthesised when follicular development must be suppressed as in ovaries of
immature animals. This is possibly why 5CC-R1 mRNA is highly elevated while
aromatase is hardly expressed in the ovaries of immature rats (as shown in Figs. 4.7 &
4.9) so as to prevent precocious secretion of oestrogens. Infact, 5a-Rl activity has been
shown to be highly elevated in ovaries of immature rats (Inaba et al, 1978; Fukuda et al,
1979; Aono et al., 1981). In adult animals, as follicular development progresses mainly
due to FSH, the over riding requirement for FSH results in an upregulation of
aromatase expression which causes oestrogen production (Richards, 1994). The
expression of 50C-R1 and hence 50C-reductase action, is simultaneously suppressed so
that the inhibitory effect of 5CC-reduced androgens (Hillier el al., 1980a; Conway et al.,
1990) is removed.. The net consequence is enhanced synthesis of oestrogens required
to complete follicular maturation leading to ovulation. The studies described in this
chapter have shown that the expression of 50C-R1 mRNA is transiently upregulated by
eCG (Figs. 4.3, 4.7 & 4.9) suggesting roles for 5a-reduced steroids during the
periovulatory period. Which 50C-reduced steroids are present at this stage and what
their functions are, are still largely unknown. It seems more likely that the substrate
metabolised by 5CC-R1 is progesterone, which is the steroid produced increasingly during
periovulation
Equine CG clearly reduced 50C-R1 mRNA expression, which was restored by
hCG, indicating down- and up-regulating effects of FSH and LH, respectively, on the
5CC-R1 gene (Fig. 4.3). Others have reported similar findings of a stimulatory effect of
LH (Aono et al., 1981) and an inhibitory effect of FSH (Aono et al., 1981; Payne et al.,
1992). Since FSH levels begin to rise during the early stages of preovulatory follicle
growth, it implies that the expression of 5a-Rl is inhibited correspondingly during this
stage. Physiologically, the gradual inhibition of 5CC-R1 expression removes the
inhibitory effect of 5a-Rl on oestrogen synthesis. It is known that oestrogens are
secreted in increasing amounts during preovulatory follicle development and are crucial
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for ovulation (Greenwald & Terranova, 1988; Adashi, 1994; McGee & Hsueh, 2000).
The one or few recruited follicles, in monovulatory species or multi-ovulatory species,
respectively, that become the dominant follicles require high levels of oestrogens which
stimulate their further growth. As FSH-induced oestrogen secretion increases, the
oestrogenic output eventually down-regulates the release of pituitary FSH by negative
feed back. The removal of any impediment to oestrogen production is therefore critical
to the developmental progress of healthy preovulatory follicles. 50C-reduced androgens
inhibit ovarian oestrogen biosynthesis by competitive inhibition of aromatase (Hilher et
al., 1980a). The down-regulation of 5a—R1 by FSH and hence, 5tX-reduced androgens
is probably part of the intraovarian mechanisms which ensure that the inhibition of
oestrogen production is removed during the preovulatory stages when the developing
follicles increasingly depend on oestrogen for full maturation.
As the dominant follicle(s) approaches ovulation, the levels of LH begin to peak
hours before ovulation takes place. The transient stimulatory effect of hCG on 5a-Rl
mRNA in vivo which occurred after hCG administration (Fig. 4.3, 4.7, 4.8, 4.9) suggests
that the peri-ovulatory LH surge stimulates 50C-R1 expression around the time of
ovulation. As mentioned above, it is not yet clear why 5a-reductive metabolism is
required around ovulation, but it might involve metabolism of progesterone, which is
the main ovarian hormone after ovulation. Since 5a-Rl metabolises progesterone to
other less biologically active forms (Verma & Laumas, 1976; Frye & Vongher, 2001) and
progesterone is a better substrate for 5a—R1 than androgens (Payne et al., 1992), it is
probably metabolised readily during the peri-ovulatory phase indicating a role of 5a-
reduced progestins during this stage of ovarian function. According to Eckstein et al.,
(1970), these steroids might be excretory intermediates, suggesting that the role of 5a-
R1 at this stage is to contribute to the excretion of excess progesterone. Or it could be
that 5a-Rl action is required during conditions of high concentrations of progesterone
suggesting that the enzyme might play an unknown role during pregnancy.
Although the studies described in this chapter indicated that rat ovarian 5a-Rl
mRNA gene is expressed in residual ovary and not granulosa cells, the cellular
localisation was still indistinct. This was clarified in the next chapter.
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Chapter 5. Cellular localisation of 5(X-reductase type 1 in the
rat ovary
5.1. INTRODUCTION.
50C-reductase type 1, the 50C-R isozyme present in rat ovary is a
gonadotrophically-regulated enzyme that modulates follicle development via control of
oestrogen production. Although the ovarian expression of the enzyme has been clearly
demonstrated in immature (Eckstein & Nimrod, 1977) and adult ovary (Lephart et al.,
1992; Haning et al., 1996), the specific cellular sites of 5CC-R1 in the ovary are still
unknown. Most recent studies of the enzyme in the ovary have investigated its activity
and gene expression (Lephart et al, 1992; Haning et al, 1996; Jakimiuk et al., 1999) in
relation to oestrogen production, but have not specified its cellular localisation. Studies
of the cellular localisation of 5CC-R1 have largely focused on male reproduction (Pelletier
et al., 1998) or non-reproductive tissues such as liver (Eicheler et al., 1995), nervous
system (Poletti et al., 1997; Yokoi et al., 1998a), adrenal gland (Yokoi et al., 1998b) and
skin (Bayne et al., 1999; Thiboutot et al., 2000) where the enzyme is crucial for normal
development and/or function of these organs.
In the previous chapter, high levels of 5a-Rl mRNA gene were detected in
residual ovarian tissue compared to isolated granulosa cells suggesting that the cellular
location was principally confined to the thecal/interstitial compartment of the ovary.
The indication of such a polarised distribution of 5CC-R1 to thecal/interstitial cells, and
not granulosa cells, is reinforced by the increased activity of 5CC-R1 in residual ovary
compared to granulosa cells, in response to LH stimulation, whereas FSH is inhibitory
(Fukuda et al., 1979; Payne et al., 1992). In addition, the stimulatory effect of LH on
both 5CC-R activity and proliferation of interstitial cells, with no such effect on granulosa
cells (Aono et al., 1981), strongly suggests that the expression of the enzyme is specific
to thecal/interstitial tissue other than granulosa cells. Verification of the cellular
location of 5a-Rl in the ovary is important in identifying the specific sites influenced by
gonadotrophs signals, and therefore, could be used to develop therapies which target
specifically 50C-R1 in disease conditions where the enzyme s activity is dysfunctional.
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In this study, the cellular distribution and regulation of ovarian 5CC-R1 during
preovulatory follicle development was studied by investigating the distributions of both
50C-R1 protein and mRNA gene. Most importantly, a novel finding is presented
showing distinct polarisation of the cellular localisation of 50C-R1 in thecal/interstitial
tissue while absent in granulosa cells in the rat ovary.
5.2. EXPERIMENTAL PROCEDURES
5.2.1. Wax-embedded tissues
Ovarian tissues were obtained from animals given in vivo hormonal treatments as
previously described (Chapter 3, section 3.2.1). Heart and skeletal muscle tissues were
obtained from control rats. The tissues were fixed in either Bouins fixative (Triangle
Biomedical Sciences, Skernersdale, UK) for 6 h or normal buffered formaldehyde
(NBF) for 24 h. Fixed tissues were immersed in 70% ethanol until further processing
for embedding in paraffin wax.
5.2.2. Immunocytochemical procedures
Serial sections of paraffin-embedded tissues (5 pm) fixed in Bouins or NBF-
fixed tissues were mounted on slides (Superfrost Plus, BDH, Cat. No. 406/0179/00),
dried overnight at 37°C, dewaxed in xylene and rehydrated. Endogenous peroxidases
were blocked with 9% hydrogen peroxide in methanol for 30 min. After subsequent 5-
min washes in water and Tris-buffered saline (TBS), the sections were incubated for 30
min at room temperature with normal porcine serum (NSS) prepared as a solution of 1
ml normal swine serum and 5% bovine serum albumin (BSA) in 4 ml TBS. Following
the BSA block, the porcine serum was removed and immediately replaced with 5CC-R1
antiserum (Eicheler et al, 1995), diluted 1:500 and 1:100 in TBS for tissues fixed in
Bouins and NBF, respectively. Negative control sections were treated with similarly
diluted non-immune rabbit serum instead of 5a-Rl antiserum. The immunoreaction
was incubated overnight at 4°C. After two 5-min washes in TBS, biotinylated swine
anti-rabbit (DAICO, Denmark, Cat No. E 0353), diluted 1:500 in NSS, was added on to
the sections and incubated for 30 min at room temperature. After two 5-min washes in
TBS, ABC-HRP complex (DAKO, Denmark, Cat. No. IC0355) in salt-free Tris buffer
(0.05M, pH 7.4) was added to the sections. Tissues were incubated for 30 min at room
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temperature. Two subsequent 5-min washes in TBS were followed by addition of the
chromagen, 3,3-diaminobenzadine tetrahydrochloride (DAB) which was prepared as
described (DAKO, Denmark, Cat. No. K3468). Specific rmmunostaining was localised
as brown pigmentation. The colour development reaction was stopped by immersing
the slides in water. The sections were subsequently dehydrated, counterstained with
haematoxylin (see Appendix I), mounted in resin, and left to dry before analysis by light
microscopy.
5.2.3. In situ hybridisation
Serial sections of paraffin-embedded tissues (5 |0,m) fixed in Bouins were
mounted on slides, dried overnight at 37°C. In situ hybridisation was adapted from
methods described by Slee et al., (2001). Prehybridisation was carried out by dewaxing
the tissues in histoclear, rehydrating, refuting, and permeabilising by digestion with
proteinase K at a concentration of 10 pg/ml for 7.5 min at 37°C. Followed by
subsequent washes in PBS and 2X SSC, the tissues were then acetylated and rewashed in
2X SSC prior to dehydration through a series of graded alcohols. Hybridisation was
performed overnight at 55°C with [35S]UTP-labelled complimentary RNA (cRNA)
probes (antisense riboprobes) generated from cDNA templates described in Chapter 4,
Experimental procedures, 4.2.4.2. I. using an RNA transcription kit (Promega Corp.).
Sense riboprobes, used as controls for non-specific binding, were generated similarly
from cDNA cleaved with Not I instead of EcoR V. Post hybridisation washes were
done in buffers of decreasing salt concentrations at 55°C, followed by dehydration
through ethanol gradients, and processed for liquid emulsion autoradiography (Kodak
NTB-2). After exposure for 3 weeks at 4°C, the slides were developed and
counterstained with haematoxylin for photomicrography.
5.2.4. Data Analysis
The specific 5CC-R1 immunostaining and radioactive signals were quantified as
optical densities and granules per unit area, respectively, by image analysis (Image Pro-
Plus software, Media Cybernetics, L.P., Silver Springs, MN, USA). The abundance of
5a-Rl protein and mRNA was expressed as a percentage of the control values. Data




5.3.1. Cellular Localisation of 5(X-R1 in Immature Rat Ovary
Using ovarian tissue sections of immature, untreated rat ovary, the cellular
localisation of 5(X-R1 protein and mRNA gene was investigated using
immunocytochemistry (ICC) and in situ hybridisation (ISH), respectively.
5.3.1.1. Localisation of 5(X-R1 in rat ovary by immunocytochemistry
Thecal and interstitial cells showed strong and specific immunostaining with the
50C-R1 antiserum, but the granulosa cells and ovarian stromal tissue were devoid of any
immunoreactivity (Figs. 5.1A, C and 5.2). No immunoreaction occurred in
corresponding tissue sections that were incubated with non-immune rabbit serum
instead of the anti-serum (Fig. 5.IB and D). The specific immunostaining in ovaries
fixed in either Bouins or NBF was localised to thecal/interstitial tissue. The oocytes in
Bouin's-fixed tissues had slight non-specific immunostaining (Fig. 5.1A) which was
absent in NBF-fixed tissues (Fig. 5.1C) or in situ (Fig. 5.4A). Figure 5.2 shows a high
power image of the cellular distribution of 5a-Rl in immature rat ovary fixed m Bouins.
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FIGURE 5.1. Cellular localisation of 5a-Rl in immature rat ovaries fixed in Bouins
and NBF. The cellular localisation of 5a-Rl in ovaries (see "Experimental Procedures,
5.2.2) fixed in Bouins (top panel) and NBF (bottom panel) was done in tissues incubated
with 5ct-Rl antiserum (A & C) and non-immune rabbit serum (B & D). Non-specific
immunostaining of the oocytes (★) in the Bouins-fixed tissue was not reflected in NBF-fixed
ovarian tissue.
FIGURE 5.2. High power image of specific 5a-Rl immunostaining in immature rat
ovary. Specific 5a-Rl immunostaining in thecal (solid arrows) and interstitial (arrow heads),
while absent in granulosa cells (asterisks), shows the enzyme's cellular distribution in ovaries
fixed in Bouins.
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The heart (negative control tissue) showed no immunoreactivity (Fig. 5.3A), but
the liver (positive control tissue) had very intense immunostaining throughout the tissue
(Fig. 5.3B). The immunoreaction was only present in the hepatocytes where the staining
intensity showed a gradient pattern with more intense staining around the portal canals
which decreased radially into the hepatocytes. Connective tissue cells were unstained.
Consistent with the ovarian tissue, tmmunostaining was absent in liver tissue sections
that were incubated with non-immune serum.
FIGURE 5.3. Immunocytochemical staining of 5a-reductase type 1 in immature rat
heart and liver. As described (Experimental Procedures, 5.2.2), localisation of 5a-Rl was
investigated in Bouins-fixed heart (A) and liver (B) tissues collected from immature female
rats. Inset panels- tissues incubated with non-immune serum; P- portal canal.
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5.3.1.2. Localisation of 5a-Rl in rat ovary by in situ hybridisation
Consistent with the findings of ICC, ISH detected intense 5a-Rl signalling that
localised specifically to the theca and interstitial cells (Fig. 5.4). The signal was absent in
granulosa cells.
FIGURE 5.4. Localisation of 5a-Rl mRNA by in situ hybridisation. In situ
hybridisation analysis of 5a-Rl (see "Experimental Procedures", 5.2.3) in sections of Boiuns-
fixed ovaries collected from immature untreated rats which were hybridised with antisense
probe (A) shows the expression of 5a-Rl in thecal (solid arrows) and interstitial tissue {arrow
heads). Note the lack of specific 5a-Rl signal in granulosa cells {asterisks). A corresponding
ovarian section hybridised with sense riboprobe (B) was the control for nonspecific
hybridisation.
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5.3.2. Effect of Gonadottophic Stimulation on the Cellular Distribution of 50C-R1
in Rat Ovary
The effect of gonadottophic stimulation on the cellular distribution of 50C-R1
protein and mRNA gene in rat ovaries stimulated in vivo to attain follicular maturity
(Chapter 3, Experimental Procedures, 3.2.1) was investigated using ICC and ISH.
Although NBF was a better fixative for ICC, to standardise tissue preparation, these
studies were performed on ovaries fixed in Bouin's solution.
Figure 5.5 shows the changes in the cellular distribution of 5CC-R1 as well as the
developmental changes induced in rat ovaries stimulated by eCG with or without hCG.
The ovaries of intact immature and untreated rats (controls) were occupied
predominantly with primary and secondary follicles, and a few small-sized antral follicles
(Fig. 5.5E). Control rats had the highest levels of expression of 5CC-R1 mRNA and
protein which were abundantly localised in thecal/interstitial tissue, particularly of
preantral and small antral follicles (Fig. 5.5A and E). Treatment with eCG, while
resulting in proliferation of the follicles and appearance of many large antral follicles,
reduced markedly the expression of 5(X-R1 in thecal tissue of the enlarged antral
follicles, even though the protein was still quite abundant in interstitial tissue around
preantral follicles (Fig. 5.5F). However, the levels of expression of the interstitial
enzyme in cells around preantral and small antral follicles was reduced significantly (P<
0.0001) to 80% of the control value. By ISH, 5a-Rl mRNA expression was also
reduced significantly (P< 0.01) by eCG to undetectable levels (Fig. 5.5B). Subsequent
12-h treatments with hCG caused further enlargement of the follicles with noticeable
increments in the sizes of the thecal layers around the larger follicles (Fig. 5.5G). By
inducing luteinisation, the treatment also caused the emergence of post-ovulatory
follicles, of which some developed corpora lutea. In addition to the interstitial
compartment where 5CC-R1 mRNA was still expressed, but at 60% of the control level
(Fig. 5.5C), 5a-Rl protein as shown by ICC was present in the thecal layers of large
antral and post-ovulatory follicles to marginally detectable levels, and also occurred in
the corpora lutea (Fig. 5.5G).
Notably, the immunostaining was higher in the thecal layer compared to the
corpora lutea. At 24 h after hCG treatment, the ovaries had attained the largest size,
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FIGURE 5.5. Gonadotrophic regulation of the cellular distribution of 5a-Rl mRNA
and protein in rat ovary. ISH (left-handside panels) and ICC (right-handside panels)
analysis showed 5a-Rl mRNA and protein, respectively, in ovaries collected from immature
rats stimulated as described (Experimental procedures, 3.2.1). A & E- immature, untreated
ovaries, (controls); B & F- eCG-stimulated ovaries; C & G- eCG + hCG for 12 h; D & H-
eCG + hCG for 24 h. P= primary follicles; PA= preantral follicles; SA= small antral follicles;
LA= large antral follicles; CL= corpus luteum; PO= postovulatory follicles.
FIGURE 5.6. Gonadotrophic-controlled patterns of cellular 5CX-R1 expression in the rat ovary.
Using ovarian tissues from rats stimulated as described (Chapter 2, Experimental Procedures, 3.2.1),
quantification of the specific 5(X-R1 signals detected by ISH (A) and ICC (B) was expressed as a
percentage of the control value. C= immature, untreated rats (controls); P= eCG-treated rats (48 h);
H12= rats treated with eCG followed by hCG treatment for 12 h; H24= rats treated with eCG
followed by hCG treatment for 24 h. Each bar represents the mean quantification (+ SD) of specific
50C-R1 detected in 3 or 10 microscopic fields analysed on each section investigated by ISH or ICC,
respectively, a, Significantly lower (P< 0.01) than all other treatments; b, significantly lower (P< 0.05)
than C; a1, significantly lower (P< 0.01) than HI2; c, significantly higher (P< 0.0001) than all other
treatments.
and were mainly occupied by post-ovulatory follicles and corpora lutea, and few large
antral follicles (Fig. 5.5D and H). In comparison to the expression of 5CC-R1 in the
controls, the longer hCG treatment also reduced the 5a-Rl immunostaining and signal
significantly (P< 0.0001 and P< 005) in tissues analysed by ICC and ISH, respectively.
The 5a-Rl signal in interstitial tissue, although significantly reduced compared to
controls, was stronger compared to thecal tissue which also had more intense
immunostaining than the corpora lutea. However, the expression was still higher
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compared to eCG-treated ovaries. Figure 5.6 summarises graphically the changes
induced by eCG and hCG in the cellular distribution of 50C-R1 in the rat ovary. At all
stages of follicle development, the stroma and granulosa cells were essentially devoid of
5a-Rl expression.
5.3.3. Cellular Localisation of 5(X-R1 in Adult Rat Ovary
The cellular localisation of 5CC-R1 in the adult rat ovary at different stages of the
oestrous cycle, ascertained by vaginal cytology, was studied by ICC (Fig. 5.7). Attempts
to localise the 50C-R1 mRNA signal using ISH were unsuccessful because the levels of
expression of the enzyme in adult ovaries were undetectable by the technique.
In the adult rat ovary, 50C-R1 immunostaining was highest in ovaries at proestrus
(Fig. 5.7A). However, the levels of expression were markedly low compared to
immature ovaries. Hence, it was not possible to generate quantifiable data by Image
ProPlus analysis (see Data Analysis5.2.4). However, it was evident that 5a-Reductase-l
was mainly localised in the interstitial tissue where its expression was marginally higher
than the thecal tissue expression. Progression into the oestrus stage resulted in
complete disappearance of the 5CC-R1 immunostaining in the interstitial and thecal tissue
(Fig. 5.7B). Further development to the metestrus stage restored very weak expression
of 50C-R1 in the thecal tissue and also similarly resulted in weak 50C-R1 immunostaining
in the developed corpora lutea (Fig. 5.7C). By diestrus, 5CC-R1 immunostaining,
although still present in the thecal and corpora lutea, was barely detectable. The
granulosal and stromal tissues were clearly devoid of 5a-Rl expression at all stages of
the oestrus cycle.
5.4. DISCUSSION
Although previous reports have suggested that 50C-R1 was present in both thecal
and granulosal tissues of the rat ovary (Hillier et al, 1980a; Aono et al., 1981; Payne et al.,
1992), the immunohistochemical and in situ hybridisation studies described in this
chapter show specifically that the cellular localisation of 5CC-R1 was restricted to the
thecal/interstitial cells in the rat ovary, and was absent in ovarian stroma and granulosa
cells. This distinction is probably due to the techniques used to collect the tissue
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FIGURE 5.7. Cellular localisation of 5a-Rl in adult rat ovary. Ovaries collected from
cyclic adult rats at different stages, (A) proestrus, (B) oestrus, (C) metestrus and (D) diestrus,
of the oestrous cycle were studied by ICC of normal-buffered formalin (NBF)-fixed ovarian
tissue sections (see Experimental Procedures, 5.2.2). Marked tissues are theca (solid arrows),
interstitial tissue (arrow heads)', granulosa cells (asterisks) and corpora lutea (crosses).
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enzyme activity of granulosa cells resulted in this misconception because collection of
rat granulosa cells by repeated puncture of the follicles as described in Experimental
Procedures, 3.2.2 or by squeezing the ovaries between glass slides, results in
contamination of the granulosal fraction with thecal/interstitial cells. It is likely that the
supposed 50C-R activity observed in such activity studies is a result of the
thecal/interstitial cell contamination other than the actual localisation of 50C-R activity in
granulosa cells of rat ovary.
The distinct 5CC-R1 cellular localisation might also be species-specific since both
the theca and granulosa cells of the human ovary have been shown to express 50C-R1
mRNA and protein (Jakimiuk et al., 1999; Akahira et al., 2001). Although the illustration
of 5CC-R2 expression was unsuccessful, it is probable that the isozyme in females is
mostly expressed in non-ovarian tissues such as skin (Haning et al., 1996). The
abundant distribution of 50C-R1 in liver tissue (Fig. 5.3B) while absent in heart tissue
(Fig. 5.3A) is in agreement with reported tissue distribution of the enzyme (Russell &
Wilson, 1994). The radial pattern of immunostaining observed in the liver tissue was
similar to previous immunohistochemical studies of 5a-reductase in rat liver (Eicheler et
al, 1995).
The specific expression of 5CC-R1 in the theca and interstitial cells in the rat
ovary suggests that the actions of the enzyme are distinct to the cell types in which they
are expressed and this is probably of relevance to the metabolism of ovarian steroids
that the enzyme uses as substrates. In relation to androgen metabolism, 5CC-R1 converts
androstenedione and testosterone into the 5a-reduced steroids, 5a-A and DHT,
respectively which inhibit oestrogen synthesis by inhibiting aromatase competitively
(Hillier et al., 1980a). It is therefore probable that the high expression of 5CC-R1 in
immature ovaries (Figs. 5.1, 5.2, 5.4, 5.5) ensures that synthesised androgens do not
undergo precocious metabolism into oestrogens, which are required for normal
physiology in adult, postpubertal female animals. It is well known that in adults, normal
follicle growth that culminates in ovulation and hence, ensures fertility, requires FSH-
induced developmental changes that equip developing follicles with structural and
steroidogenic maturity which is dependent on oestrogens (Hillier et al., 1988; Palter et al.,
2001; Rosenfeld et al., 2001). The changes in the localisation of 5CC-R1 in hormonally
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stimulated ovaries in immature rats (Fig. 5.5) or adult cyclic ovaries (Fig. 5.7) illustrate
the regulatory role of gonadotrophins in the enzyme's cellular distribution in the rat
ovary.
The stimulation of ovaries of immature rats in vivo allowed the study of the
effects of gonadotrophic regulation of 50C-R1 in an animal model. Whereas the enzyme
was highly expressed in the thecal/interstitial cells in ovaries of immature rats (Fig. 5.5A
& E), the down-regulation of its expression in thecal cells of larger antral follicles by
eCG (Fig. 5.5B & F) suggests that the enzyme is downregulated by FSFI. In fact, this
FSH effect was clearly demonstrated by in situ hybridisation where the expression of 50.-
R1 mRNA in both theca and interstitial cells was reduced significantly (P< 0.01) by
eCG (Fig. 5.5B). The findings agree with other studies that reported the inhibitory
effect of FSH on 5CC-R1 (Aono et al., 1981; Payne et al., 1992). Whereas the 50C-R1
mRNA gene was completely turned off by eCG (Fig. 5.5B), the protein was still present
in the interstitial cells of preantral and small antral follicles (Fig. 5.5F) suggesting a
temporal association between the gene expression and protein synthesis. The abundant
expression of 50C-R1 protein in interstitial cells of eCG-stimulated ovaries, albeit
reduced compared to controls, while almost absent in thecal cells might be due to the
expression of the protein lagging behind the gene expression. When eCG switched off
the 5a-Rl gene, similar effects on the protein expression would be expected to follow,
as suggested in studies of adult rat ovaries where the decline in 50C-R1 protein activity
lagged hours behind the gene expression (Lephart et al., 1992). The restoration of
detectable 5CX-R1 immunostaining within thecal cells by hCG administered for 12 h (Fig.
5.5G) showed the stimulatory effect of LH on 5a-Rl expression, as previously reported
(Terakawa et al, 1978; Fukuda et al., 1979; Aono et al., 1981). However, the increase due
to the 12-h hCG-treatment was transient, as shown by the significantly lower
expressions of 5a-Rl mRNA in ovaries treated for 24 h (P < 0.05).
Although present in adult cyclic ovaries as shown by immunohistochemistry
(Fig. 5.7), die expression of 5a-Rl was very low and could not be demonstrated by in
situ hybridisation. It is probable that the enzyme does not have as prominent a role in
adult ovarian function as in the immature ovary. However, the 5CX-R1 expression was
developmentally regulated throughout the oestrous cycle. The highest levels of 50C-R1
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expression occurred during proestrus, and the enzyme was localised in the interstitial
tissue. The thecal cells of the adult ovary were essentially devoid of 50C-R1 protein
suggesting that 5CC-R1 activity is lost from thecal tissue, but retained at very low levels in
interstitial tissue. It is unclear why this change in cellular distribution occurs. Possibly,
the removal of the inhibitory effect of 5CC-reduced steroids, particularly androgens, is tire
driving requirement behind the loss of 5(X-R1 expression in thecal tissue of adult
ovaries. The physiological consequence is the removal of aromatase inhibitors, which
reduce aromatase activity that is crucial for reproductive function. Examples of
aromatase 'action' are the oestrogenic effects in the ovary and vaginal wall. Oestrogens
induce concomitant proliferation of the epithelial cells of the vagina in readiness for
coitus (Johnson & Everitt, 1995), and ovarian granulosal cells in preparation of oocyte
release at ovulation (Gaytan et al., 1996; McGee & Hsueh, 2000). The effect on rodent
vaginal cytology is particularly marked such that the stages of the oestrous cycle can be
assessed quite accurately by examination of tire cell types present in smears of swabs of
the vaginal epithelium. The ovarian and vaginal changes are vital for successful
reproduction, and any hindrance to oestrogen release, particularly, oestradiol, the most
potent oestrogen, must be removed to ensure fertility. Therefore, the changes in the
cellular distribution of 50C-R1 protein in the adult ovary during the stages of the
oestrous cycle are likely to be a response to this requirement.
During proestrus, rising FSH levels induce granulosa cells to produce rising
levels of oestrogens, which drive different reproductive processes. As a result, oestrus,
the period when FSH is at peak level, is marked with complete loss of 5a-Rl
expression, even in the thecal cells (Fig. 5.7B). The critical dependence of oestrus on
oestrogen production requires removal of the ovarian mechanisms that inhibit
aromatase activity. Following the drop of FSH as the cycle develops, production of
oestrogens by the granulosa cells also drops precipitously such that the proliferative
effects on the vaginal epithelium are removed. During this metestrus phase, the rising
levels of LH which induce synthesis of progesterone also stimulate 5CC-R1 expression
which is then expressed faintly in the interstitial and the corpora lutea that develop (Fig.
5.7C). Since progesterone is readily metabolised by 5a-Rl and is a preferred substrate
for the enzyme than androgens (Eckstein & Nimrod, 1977; Normington & Russell,
1992; Payne et al, 1992), 5a-Rl action probably converts progesterone into 5a-reduced
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pregnanes which have been suggested to improve reproductive function in oestrogen-
primed rats by facilitating the females' sexual receptivity of the males (Frye & Vongher,
2001). By diestrus, which is marked by low oestrogemprogesterone ratios, the
expression of 5CC-R1 is reduced in both interstitial tissue and corpora lutea (Fig 5.7D).
Studies in 50C-R1 knockout mice have shown that the enzyme is crucial for
successful pregnancy outcome through its conversion of progesterone into 5a-reduced
pregnanes which are necessary for cervical ripening (Mahendroo et aL, 1999) suggesting
that in the adult, 5CC-R1 is a more important enzyme in the endocrinology of pregnancy
rather than preovulatory follicular development. Infact, the uterus was shown to be a
site for 5CC-R action where progesterone was metabolised, particularly in oestrogen-
primed animals into various steroids among which were 5a-reduced pregnanes (Verma
& Laumas, 1976). Therefore, it is likely that 5CC-R1 in the adult female has a more
important role in uterine rather than ovarian endocrinology.
Interestingly, in women, increased activity of 5(X-R1 is indicated in polycycstic
ovarian disease (Agarwal et al, 1996; Jakimiuk et al., 1999). Evidence for this was
investigated by measurement of 5CC-reduced androgens in polycystic ovaries, which is
discussed in Chapter 6.
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Chapter 6. Measurement of 17-ketoandrogens (17KA),
androstenedione and oestradiol levels in normal
and PCOS follicular fluids
6.1 INTRODUCTION
Since the description of polycystic ovary syndrome (PCOS) as a major infertility
problem arising from anovulation (Stein & Leventhal, 1935), the syndrome has been
well recognised as a common endocrinopathy ofwomen of reproductive age (Franks &
White, 1993; Knochenhauer et al., 1998; Franks et al., 1999; Marshall, 2001). However,
there are many causes of anovulation, and hence, of PCOS. While the pathogenesis of
PCOS remains elusive and is still a subject of controversial debate, a common symptom
is hyperandrogenemia (Barnes, 1997; Legro et al., 1998; Nelson et al., 1999; Dunaif &
Thomas, 2001; Zborowski et al, 2001). Whether secreted by either or both androgen-
secreting organs, the ovaries or adrenals, the circulating high levels of androgens
contribute significantly to the clinical presentation of PCOS (Speroff et al., 1983). Of
particular interest in this study, are the 5CC-reduced androgens that are part of the
hyperandrogenemia of PCOS (Lawrence, 1968; Laatikainen et al., 1980; Matteri et al.,
1989; Agarwal et al., 1996; Franks et al., 1999; Jakimiuk et al., 1999).
Although the involvement of 5a-reduced androgens in PCOS is still unclear,
their inhibitory effect on aromatase action in vitro (Hillier et al., 1980) suggests a
modulatory role of ovarian follicle development via their effects on oestrogen
production. Since the levels of steroids are much higher in the ovary as compared to
the general circulation, it is likely that 50C-reduced androgens inhibit follicle development
locally. Therefore, measurement of the levels of 5a-A, the 5a-reduced metabolite of
androstenedione, the principal androgenic substrate in human ovaries, as well as other
5a-reduced androgens in follicular fluid, is important in assessmg the magnitude of the
role of 5a-reduced androgens in the aetiology of PCOS. In the absence of a standard
method to measure 5CC-A, a RIA was developed to quantify 5CC-A. The availability of an
antibody that was raised against androsterone, but has high cross-reactivity with 5a-A
and androstenedione, enabled the development of a RIA, which measured 5a-A,
androsterone and androstenedione simultaneously, hereafter defined as 17-keto
androgens (17KA) RIA. As described by Hillier (1974), androsterone, a small non-
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immunogenic molecule (MW= 290.4) was linked covalently to bovine serum albumin
(BSA), a carrier molecule, to form androsterone-3-BSA, which is immunogenic.
Injection of androsterone-3-BSA into rabbits raised antibodies against androsterone-3-
BSA. Characterisation of the rabbit serum containing the antibodies (antiserum)
showed that the antiserum cross-reacted and had greater affinity for 50.-A than the
parent steroid, a property used to establish a RIA for 17KAs. Thus by performing this
assay on biological samples along with separate specific RIAs of androstenedione and
oestradiol, it was possible to estimate relative concentrations of 50-reduced-17-
ketoandrogens (5al7KAs), androstenedione, and oestradiol in follicular fluids of
normal and PCOS subjects.
6.2. EXPERIMENTAL PROCEDURES
6.2.1. Titration ofAnti-Androstetone Serum
Rabbit anti-androsterone-3-BSA serum (provided by Prof. S.G. Hillier, Univ. of
Edinburgh, Dept. ofReproduction and Developmental Sciences, Litde France, UK) was
stored at -20°C and diluted (1:100) as required in phosphate buffered saline containing
0.1% gelatine, pH 7.2 (PBS) to obtain a stock solution, which was also stored as 1.0 ml
aliquots at -20°C.
After an initial dilution (1:2.5) of stock antiserum in PBS, 200 |ll of serial
dilutions (1:4) in PBS were mixed with a constant amount of [3H]androsterone (~ 10,000
cpm/200 pi PBS). The reactions were incubated overnight at 4°C. To terminate
incubation, 0.5ml 1% dextran charcoal suspension was added to the reactions, which
were vortexed and incubated on ice for 10 min to separate bound and free
[3H]androsterone. After centrifugation at 2500 g for 10 min at 4°C, the supernatant
(containing free [3H]androsterone) was decanted into vials to which 3.5 ml scintillation
fluid was added. The radioactivity was then measured by (3-scintillation counting
(Model Tri-Carb 2100TR, Packard, A Canberra Company, USA). Plots of the
radioactivity against the antierum dilutions generated titration curves from which the
working antiserum dilution (titte) was obtained.
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6.2.2. Preparation of 17KA RIA standard curve
200 pi aliquots of freshly diluted antiserum (1:2000 in PBS) and 200 pi
[ H]androsterone (~ 10,000 cpm diluted in PBS) were added to duplicate tubes
containing 100 pi of 5a-A standard solutions of concentrations, 0.04, 0.08, 0.16, 0.31,
0.625, 1.25, 2.5, 5.0, 10.0 and 20.0 ng/100 pi. The standard solutions were prepared
from the 50C-A stock solutions of concentrations of 20 ng/lOOpl by serial dilutions in
PBS. After vortexing, the reactions were incubated overnight at 4°C. Separation of the
bound and free [3H]androsterone by dextran charcoal (as described above) yielded
fractions of unbound radiolabelled steroid that were inversely proportional to the
amount of added unlabelled 5CC-A. The plots of the specific binding against the 50C-A
standard concentrations (standard curves) used to measure the steroid concentrations
were calculated by an assay calculator (Assay Zap, Universal Assay Calculator, Biosoft,
Cambridge, UK).
6.2.3. Specificity of 17KA RIA
The relative affinities of the heterologous steroids, androsterone, DHT,
androstenedione, testosterone, 5a-androstane-3a,17(3-diol, 5a-androstane-33,17f3-diol,
oestradiol and progesterone, for the androsterone antiserum were determined by
competitive binding with 5CC-A. Stock solutions of the listed steroids (pure grade) in
ethanol (2mg/ml) were diluted 1000-fold in ethanol followed by a 10-fold dilution in
PBS to form standard solutions at a concentration of 20ng/100pl. Serial dilutions of
these stock solutions in PBS generated steroid solutions with concentrations ranging
0.04 - 20 ng/lOOpl, which were assayed alongside the 5al7KA standard curve described
above. Taking arbitrarily the crossreaction of 5aA in this system as 100%, the percent
cross-reaction of steroid X is calculated at 50% displacement of [3H]androsterone. The
percent cross-reaction ofX equals:
mass of 5aA required to displace 50% of [3Hlandrostrone
mass of steroid X required to displace 50% of [ H]androsterone
6.2.4. Synthesis of [3H] 5a-Androstanedione:
6.2.4.1. By COS cells transfected with 50C-R1 cDNA
Simian COS-7 cells were transfected with 5CC-R1 cDNA as described (Qiagen
Superfect, UK). 5a-Reductase-l activity was then used to synthesise [3H]5a-A in vitro as
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described (Andersson & Russell, 1990) except that the radiolabelled steroid, incubation
periods and TLC system used were [3H]androstenedione (final specific activity- 93
pCi/mmol), 30 and 60 min, and alumina pre-coated TLC sheets developed with
cyclohexane:toluene: ethanol (100:95:5 v/v/v; see Chapter 3, 3.2.8.1.), respectively. The
conversion of [ H]androstenedione to [3H]5ot-A was monitored by
radiochromatography.
6.2.4.2. By endogenous 17P-HSD2 in COS cells
To exploit the 17(3-HSD activity endogenous in COS cells (Poutanen et al,
1993), non-transfected Simian COS-7 cells were treated as described above except for
the radiolabelled steroid and co-factor which were changed to [3H]DHT (final specific
activity 100 pCi/mtnol), and 1 mM NAD, respectively.
6.2.4.3. Purification of [3H] 5a-A
Tritiated 5a-A was purified by TLC (Chapter 3, 3.2.8.1). Recovery of [3H]5a-A
from the TLC sheets was achieved by solvent elution using the apparatus shown in Fig.
6.1. The position of separated [3H]5CC-A on the TLC sheets was identified by running
5ct-A standards (2 jig) on the sides of the sheets at positions widely spaced from the
experimental samples to avoid contamination. The positions in the lanes containing the
synthesised [3H]50C-A were excised and eluted with 4 ml methanol. The eluate was
collected in 16 x 100 mm borosilicate glass tubes (Corning Inc. NY, USA). To ascertain
the radioactivity and purity of the synthesised [3H]5CX-A, 50 jil aliquots of the eluate
were analysed by scintillation counting as described in section 6.2.2, and also dried
under nitrogen gas in a heated solid block at 55°C for analysis by radiochromatography
(Chapter 3, 3.2.8.1). The remaining fraction of the eluate was dried similarly and the dry
residues of purified radiolabelled [3H]5a-A were dissolved in 1 ml toluene: ethanol (9:1
v/v). The 30- and 60-min [3H]5a-A preparations were pooled and stored at -20°C until
further use.
6.2.5. Extraction of Steroids from Follicular Fluid Samples
Follicular fluids were diluted 1 in 10 PBS. Duplicate 100 pi aliquots of the
dilutions were transferred into 16 x 100 mm glass tubes. To each sample, a solution of
[3H]5a-A in ethanol (-2000 dpm) was added as an internal recovery standard. Identical
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aliquots were transferred to scintillation vials in duplicate for determination of the total
radioactivity added. Extraction of the steroids was performed with 1 ml diethyl ether as
described (Chapter 3, 3.2.7) and followed by dissolving in 500 |Xl PBS, which was
completed by incubation in a waterbath at 37°C. After vortexing, 250 |ll of the PBS
solution was transferred into a scintillation vial for counting to assess the recovery of
[3H]50C-A added to the follicular fluid samples. Duplicate 100 [ll ahquots of the
remaining PBS solution were analysed by the 17KA RIA. In addition, duplicate 100 fll
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50C-androstanedione, androsterone and androstenedione were measured in a
single assay as described (Section 6.2.3) using an antibody that showed a high degree of
crossreactivity with all three steroids. The inter-assay coefficients of variation for the
low (0.4 + 0.1 ng/100 fll) and "high" (2.4 + 0.3 ng/ 100 pi) 50C-A quality control
solutions were 22% and 14%, respectively.
6.2.6.2. Androstenedione radioimmunoassay
Androstenedione was measured in extracted follicular fluid samples as described
previously (Hillier et al, 1991). The intra- and inter-assay coefficients of variation were
11% and 9%, respectively.
6.2.6.3. Oestradiol radioimmunoassay
Oestradiol was measured as described previously (Chapter 3, 3.2.8.2). The intra-
and inter-assay coefficients of variation were 8% and 11%, respectively.
6.2.7. Data Analysis
The steroid levels measured by the RIAs were determined using an assay
calculator (AssayZap, Biosoft, Cambridge) and analysed by one-way ANOVA and
student's t-test.
6.3. RESULTS
6.3.1. Establishment of 17KA RIA
To measure the 17KAs, a RIA system was developed using androsterone
antiserum, unlabelled 5a-A as standards and [3H]androsterone as the radioligand.
6.3.1.1. Evaluation of androsterone antiserum
Knowing that the specificity of a RIA is dependent on the antiserum, the
androsterone antiserum was evaluated by antibody dilution and cross-reactivity studies.
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I. Determination of antiserum titre
The dilution of the androsterone antiserum used to set up the 17KA RIA,
1:2000 (Fig. 6.2), corresponded to 50% binding of [3H]androsterone (see "Experimental
Procedures, 6.2.1").
FIGURE 6.2. Antibody dilution curve used to define antiserum titre for the 17KA
RIA. The specific binding of [3H]androsterone in serial dilutions (1:4) of stock antiserum
solution (see "Experimental Procedures, 6.2.1") was employed to identify the antiserum titre
that was used to establish a 50C-A RIA. The titre read off the plot of specific binding versus
dilution of antiserum (antibody dilution curve), corresponding to 50% specifrc binding of
the antiserum, 1:2000, was used in the 17KA RIAs.
II. Specificity of anti-androsterone serum
The relative specificity of the antiserum for 5CC-A was determined by comparing
the relative affinity of the antiserum for various steroids structurally similar to 5a-A and
known to be present in follicular fluid as described (Experimental Procedures, 6.2.3).
Androsterone and androstenedione cross-reacted significantly with the
antiserum (Fig. 6.3). On the other hand, cross-reaction with testosterone, DFIT, 50C-
androstane-3a,17P-diol, 5a-androstane-3(3,17|3-diol, oestradiol and progesterone was
minimal (< 0.1%). Therefore, the assay showed class specificity for 17ketoandrogens.
Table 6.1 lists the cross-reactions of the steroids with the antiserum.
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FIGURE 6.3. Cross-reaction of heterologous steroids with anti-androsterone serum











TABLE 6.1. Cross-reactions of various steroids with anti-androsterone antibody used for
the 17KA RIA.
^Calculated as- ng5a-Aat 50% binding x 100
ng heterologous steroid at 50% binding
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6.3.1.2. Synthesis of [3H]5a-A
To improve the specificity of the 17KA RIA, the steroids were extracted with
ether prior to measurement by RIA. The extraction efficiency was assessed by analysis
of samples spiked with trace counts of [3H]5oc-A (~2000 dpm). Tritiated 5CC-A was
synthesised in vitro using the enzyme activities of 50C-R1 transfected and endogenous
17|3-HSD2 in COS cells.
I. Synthesis of [3H]5tX-A by 5a-Rl activity
COS cells transfected with 5CC-R1 (Experimental Procedures, 6.2.4.1) converted
[3H]androstendione into [3H]5a-A (Fig. 6.4).
FIGURE 6.4. Synthesis of [3H]5a-A by COS-7 cell transfected with 5a-Rl. The
conversion of [3H]androstenedione (A4) to [3H]5a-androstanedione (5a-A) by COS cells
transfected with 5CC-R1 (Experimental Procedures, 6.2.4.1) is shown by radiochromatography
performed on alumina pre-coated sheets developed with cyclohexane:toluene:ethanol
(100:95:5, v/v/v) solvent system. *h unknown non-polar steroid metabolite; *2: unknown
polar steroid metabolite.
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II. Synthesis of [3H]5a-A by 17|3-HSD activity
Endogenous 17(3-HSD activity in COS cells (Poutanen et al, 1993) also converted

















FIGURE 6.5. Synthesis of [3H]5a-A by endogenous 17P-HSD in COS-7 cells. The
conversion of [3H]dihydrotestosterone (DHT) to [3H]5(X-androstanedione (5ct-A) by 17(3-
HSD endogenous in COS cells during 30- and 60-min incubations (see "Experimental
Procedures", 6.2.1.2) is shown by radiochromatography performed on alumina pre-coated
sheets developed with cyclohexane:toluene:ethanol (100:95:5, v/v/v).
6.3.1.4. Precision and sensitivity of 5CC-17KA RIA
The standard curves of the 17KA RIA (Experimental Procedures, 6.2.3) were
typically sigmoid (Fig. 6.6), and covered the range of levels of 5a-A expected in follicular
fluids from normal ovaries (Milewich et al, 1992; Agarwal et al., 1996). The specific and
non-specific binding (NSB) of the assay were 53.9% and 3.7%, respectively (n=20).
Precision at the 20th, 50th and 80th quartiles is shown in Table 6.2.
The sensitivity of the assay was 0.02 ng/100 pi (0.67 nM). The intra- and inter
assay variability, determined using pooled follicular fluids with 50C-A levels of 2.62 ± 0.07
ng/ 100 pi (mean ± SD, n= 4), were 10.4% and 10.6%, respectively.
103
FIGURE 6.3. Standard curve of 17KA RIA. The sigmoid standard curve prepared with 0.04 -
20.0 ng/100 pi range of 5a-A concentrations was generated by Assay Zap Universal Calculator
(Biosoft, Cambridge, UI<).
Quartile Mean + SD
<NII
ED 20 2.7 ± 0.9
ED 50 0.8 ±0.3
ED 80 0.2 + 0.1
TABLE 6.2. The precision of the standard curve of the 17KA RIA was shown by the 20, 50
and 80 effective doses.
6.3.1.4. Determination of accuracy of 17KA RIA
To determine the accuracy of the RIA for 50C-A, the concentration of 5tt-A in
pooled follicular fluid samples with and without 10 ng 50t-A added, was measured by
the RIA (Table 6.3). Adjusting for extraction and buffering losses, the differences in the
concentrations of 5a-A between follicular fluid samples where 5CC-A steroid was added
and those without added steroid were on average, 12.2 + 1.1 ng/100 pi, values that
correlate well with the amount added, i.e., 10 ng/ 100 pi. The extraction and recovery
losses were assessed by recovery of [3H]5a-A added to the samples and were
determined as percentages of the added radioactivity. Blanks obtained by extracting
PBS and distilled water (in parallel to the test samples) were undetectable.
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Sample 5a-A (ng/ 100 pi)
FF pool
FF pool + 10 ng 5a-A




TABLE 6.3. The concentrations of 50C-A in samples of pooled follicular fluid (FF) with and
without added 5(X-A at known concentration were measured after ether extraction (see
"Experimental Procedures, 6.2.5) in quadruplicate in 3 replicate RIAs. The values are 5CC-A
concentrations (mean ± SEM) measured in each indicated group after adjusting for
extraction losses.
6.3.2. Measurement of 17KAs in follicular fluid of normal and PCOS women.
Although the two TLC systems developed , i.e., alumina- and silica pre-coated
sheets, could separate the follicular steroids, specifically androsterone and
androstenedione from 50C-A as shown, (Chapter 3, Figs. 3.4 and 3.8), they were
problematic in the complete recovery of [3H]50C-A. As a result, the assays on follicular
fluid were done without the chromatographic step, and hence, measured the two 5CC-
17ketoandrogens, 5a-A and androsterone, and androstenedione simultaneously.
Follicular fluids from normal and polycystic ovaries were provided by Prof. S. Franks
(Department of Reproductive Science and Medicine, Imperial College School of
Medicine, London, UK). The follicular fluids analysed are described in Table 6.4.
Normal Ovulatory PCOS Anovulatory PCOS
Phase ofmenstrual cycle Follicular Follicular -
Number of samples 39 44 36
Follicle size:
Mean 13.9 mm 8.4 mm 6.3 mm
Minimum 5 mm 4 mm 4 mm
Maximum 27 mm 21 mm 9 mm
Range 22 17 5
TABLE 6.4 Description of the follicular fluids.
The results of the RIAs of the follicular fluids are summarised in Table 6.5 and
Fig. 6.7.
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Table 6.5. The concentrations of 17KAs, androstenedione and oestradiol in follicular fluids
from ovaries of normally menstruating (normal) and polycystic ovulating (ovulatory PCOS)
women in the follicular phase of the menstrual cycle, and women with polycystic
anovulation (anovulatory PCOS) were measured in duplicate using the RIAs described in
"Experimental Procedures, 6.2.6." The values are mean ± SEM steroid concentrations (nM)
measured in each group.
The levels of the 17KAs were elevated significantly in follicular fluids from
women with both ovulatory (P < 0.01) and anovulatory (P < 0.05) PCOS compared to
follicular fluids of normal women (Fig. 6.7A). By comparison, the levels of
androstenedione were only raised significantly in ovulatory PCOS women when
compared with follicular fluids of normal women (P < 0.01; Fig. 6.7B). This increase
was also significant when compared to anovulatory follicular fluids (P < 0.05). In
contrast, comparisons of the levels of oestradiol in the same follicular fluids showed
that follicular fluids from normal women were significantly higher compared to the
PCOS subjects, whether ovulatory (P< 0.05) or anovulatory (P< 0.01; Fig. 6.7C).
6.4. DISCUSSION
Previous studies of the metabolism of 5a-A have shown that it is
synthesised in the human ovary (McNatty et al., 1979; Agarwal et al., 1996) through the
action of 50C-R1, which is expressed locally (Haning et al., 1996). Of interest in this
study, 50C-A was previously implicated to be a major factor in the endocrinopathy of
PCOS Qakimiuk et al., 1999;Agarwal et al., 1996). However, the absence of a
standardised method for the measurement of the steroid created limitations in the
quantification of the steroid. In addition, an antiserum that is specific to 5a-A is still
unavailable because 5a-A is structurally similar to other 17keto steroids, particularly
androsterone and androstenedione (Chapter 1, Fig. 1.7). The high degree of
crossreaction of antisera with both androstenedione and androsterone is a problem that
has been reported in other studies (Milewich et al., 1992; Agarwal et al., 1996). As a














































FIGURE 6.7. Comparison of 17ketoandrogens, androstenedione and 17|3-oestradiol
measured in follicular fluids by RIA. Follicular fluid samples were obtained from women
with normal menstrual cycles (Normal) and women diagnosed with ovulatory or
anovulatory PCOS. Each bar represents the average concentration + SEM of the steroids
measured by specific RIAs (see "Experimental Procedures, 6.2.6) in the study groups. The
summary of the RIA data is shown in Table 6. 4. Significant differences in levels of steroid
when compared with controls are indicated by a (P< 0.01) and b (P< 0.05). c represents
significantly increased levels of androstenedione in follicular fluids from ovulatory PCOS
ovaries compared to anovulatory ovaries, n represents the number of follicular fluid
samples assayed in each RIA.
samples, attempts were made to isolate the extracted steroids prior to the actual
measurement. However the systems used to separate the steroids, i.e., HPLC and TLC
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where problematic in that the recovery of known amounts of unlabeled or radiolabeled
5CX.-A from procedures incorporating such steps was irreproducible (results not shown).
Therefore, the assay that was developed measured 5(X-A as well as androsterone and
androstenedione, simultaneously. Although such an assay was limited in measuring the
specific levels of 5cc-reduced androgens, it was useful in studying the patterns of the
steroids' levels in biological samples.
The levels of 17I<As measured in follicular fluids from normal, ovulatory and
anovulatory PCOS ovaries were 364.5 ± 46.3, 828.7 ± 168.1, and 618.9 + 127.9 nM
(mean ± SEM), respectively (Table 6.5). Given that the 17KA RIA measured the three
steroids collectively, it is not possible to make specific inferences of the individual
steroids directly using the data obtained by the assay. In addition, androstenedione is
the most abundant androgen in the ovary and it is likely that the steroid levels detected
by the 17KA RIA largely reflected the concentrations of androstenedione in the
follicular fluids. However, inspite of this limitation, it was shown that the levels of the
17KAs measured collectively were approximately 2-3 times those of the
androstenedione levels that were measured using a specific assay (Figs. 6.7A & B),
suggesting that the 17KA RIA measured other 17KAs in addition to androstenedione.
It was also shown that the levels of the 17KAs measured collectively were higher in
follicular fluids from women with PCOS regardless of ovulatory status, when compared
with samples from normal subjects, and that the elevated androgen levels were
significantly higher in follicular fluids from anovulatory PCOS compared to the controls
(P< 0.01; Figs. 6.7A&B).
To estimate the levels of 5a-17KAs in the follicular fluids, the mean
androstenedione value for each group was subtracted from the corresponding mean
17KA value. The concentrations of 5CC-17KAs obtained for follicular fluids ofwomen
in the follicular phase of normal menstrual cycles and women diagnosed with ovulatory
and anovulatory PCOS were 220.7 A 30.9, 564.4 +. 134.0 and 435.1 +,101 nM,
respectively. It is important to note that the 5a-17KA values obtained were only an
approximation due to variable cross-reaction of the individual steroids quantified with
the antiserum used. Still, the levels of 5a-17KAs were again shown to be raised in
polycystic ovaries compared to normal (Fig. 6.8). The levels in follicular fluids from
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ovulatory polycystic ovaries were approximately 2.5 times those in normal ovaries while
levels in anovulatory polycystic ovaries approximated twice the levels in normal
follicular fluids. However, there was no significant difference between the levels of 50C-
17KAs in follicular fluids in ovulatory or anovulatory PCOS.
Normal Ovulatory Anovulatory
PCOS PCOS
FIGURE 6.8 Levels of 5al7KAs in follicular fluids. The levels of 5al7KAs in follicular
fluids of women in the follicular phase of normal menstrual cycles (normal) and women
diagnosed with ovulatory and anovulatory PCOS were estimated by subtraction of the
specific androstenedione concentrations from the corresponding total 17KA values. Each
bar represents the mean 50C17KA concentration + SEM (nM). Asterisk (*) denote markedly
increased levels of 5al7KA compared to normal.
The observed hyperandrogenemia supports earlier works where elevated levels
of androgens were reported in women with PCOS (Speroff et al., 1983; Gilling-Smith et
al., 1994; Agarwal et al., 1996; Legro et al., 1998; Dewailly, 1999; Nelson et al., 1999;
Dunaif & Thomas, 2001)). The estimates correlate with the 3-fold increase in levels of
5a-A in follicular fluid from polycystic ovaries compared with ovaries with 6-8 mm
cohort follicles from regularly menstruating women (Agarwal et al., 1996). Raised
androstendione levels have been illustrated in vitro using thecal cells from PCOS subjects
(Gilling-Smith et al, 1994). It is thought the characteristic hyperandrogenemia in PCOS
is due to increased androgen production within the ovaries (Gilling-Smith et al., 1997).
Specifically, it has been suggested that the production of 5a-reduced androgens occurs
as a result of the upregulation of the 50C-R1 as indicated by Jakimiuk et al., (1999) and
Chin et al., (2000).
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In contrast the levels of oestradiol were significantly low in follicular fluids of
both PCOS subtypes, i.e., ovulatory (P<0.05) and anovulatory PCOS (P< 0.01; Fig.
6.7C). It is worth noting that oestradiol production was also significantly lower in
anovulatory PCOS compared to ovulatory PCOS suggesting that the anovulation in
these subjects could be explained in part by lack of adequate levels of oestradiol, which
is necessary to attain ovulation. Collectively, the findings suggest that high levels of the
non-aromatisable 5ct-17KAs co-exist with decreased oestradiol production in PCOS.
The data suggests that the enzymes responsible for 5ot-A, androstenedione and
androsterone synthesis are upregulated in PCOS while aromatase is inhibited. Infact,
oestrogen production was inhibited by 5CC-A in human granulosa cells in a dose-
dependent manner suggesting that the increased concentrations of 5CC-A (as in PCOS
follicular fluid) inhibit aromatase action (Agarwal et al., 1996). Similar inhibition was
also shown in rat models (Hillier et al., 1980a; Ebong & Peddie, 1990). An appreciable
fraction of the androgenic output of ovaries of women with PCOS ovaries constitutes
of 5a-reduced androgens. It is known that 5oc-reduced androgens are constituents of
normal ovaries (Eckstein et ai, 1970; McNatty et al, 1979; Gore-Langton & Armstrong,
1988). Although the steroids do not inhibit aromatase action when produced within
physiologically normal ranges, they become inhibitory when their production is elevated
markedly as can occur in PCOS (Agarwal et al., 1996). Since the follicles in PCOS were
shown to be at stages of arrest as opposed to being atretic (Fauser, 1994; Takayama et
al., 1996), it is likely that the increased metabolism of androstenedione and testosterone
into 5(X-reduced androgens contributes to the local ovarian environment that maintains
follicles at small undeveloped sizes due to the lack of adequate oestrogen production.
The result is a multi-follicular ovarian phenotype that is characteristic of PCOS. The
lack of adequate oestrogen levels also perpetuates the inhibition of follicle development
by removing the ovarian oestrogenic signal that stimulates and augments FSH secretion
from the pituitary. As a result, follicle developments arrests and the development-
dependent changes that metabolise androgens into oestrogens are reduced greatly. The
outcome is the exaggerated androgenic ouput that exists alongside reduced oestrogen
production in PCOS as illustrated in Fig. 6.7.
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Chapter 7. Summary
During reproductive years, the adult ovary is a dynamic organ, which undergoes
continuous structural and functional changes that are predominantly controlled by
gonadotrophic signals. The main ovarian steroidogenic processes involve conversion of
androgenic precursors into oestrogens, mainly oestradiol which is a prerequisite for
ovulation (Adashi, 1994; McGee & Hsueh, 2000). Because this function is dependent
on the enzymes present in the ovary, understanding the role(s) of ovarian enzymes that
metabolise androgens are vital to reproductive function. The focus of the studies
described in this manuscript is the 5CX-reductive metabolism of ovarian androgens. The
studies were performed in the rat which has also been shown to be a good animal model
to study the pathophysiology of PCOS (Mahesh et al., 1987).
Investigations of the metabolism of androstenedione, the most abundant
androgen in the ovary were performed in cell culture systems of granulosa and thecal
cells isolated from immature Wistar rats stimulated in vivo with gonadotrophins (Chapter
3). As expected, oestradiol production was evident in granulosa cell cultures because of
the expression of the enzyme aromatase by these cell types (as shown in Chapters 4 &
5). In reference to previous reports of the conversion of androstenedione into 5a-A by
granulosa cells in vitro (Hillier et al, 1980a) and knowing that 5cx-reduction is an alternate
pathway to aromatisation during ovarian androgen metabolism (Aono et al, 1981; Payne
et al., 1992), it had been expected that the immediate 5a-reduced metabolite of
androstenedione, 5a-A could be detected and measured in cell cultures as part of
studies investigating the role of 5(X-reduced androgens in the ovary. However, 5CC-A
was not detected in granulosa cell cultures even though oestradiol and testosterone were
detected in the same cultures (Chapter 3). Thus, die main enzyme in the granulosa cells
in immature rat ovary was shown to be 17(3-HSD, which is expressed constitutively in
these cells (Bogovich & Richards, 1984). Disappointingly, despite concerted efforts, the
thecal cell cultures failed to show any metabolism in any of the experimental cultures.
In view of the findings shown in Chapter 5, it is now clear why 5CC-reductive
metabolism was absent from granulosa cells. The rat ovary expressed the isozyme, 5a-
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R1 which was localised specifically to the theca and interstitial cells where it was up- and
down-regulated by LH and FSH, respectively (Chapters 4 & 5). Notably, the enzyme
was absent in the granulosal and stromal compartments of the ovary (Chapter 5). It was
also illustrated that 5CC-R1 is expressed abundandy in ovaries of immature rats and
barely detectable in adult ovaries. If this finding holds true for other species, it suggests
that the inhibitory action of 5(X-reduced androgens on oestrogen synthesis (as suggested
in Chapter 5) is principally a phenomenon of immature, prepubertal ovaries. It is
possible that the 5a—reduced androgens formed in immature animals are part of the
intraovarian cues which ensure that follicular development, particularly granulosa cell
proliferation and the ensuing oestrogen production are suppressed in immature animals.
They might also have an additional role as steroid intermediates in degradative
pathways, which ensure removal of steroids that would otherwise be used as substrates
for precocious prepubertal synthesis of oestrogens. Infact, the lack of 5a-R has been
postulated to be fatal in fetal animals due to oestrogen excess (Mahendroo et ai, 1997).
Therefore, the enzyme probably has a different function in normal adulthood where it
might be more important in physiological responses related to pregnancy such as
parturition as suggested by (Mahendroo et al., 1999). However, it can still be an
important catalyst of 5a-reduced androgens if high levels of substrate are present. It is
very hkely that in a condition like PCOS where exaggerated androgen production
provides excess substrate, 5a-Rl may convert androstenedione opportunistically into
5a-A and subsequently into andosterone, resulting in an intraovarian microenvironment
that suppresses aromatase action locally. In such situations, 5a-reduced androgens act
as paracine modulators of oestrogen production. Further studies clarifying the
localisation of ovarian 5a-R in other species, particularly man are important.
Analyses of RIAs performed on follicular fluids from normal and polycystic
women showed evidently that PCOS is a condition of elevated levels of androgens
(Chapter 6, Fig. 6.7A & B). In contrast, the levels of oestradiol were decreased
significantly in PCOS. Given that PCOS is a multi-factorial disorder, the studies
described in this manuscript attempted to analyse the levels of 5a-reduced androgens in
follicular fluid because they are inhibitors of oestrogen production. Hence, they are
potential local enhancers of the pathophysiology of PCOS. Even though the non-
specificity of the antiserum used to detect the 5a-reduced androgens rendered the assay
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incapable of quantifying specific steroids, the comparison of the levels of 5ccl7KA,
androstenedione and oestradiol in the follicular fluids illustrated the elevated androgens
in PCOS, particularly the ovulatory PCOS. Possibly, ovarian function in anovulatory
PCOS, for example, aromatase activity is greatly impaired such that the conversion of
androgens into oestrogens is hindered even in the presence of high levels of androgenic
substrate. Since 50C-reduced androgens inhibit aromatase locally, it is likely that
unknown cellular transcription factors are also involved in effecting this response.
Investigation of these sub-cellular modulators could provide clues to specific therapies
targeting the action of 5CC-R1 in conditions of hyperandrogenemia.
Although the described studies investigating 50C-R activity were done in the rat
to address the physiology of a human condition, PCOS, the findings are still relevant
because the preovulatory follicular developments within the ovaries of both species are
similar. Although man is monoovulatory while the rat is multiovulatory, the regulation
of preovulatory development in both species is mainly by gonadotrophins. The
sequence of preovulatory follicular development is initiated by FSH stimulation and
ends with LH action during ovulation. Thus, studies of the gonadotrophic regulation of
5a-Rl activity in the rat model are relevant to the regulation of 5a-Rl in the human
ovary. In addition, the cheaper upkeep of rats as animal models compared to
monoovulatory animals such as sheep also makes the rat a good experimental model to
study preovulatory development.
Together, all the data indicate that under gonadotrophic control, ovarian
androgen metabolism via aromatisation and 5a-reductive pathways occurs in a
synchronised fashion related to follicle development. Because of the polarised
localisation of aromatisation and 5a-reduction in granulosa and theca/interstitial cells,
respectively, the two processes are distinct ovarian steroidogenic processes that occur
concurrendy to create an intraovarian environment that enhances the follicular changes
at each stage of development. Thus, nature has ensured that the release of eggs capable
of fertilisation occurs when the female is physiologically mature to carry a conception to
term so that the perpetuation of its species is assured.
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7.1. Future Work
As discussed earlier (Chapter 2), the roles of 50C-reduced androgens in ovarian
physiology are still unclear. This has been largely because these steroids are
quantitatively minor in female reproductive endocrinology. In addition, recent progress
in research on 50C-R and its metabolites in women has been in dermatology (Thiboutot
et al., 2000) rather than ovarian physiology because the stimulation of acne, hirsutism
and other masculinising symptoms are a major concern of the cosmetic industry.
However, the finding of increased expression of ovarian 50C-R1 (Chapters 4 & 5) during
the periovulatory window leads to investigations of the role of 5cC-reduced steroids
during this phase of ovarian function.
Whereas 50C-reduced progestanes were identified as excretory products of
progesterone (Eckstein et al., 1970; Lerner & Eckstein, 1976), it is still unclear whether
that is the only role of 50C-R1 during ovulation. Investigations are necessary to clarify
how 5a-reduced metabolism affects ovulation. The strategies adopted could be use of
in vivo studies in animal models treated with 50C-R inhibitors. The selected animals must
have normal ovarian cycles. By targeting treatments for just before ovulation, the role
of 50C-R1 on ovulation can be studied by immunocytochemical techniques highlighting
the morphological developments within the ovary. Gene expression techniques can also
be performed on ovarian tissues to study the expression of 5oc—R1 during ovulation and
early luteal phase.
Alongside investigations of 5a-R, it is important to identify and measure the
particular ovarian 50C-reduced steroids synthesised during ovulation. The levels of
steroids could indicate the physiologically important 5a-reduced steroids during this
stage. Ideally, follicular fluid samples would indicate what is occurring locally in the
ovary, but these samples are not easily collected. It is easier to collect urine samples, but
this results in measurement of metabolites of the 5a-reduced steroids and may
confound investigations of the actual ovarian steroids produced. Measurement of the
steroids could also be done on blood samples. Because the less studied 5(X-reduced
steroids such as 5a-A may not have established assays for their measurement, well-
characterised antisera should be developed to ensure their accurate measurement. In
the absence of such antisera, inclusion of separation techniques in the assay protocols
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may improve the quantification studies. The establishment of a standardised 5CC-A RIA
would be essential to these studies and could be adapted to measure specifically the
levels of the steroid in various biological fluids. Aside the obvious need in reproductive
endocrinology, the assay would also be used in dermatological investigations.
The studies of the 50C-reductive effect on ovulation are important because they
can broaden the scope within which contraceptives are modified. And should
regulation of progesterone metabolism be indicated, such studies may warrant further
research on the function of 5CC-R in pregnancy and the uterus. Infact a physiological
role for 5a-R in pregnancy has been suggested (Mahendroo et al., 1999).
The finding of the 5CC-R1 gene in rat thecal/interstitial cells (Chapter 5)
indicated the need to clarify the cellular localisation of the enzyme in other species. It is
particularly important to investigate this in women since the enzyme contributes to the
pathophysiology of PCOS which is a major cause of anovulatory infertility. With the
development of therapeutic drugs that target specific enzymatic processes, such studies
would highlight the tissues requiring special study during investigations monitoring the
effects of the drugs.
Although the research described in this thesis focussed on female reproductive
endocrinology, it is worthwhile to note that 5CC-R is crucial in male physiology. Infact it
is essential for the normal development of a male phenotype (Andersson et al, 1991).
Hence, studies of the regulation and localisation of 5CC-R action in females might allude
to the role of the enzyme in males.
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